var title_f11_7_11376="Verruca vulgaris";
var content_f11_7_11376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verruca vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple common warts are evident on the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11376=[""].join("\n");
var outline_f11_7_11376=null;
var title_f11_7_11377="Sequestration CXR II";
var content_f11_7_11377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph several months later reveals that the multicystic structure is now gas-filled due to decreased drainage of secretions with subsequent infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11377=[""].join("\n");
var outline_f11_7_11377=null;
var title_f11_7_11378="Yale Brown OCD rating scale";
var content_f11_7_11378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Yale-Brown obsessive-compulsive scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 598px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Goodman, WK, Price, LH, Rasmussen, SA, et al, Arch Gen Psychiatry 1989; 46:106.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11378=[""].join("\n");
var outline_f11_7_11378=null;
var title_f11_7_11379="Membranous VSD with LV to RA shunt";
var content_f11_7_11379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73264/Memb_VSD_LV_RA_shunt_movie.mp4?title=Membranous+VSD+with+LV+to+RA+shunt\" style=\"width:496px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Membranous VSD with LV to RA shunt",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     This movie clip obtained from a subcostal coronal imaging plane shows the relationship between the jet of flow (orange) from the LVOT to the RA and the tricuspid valve. There is also a small jet of flow across the atrial septum from left to right, consistent with a coexistent patent foramen ovale.",
"    </p>",
"    <div class=\"footnotes\">",
"     LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; IVS: intraventricular septum; LVOT: left ventricular outflow tract; TV: tricuspid valve; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11379=[""].join("\n");
var outline_f11_7_11379=null;
var title_f11_7_11380="Urticaria 1";
var content_f11_7_11380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72519%7EID%2F81678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72519%7EID%2F81678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 384px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGAAPwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwaDJ7Y/Ct7TuFyF+6OhOM/SsW1yQOOa6LTNx2nZkYJz7dzXNWloTh43ZtWOSpJXByOh6H+g+ta8WW2Hng5PPPv9azbQMVAIO3+Ljrj+tbdnuWEDbuIxnt/nivKqSPXgrGhbKzGIKSuO2eOnQ+vWr8fy8oCXIGB/e9/Y1FbrnBI56+g/z1q9CoLR7QcHnHQDjiuZs0I5PKWSAMgzyOuN2cDH+fWtKPKxuSdzcD5jjgAevaoWijLgyKCkq7X3Dgj+h4qZEKx/KnO3BBHTipERggNIMAfNtB9ABj+lUblwiLu+Y/y9z71fm2qoQjJIG4gdf84xWHrN0VGEVgy+44NVFCbOX8X6qIofKiILSZU+1eZPIWdnbOXPfvXQ+J7kz3qpuIAzkgHp3xXOAlmwPu7ua9zDQ5YHj4mfNI9S8Lxsmgad5Gzld7kt1YZOMfh/nml8VWyzWUlxFHhk+cDJ/L/OKu+GZ4JbTToNgii8syIijLSZDgfhx09uta2rW73FqFVARsAY9AOOMAd+nFebKVqnNbqejBJw5fI87tnaCPDsNrgjbjjbjI57dazL6NmYTquS3LAnrmtG8Sa2lltXiOFO4YzgKTyPbnv71Unk88YKAOD3JJrsi7O4qlpRszJaYrgquM9ParEN6fK4b5iexPT3qGUFJGVlA3fkTjt6Gq0qzRfNgkdfp9a6UlLQ4FKUHoaqXJwyBQpzkAnimpcmLO5RtY/Njt/WslbtgpBAOfWpxcFsAjnGACOlJ0/Ift7mzHdeVHvaTkEEBSTnp6VuWmoJMJAUCbSv3iAD/kfhXFJclThAcnqR2rVsNRMcBXbuLHq2eB05+vPNY1KWhtSrq9jcvrkmPI2mIAkbcsAM+v1/zzWHcR48wMoZyNxJOCOKnuNRV1IjbBVcbAhAXnOeOuPU1QvNS/chFXDcYyp/CinBroFSpB7lIyh5wUX1PtiqzMcsce+Ksxo6iR3TBI9O1VN2c8d66o+RwSFVhkA+or16wYiwtgc/6pe/HSvIUOWQYzz3Fev2gZbO3wpyI1AH4VnWJW5IMk9D9PT/PpQH9QBz1PakBPOVJ44p7Ek8Jznp61iO5Ysj8x44HbuKsByQOAD35qCyJLHI4HYf8A16s5P92hB0PDbPJIwvPsK6LTd4K7VYbT1x0Pt2rAst3BAGB1roNPc/KuDj1A/KqrM7MMjftmcMFAz0UYFbdkeFG0tznHvWBZ79u3+MH1BB+tbenmTghSvHTGa8yoepE3bYDaSc59utaNscHLZz0xWZaNhwMH9Mj/ABrRi+4NgU+g9q5mWXScx5YEAHJxweP8/rTd0hlIJHIzxwFHp+tLEMxgMoKqR1747ce9R3DjaSBjHYelArFe7lIL4HfAPX8a5DX7zyoyz8r34/StrUb8pG5c7cDt6+n/ANauB1K5n1O4aK1ilGxtuR/Dnj88HvW9GHM79DKpLlRgXiyOj3M6EEqSCx55PGfyzWJEWLqCMc5wa6PWbeeKymlkEYjeULhRgnCjAHqMD86wbCCW5uFijUl2OOuMfielezSkuVs8mrG0kj0Dw1KsCSGUx7ywJcljtBO3oOCMZ4HvXY2uqQ3CY82MS4IQsQen/s2K5rw34Xtp9LMt6he4mi3R5J+U+oHXtjPHWugs9PSymQx70VegU/KMgZ+ozk815dZxcnY9WhF8mqOY8XxiO6jni+ZA2GYg4CnH8qwnhkBKmMMQOgXJ/wA/Su88UW4u4pdyklQfmxtIGAPxrz6ItFZkJvWSHKyQtnaR2I9M+3ftWtKV4j0vyspXSK4CKp3AfNtHGf6VnyyTKu3BZemSOauXsjquGQxg4IVh1OOue/0rJkd8kL069K76aujzq8kpaGvottHPFM9zEGUttHGdoHX9avto1oRu8tkXk8E4x/n9KybC42wgpkY4A6GtS1nxIRGpEnGD1J9c5NZVOdSbTLpqm4pNGVqFj9nZSM7M4wRxUXAO1E/L+da2qgvG+E4Jxx61hhyuMDGecjtWkZOS1OecVGTViwEctw7JjPYDAqUDy3YqjA56N82PbNRwuzPjb0qUkt97OM+lDbGkhjyPsJIJPuO9Z5YgHjvV6TOz7pxj06Vn5PBGe9aUzOoSQk7064LAdK9khyYIcDjYAR6HFeN2+WmjyucsOK9mjDeVGDk/KOcewrOt0IQ05P3R27dqcpJ4w3TOcUh3E855wRj0pQWxyPb61iDRZsWYjJHtjuKsg4GDuP4VXs2I3ZByfX+dTsWBwFz+IFAdDxC0J4/oMVu2RfAVcHA7EAj61g2YJwAev61sW+8bdpHzDI5FaVVc66BvQLKqhC+/jA6A/wCf61v6YzhwVIwc5XIwRniuYtC2UU4I7gnn/wDVXRaejKoOM5A6nuOf8/WvNrI9OnqjpbcFirr65xxx7GtKFCCp4XsucZ6f5/OsewJZUZiAwyAc4P8An6VqxsUIPGR2J6n0rkNbWLJO0hVbcV4IHUVl3c7iMlGUk9Mj8KstKYwWMjEknjP8/wBPzrBvrxmkYAZyOo4FNLUpRbMTXrufZIqMARnlcEn6Ve8MaFLb6ZE8+3e6kMq9SxPPXocZGfT61u+GPD7TXSXN0hkJXKA8gd8/lWhqEM1kstuiZDH5HB+Zc8/jxj6ZrfmsuVHPKN5XPLfG0J8u0dnVTPLM23AHlqu0A+2cE/iPSsfwpDi7dWJSOePy/MK8Jkggke/IHoTXW/EWIwaXapIwMu8ZKn5YxtJ29PfJ/H1rntOtVt7h4XeVHaPISNuQ52jB7dCc13U53pWOOpH97c7jw9LJaOLaSQlySiyOw8xUySCBjDZ5HXqPatq4fNxbeaDLE0e8hWwzt6DH+cDiuWtLhLSQRG48xoZFi+c4RGyBlSB65GOPXPaul0y4S2upo508oQKESJXBLHcT+fOOneuKa1udcJWK2o2rPti3fIRudYlOCMjgkZJ7CuC8RwNZXE80UeI921oyuML24PUgivV7eOQxsVILvli0ZwACeOfp/jXK+K9OMemTTSK6YwGwAc5IH9RWlGVnYVXVXPL76UsnAJyoPzEHr0rHJO48kfqKs38c1pO1vITtU/Jk9KqdGJzwD3r1qaSWh5FWfM7smglZGJBIPrV+2uJFZT1+vbj/AArJAPJ4yM5zViKR2TbnJJ9eac4pkwlZm0LgyRKHblV71lspSRlI79PWrlszBSqncQSSQarTq3mqQQxP9KyirOxtLWzFh3ZyvTsM1LlvmyMZ+lMQMchec8/Slw+M5FD1BCTbimcYB561n5q9NvEbEtnjtVAZAGMc1pT2Mam5PahjcwjvvHXHrXs6h9nBGMAfTivGbAE31sAc/OK9mIfIwc4/UVlX6CihnzZIxkkcHIpRuU7gOpwADimktx0OfQ9qMnHI5/z1rIC5Y7thyRjPNTkbjk7vwqvZhjHx2GPr2qfYSBgqfrR1BHh9pu4AYZ960od2VG4nb056VlWoPZiK0IyVUEOemOT2raZ0UnobFk7CUbSOOM9x+FdNpYYgfMTkZHPcf5NchZ7iwG7kYx3ArrdHZiAd2UHbJ9a4MQrI9Kg7o6axQcdSp6Y5z/kVsABYwc7QOvc4x3xWTYo5CKjbWJJBbtjPat/Z/ou8PxnBCjPPX/69ec9zqMO9uDM2Fb5R8vPf2x1rOWylllVv9rnB59QP8+lX4LbgtNuUfdB6liT6D8a19OtjFK24KFGAO2M9vrWkXbY6G+VWRqaUBDZLuBVxgkk4Pvj+WO9QahE8glRGD5O5C+QoJ7H04J6djVe5wU/dpuIJwP7/APn/ADioruZdkMXmyOJSFl2gq4UAs3OOvGBjnrTOWouxzHiVJbnVLSzhCs/zOcn92gyMue5OTgDvg+lcffhbKe4uodqxW0CpbKeSzu2FJ9+rY9MDmu31CORL27LN5U0kHCxkb4kCsAPQY3MxJ4GD3rhNW8t7Y/PtEkizQwqMsVJAjHPUbTnp/CPWu2jrocVR2Oj0i2kFmlmJYxG0MKsQSxKsSCQW6Dgn1J4rc0CwSGzhDRIZw7l2YY3OCQCcjkYYH8K5zwvZRNFPNNNNtCqFRiWVgFBZQOOQWAHuPrXVaHloX2oyJGx8rcCu1eo4P1/EYrKpo2VHY6K1R0IDqQGO8Adzxyf1P41ma6odXxliC3Qf4VuxfvgGkO1hxgDoaytWjJiWU4Xcu3bjvxis7l7nifjHTXJ83Pz5zyOvFcdlick+xPWvXvEliJEYcqq5GSevB4ryrUbY29wyngH+derhanNHlZ52Lp2fMiBSex+tSR5BG3oT0qBevXH1qWPJ5BPX5ga6mciZoRCRXCg5PI4pJCWAYHADUoAB5PzD5ssT6VHICN2DkDjr+VZG/QmjDdjinZYAckDPQU2HfjoDnoc0pDFSCeM1BRDPu2t8w6etU+cdeauTL8h5OcetU+SBmtYbGNTcs6aCdQtgGAPmDB/GvZZC3IJzz7Zrx3RFLataDP8Ay0HH417C3+s54JPPPb61jW3RKGHfnk8Z/CjDBcluQO9NC8cnIB9+lKQcDHUg8noKyBl2z3eWfm+bpkipD7sqn0YgVFaKDEQeVzzz09RU+0tyCPfNIaZ4VEp/vEc9avxkhMhgOxwKzwnOcmrEI+Yc+1dUtTaDsbWlxsZAC2Aev+GPSux0RSrhQcg4A9//AK1cppFuWKNhuDkj2/P/ADmuy0yEswYvg8FiF/LFeZiZdLnqYZe7dnTWURK+YoI2jKkDpx+vataHfJDGpZSDlmBx+n+e1Z+nqrIFkJDdNo7fjWgkbNEVQ/Pkcn5ieentXA7s7IuwQW0aRqVZ9q9x/jU6oY8+WowF79V44/Gmozx4RiflGSewPpUq/PGcBiNuMdB/+rHc0XNWrlWKMvdxqnzZGQ3GFHuKZqVyba3UxRyTSDiEKQAGbvk44wD/AMBDGrFvDuaVQzhXTYMLgEHrz+Gay9XSa4vY2tovORIfP2EcAn5ccc/dyPzrRO5hUWtijaaa0ej3V/cxzT3V3C8Z88YVFK/Lu6bs7shcY5GeM1wVnoMjLBM8UmJ7zERZslYkVhHg992M/THSvTNYWWW0up55JI0CsofbgyMeEyAfuqfxPSuXURx2mixTrJE9icSKwwFMcLLux0GeoP8AXiumnUaTszlnC71KHg4p9g8u5G+CKQJLGM8neQOT/tfyrt9J2StcQOxM0LMCQuAzH5hkdzg9vQ1534fdbPTjckfPNdHenBwFYsGUf3icD8x3rvPCDCeQy3MfWRiqpkZY4AAJPBAGPoRTq7smC0R0Yj2SAkHayhtvOFPHI9OvSqt+pCjA2NwTn2P+NT7o4Zp7UjAQCSMyKduCMYz7f1HvVXzkuYg0YOM53dN30Pf61hco5jVbdWKEBlz1yfyry7xNZNv3YIJ5I9T3r1m8j3lupG7/AD9K4jxDY71IB568Dlvw/GujDVOWW5NWnzxseaMhViOcUqZDDn/6xqS9hMczKccHtUIGMYxmvYTujxWrOxajcnAB49B+tKTlgCxyf1qFByFyevGOcmpposRoQRnuMVLtctXaLNvkxgE+o5qQqQOuf0qjbtliCT/KrDY4wRjOenNZtamkXoLOCI35xxzVEA8YqzcZ8pvbiqpHA7A1cNjOoaGgru1izDHgSAmvXnGCRuGCf1ryPw0hOtWe0EkScV63IPmPPJP+f8+1Y1nqShoBYj5iD/8AXpWRuDj6daaEGDkcL2P+fwpQgC4XqepH9fzNZ38wZdtEbySAMHpk81MoG0bmA9OCais4wIFzkD+VSfKAM5/AZ/rSuHQ8KbhetTWaZfJPHGaqcE4NaOmxZcZ6dM8d+9dMnaJvTXNI6fRrcttVSOO5rr7FFjQKCVyc/h6ZrntLhVcbcbscdMEV0dmqoUG3uCDnOP8AOK8atO7PbpxsrG9ZjMa7sK38IrRJV4mwGzjPAPP8qwVuWiMa7flyQG/xret7dbtSGBztwCOcf5z2rn21NVG2rLduuS2/aeeoz+tXFQQxthgQQONvJ6/nWQjTW9wYmUkHnKdK2dLgMrtJKoVV+6D6/T+lK5tayuxzJstZVaP97g8kcnPT9eKjNqiGZlyZJPklx07cD3xwAP8AGtSeLzQowVXI4Q9x6/4Uz7NmUuBnn5V6kcd/8iqTscsnzMx7y1zAjSqhdG2qij5OGGf0FcX4us47idnRJBMA8aFUwCHJzjGc46Aj1PYV6DLsMbLIjSyv95QcAj09MetZV7ZB42muiryqf3WMAIOBgH0xzWilbVGdtTzrQNJW4sxazoDulmbLfKSQ+Nu7tkjBI9TWjoU8mn3Elu5DyWtx5cyuuCVKgq5HoV+QnplfUitrw5YRyWzTTphy04VB8o2vICCAOAckke1VbnSF/tS4KyB1uYI5wHGSuGK4HtwOD/ewat1Lt3YKOljW1i086NmeVhBuAKoxAjDcE55JAyDj2+tPsklIlimnDNGAnKjOcdMDA/8A11Dp6TfYk3zbreTMLM/3o8HnnOenQ/StK2t9r3Ecj4mjPzkgDnoPwK/yqG9CLWMm8hVixCqFI+ufYVx2uW0eSJFXBGT9P8a7u+DHJUFsjg1y2rRHHI+XOOTn8KIysy1qeT6/ZiK4kAG0NyBjvWFgd+1dz4jto3hL5A5GQx+vHvXFTxBJMjtXtYefNE8jFU+Seg+NNzrhsDOM4qfaRE2SCcgc/wCe1QQ7RkZ4IyMU9G3EKSepGWPHPetGZKxHgK6njI6+9WsBunWq0i/O24jg4zU8S5jXkHnoetKWwR3sJMnytzkYqvjgYNWpxhD69eaq46YqobCqbmt4VTdr9mAcAvzxnFesuvzHOCTyAR/n3ryjwcgbxDaZ6bq9WZQrZ6nv/hWFZ6hFDNgzhTkHnp1pSmR1HXjj/PtQqqMk8D68Gl6DAxjpz2rO4i7bKBDyTj0A6e319qeyqW64/HFJbL+6x19STyKcR03Lz70l6jSR4JGo3DkZ9q3tIiTzFViOecE/qaw7faDwe/NdDpATcTkZ75rWs9Drwq96512nlNoXensOv41qWz7WAYqvOccVhWpjAUM2R0I7GtC1OZiF384GOhryJo9mKR1dqqudx5x37Z44/lW9pyBlGGIxjocYFYWnMpxtOMLlh3J9a6bT+XwpHTr3zXPdga9taAyHa54HTaMEnv8ApWiINg81vvHAG3jI9D/9aqlqqswjXcHPXPTrz/LtWvAkahieFHU4J9iKVxWKDoVQkZZiCx2jpmoJnQqF5QHOf/11ou8bBsluDg5HbPb9OKqSPvDFMBSeScU49yZFN0BQEDcwGMGqM9uLl40fcUQjI7dc4/QVoSquwqzb8E8Z/wA+nSokCnDAjjGSvTg1p0M0ZccCx3s8hKhWB257nOfy5FVryISXLysGzOvl4LYOO+Px5rWkAW83NgDaW6ev8qqPn5pDtJ3HGT0FJPsMzrKBXRhOFO/EbnOMgjoP8960ILQGbcctKEC7nPGB0/Dr9KRIEERaPgAcjH5/yrVso8hflBx7U2xWMK+hEinf0xkgnr161y2qQrLG7sPkVSMAdcHPH5V31/ArFssw4Az175/pXL6rBhMLjZycjrjrxQmNaHmuuWMTLJKWLL95gWyPY9OK4PU7cKWBOGjyPqP64r1a8jhxJGzbSi7Sd3QAH+led6vAizPxhhnK/wB4Z4NejhKjvY5sXTTVznI9pGM1NCfVuU+Yc/SoZFVJDhht6ZqxZnDYBySCACfvA9RXoy2ueVHccFDxZDDk5Izg0yBgJdpOMmnq0b7dwAJ7+nFV24l4PQ8e/wBaS10G+jRZuSvlnt071WwCcGpXYGM5HB6ZqLjA74px0Qpu7NzwUqnxFa5IyCfpXqrhS/BHHOa8u8BhT4kt8Hsf5GvUGK47Z6kA1z1viBCEAdS2RxiggEkZ5NKFQAcjHTApcJsrMC5bKPIXBBBHrUoA77fxbFJAAYUycgc4PWl2oegJpbhseBQbfT61u2ToMMByORz1rDtlBPcf0rXgKKOV5/pW9XXQ68Po7nR2ki71wMntzW7YvGCu8KGB781ydjMm8AYA6YrpNPdQECqRk45OR9BXmVo2PWpyujsNLbeOMDBA9OO9dLYTeUq/KSR04zXI6W6bcgEIO2M11unlFUMCoGRxn+dcTWpfU3beYkqNoK8Z56d6v3d6I4HcKF+XOB1AHFUYPL27jnI4DL69zUOo+QFwzcHgDJ9elJastJXsV5buS4cbSI48Ywv+NFtdSGUxkksT39e1RkKuTnhFGBjnH8s1Esm5xtzuyDleOPqO9WmXJKxrhgxBwOOQSfzo3AyANjgEgZ/z61BFJiTbGQD1LFeg+lMe5XnaMKemRzjnmg5LahctGBvLYynOO9UWYGMbQRuXAz/CasXLLL8p7DpiqsbAyq2VVs5wvBoGadvANm1lyAMHODn/ABrWjtmRCyLHjGFyP8ar6XABhyDwMj5f89a2IkV0YfIFUAAe3oaGxWMi4ty6n5wRnp19ea5fV4U8t3YM20HPoMfy4rtbkLGNvIXHOR0PP+frXL6zGZrdl/hckMQOT3JFEWFjy/xChWZ3KFgPlIHHOMqc/gOvv+PD68Y5xDJGxJOAjdiV6g/gQcV6N4qWKFLqRlRkjdJAVHZVGfbP+Feaa5JDaXc8ZUbH5UKc456c9CMDjjv2xXfhVdqxjiH7upzt7DgvwBhiCPSqqEDn8cZrUuyrYPy7sHO3ow9jWSwCuynqPbpXqwd0eRUVmXUeMnGCWyMH29KSdUPK5PPGf8/rUcWHxgqpB+9/Kp5BtXJ6eo4P/wBek1ZgtVqVcggoOSOh9qQfe6UhYAkY4xn8KFYbjwenT+lXYzOm+H6g+Ios44Vj+hr1HaCwGBkDvXmXw3wfESn0jbt7V6gFXIxwM9McfhXJWvzFxWhGqrwO3setAwD0GQf/ANdPbkcE5HU4703KkHI7cHsf8/0rNBY0IVHljqTj+VKQP7zCkjVQiYHbnjHNLhD979P/ANVK9h2PBbPbkdcfStZSpiAA44zx39qybQr6D8a2UZPLA2gc/pW9Xc66FrFqzdFcYyVBz0ro9OCbQ/LenQ9/1rnLYo7Z2rnvXW6SqmNAq9cEYxnNcFc9KjsdLpi4Kdhx/D3/AMK6W1UBsnJUdcj/ADj/APXXN6eOUZgQp6kdR71vaccxqy5cgfxcn/PFee1qa2N+BiApUspP3toznHQZ/pUF5byTwgxvsAIIBXI9806yY7Nyjj/e/DNaEWMZcjHUHrn/ADmpSKUuXUyZLKYo2yVWOOSQcDHqKfbQeQCmQ0hHUDjBFW1JRHTZuLNn5j7+p71C7iKVeQHPOScnjv8AWq2E5N6DVwxLKWJzkf1pGIMhy3TB5XAORQ4Yn5yQQcf/AFqjLKrMcjcfl/pTM7CNyrbiFzxz/X0qeziVWPGXB4x39/eo4Y8ld4Jzjjua1bRMEZOCB93Hc80WCxqWAULuXARTzkdCB1/WrjsYyHUfe7BarxqiqeQox2/i781Z3+YFySQecDv+fvUNhYp3AZ0+VtoB/iGOPSsXU0G1QC5Ow/KASw47CujmjUo4I3LuOCOO3esXUkYxSCPBUg9D7dM/nVINzyPxoWTSJ2dGElzKYlXGT0x+oDHivIbqPy7qRZAzM7sGJHRs8/SvevF9t5kZfy1EVnvkUlgQTsIbgemcD8a8r8WabJBdN5LHybiKJ5OfvHaDnHocdfWvRws+X3TCtT51c4tzsxFJksPX19M1VuCp2/TB45rV1aPaYXYAPKoZuMdScH68fmKz5jklgOeDj0NepB31PIqR5XYrowB4zg8GrkMoMeGGQDt6deKo5UYG0+tWbdtrMvBDd8e3UVcldERdmRvgbuuPpSR4y3Bp0205I5pinB4HX/OaFsJnXfDUj/hIG4/5ZMRx7GvTztyOgycg+teafDQA61Ngc+UTXpm5QOg68ciuOt8Ra2EG3Occ478k0hAAUFc+lOBAx8oUepoPYBTjPfj/APXWWoy6p+QZz060hwTwOPanJjyxjn8ajd1B6j8cU0n2EeC2ZUMBnAzWqJF4JHTqaxraQcZrThkyQDjHbmumojpovQ1NOcK2cA4H5V1elTZiVW4AxnpgiuUsWwoxgEdATxXUacylUVBzycHjg4/wrz668j1aCvE7XTZEKoBtz3P5YrdtxGj7mYdOuOtcxppSNRgDCcfN/L+n4VqafczvdPKzjauQqHoV7DFcHKbct9jqbQqpKquxjj7uOefT+lXNx2EYPbHHGf8A69ZFlcSfxDAPA4/z/wDrrUikCMFbO4nIzxx/TrU2JaYgJPBzg9Acenv0qCVEWTJDFwMDJ5qxIS7BQQu3HB54FIY9zlgoTByOMj2pMZAQCTxx/e9f8/0qOZS0rKqkAdWyMge1WwNrnooz69h/X/Cjysn5Plc9FH8Pt/OqEkJHEvl7GJOCOT6Z/wAKvoqxruYgsTkHHVRRDEOSyhCMZA6/5/rU8AXzMtIFO0LjHByaQEsMgO1eQvueo/pViJ/mO3omThTz7VXSMZDLyoxwOw7n3qdMLKVYDBAwD/D3x+gpWEWJHRgrZX5Qc8cn8fesu4VNjkZBfJJH4f8A1q0p2XYu4DcepPP0rOuXJBj3twRuHqB25ppCOU1a0X96uGkUg8dsYrgvF9m9mkDNGtxp/MMw43LGenHopweORzXp9yFmLH5Q4XJOM4P+f51zevxI9oTJgj7xwM8Y5/DH862g7NMTR4R4lW2ExS0C/Zig8sq24Z9M/mfwNc4WDMS3cDqec/5FdP4qtpLS8hM0ZBkRG4Iw/H3sdj9O/wBa5mZSsqhR15/GvboW5UePiV77KjHa3Sljfpx78UStnBx1pu7078deorp6HJYl+Vk4IP8ASmhvTmmq3OePxpwbk5x0pWG0dn8MW/4mtwf+mXb616PvAHynqex6V538MT/p92Rj/VD+deiM+5kxgkcYPauOqvfZa2HKRkfLgjoD1o3g44zj36flTQwAyV5IzyelODjOPes7eQy8Hwqew4AqJ5EBG5c8cfMBj2qcPjg4A75Peoi0h6Z/M00tdUJnz3byEHvwe9aVtIc85xjpWMrYbjuav28oLAdDjiuypG5VKVjpbGTdtXqK6XTZTjjknkjPv+lcXYXIGAen6YrpNLuC7qxj3EALx7+lebXgezh5po7eymPlowB3Njnr+BzVu0uF+1ywSg5JBQk5GD/Tj1rE0+UspDEY9x6d634rO1vseYrLKpBDr1GK85q26OtNLc6LSsO5ZQcbQmcHArcgUk4LkDGfUn/63IrG0oLBCkSSMwzncSe/9K3LYCQcdSOO+B7c1myJPURhJhuFyMKDnt/Wpwhc/wB7jBJPanRp5hZm2sUI6jPWrFs25Ru6b88HgcDt+dJoCssbCTnOc4yx/n+VTBMyBlztA456U9VVVBHyr02nn9fzpY1IkLA84wMDJH1phYWQPgjqpXPuPfNL5bCPa7HIwD2xSjq6nAYgZY5yfxqRFLsccKwwARnOf59D+NLYLDmkG9VPJGfqehIP+e1NUsfmwyAA5JP5DFR7WebbtORzgdPz/WnuRv2pggjOAOFx/T/CmBZzngqNpGMY5z/ntWbfMVdj2X5VHI49f/rc1aMoKnAKj06HI7mqLHe37w/dGACM4Hpj9Ka0J2KMk+0shGSSR7nHt+tYupJuhdXCqrcHkdOen+FbV1IVG4cqDhgBk8+9Zl4EYjB3A425HSqBnkXjmw84WDMhZWYRsAcFeNwwfoD+deZzh42USA74+D/n+le1+IYtt4gkUGOJcjA7nhW/LcK8k16MC7ZTHtY5I49/1616mDm/hZwYylpzoxJ/lOOOvr1qJXxgDNSztnnHPcVAvpxXprY8prUmGV4PPvmlZueB1pY/mXoCR6CjoAeo7fSkFtDt/hef9OvuMjyx/OvQC2GOc7c81wHwvIE9/wDISSi8Y9674ZIGF5GDkCuSqveZa2F3kDHU+gPU08k+YCwYHPrTYzwvyjBG7nn8aeOGAI5JAx61lbyDoXycDkf/AF6hJx1LA98d6lfGMkcD86jdyrcg5PX3ppXBnzoTx0FTRHnoagyQMdqljzuye9egyEaFtOVZTxkY61u6VcBXweMmubQMADVu1nZWA7elc9SHMjtoVXBno+kXLDgE5Zup7f8A1zxXW6e6kKoxnOcenFec6JdSM0ZEnYjDew7122kyuYV8z7w6kY5/GvGrQ5WexFqSujttNUSFQQCOgHT/AD/9etuzxkAFwDgg8dO55/zxXNWMskShRuzjbzg5Fb9mSrh2wxzk7jjHXP8An2rmsM37bAAB+TnoB2PI6d/8acyA8DCgDqR75z/gfao7OYHBJKkcYPbpmrGGRA2VHygKByWOOO1FhIrockrsf5Cc8e45/WnxKv3l2bQT82SMHuP0FIUcPzgMp+6Tz+H6/mKhUy5U7m2jAQ4Pb/8AVQkW1cmuAqIik7WwHGDzt9aRndlAy4UZBAHOMZqtd6h5blZCzseQQuTj8vrWZqEsktmoiZdnLcHqPQfj/Wmo2CMG7XNVXaOYbjyRw2RjHUj24+vND8jO0CPOdo4x6Y/SudS8nsmhMz+ZbOSBtILx4xyR2HPB74PpW0ki7VKjO/ACjmjlCcOUmaQ+XtX5R/CR17fkapSvsycjJ+YZ6CpZn8oHD7mOF57f49Kh3/u88bjwAcZNBBVuXIcgD5geCeOv/wCus1yfmXGEzuI9G9f0q5O+44C85IJbnFUrthJEeeMjP9OKPUZzPiAM052noGy+OoOOnXjqce1eVeJLZlcPt2qrYC46ZAyB7ZH/AI9XrGr7iE2ITOnAzyCO4Pr2rgvESsTKTgHaGGO5Bxx/L8DXVhZcsjGrDni0ebXa4AYD1B/Oq65wPXmtPUoWAcKBguTxWWrHIPfrXvQd0eDONpWLVl1bCknpxSzDCr6kc/nS2THzCAuVOckDpxUlwcjPJHr/AJ/Cpb94aXunXfC/IlvuWIwCfpzXoB3Yy5Pr+FcN8LchdRcjBwg/U13WWJxyGyOvrXLU+JghQSB0b/HipI8l1HIAOTkdaYoIOSOAeg706LO9Ny9+M1mN7F/nAwO3btUDMVOCcfQZBqdzxyeB1qL5sDJAP1AoQHzkCcmnxkhvf0pig8kYpy53ZyfXNekzJFyMn/62KnXdjIzmqkROMc9PWrEZPIz+NYyR0RZu6RNJGQATgnpjNeh6Pc+aq5J3HlscDtXm2lljgAqDiu60FiFTJwfTP615mLitz18M7xO906XcqZ5IxknuMV0VtJja7Z2EADB9K46wkKEIjcY6nn/PWultZZHiCfKM8Aj+L/P1rzjoNyOdlffFuYkHgjp+fTpV+OQFUWRXdRwcZHX6dM1lWimIEyDr3UVehyUwpbDZJxwOvIz+NDA0dyhcEhhjgqOh9R7f/WqvPMkECtMy/Mx2lOc/X06c+op1oAyGQMCnKgpyeO45qvr0AbTy8aHMeDtUDqR1PtxSRS3szIvIvKvZS3Mb/OuGxjjoRU8LKlskRIHU8jp71krNgnaCHYgjeMfhx0qxcMrBGU4HHzZ5JP8An/8AXVM3a6CX6K6OQOAOOMY96m0m4Dh4pnAZTxjgFfes6e7IUhD83TbjgimaLKxmadl3QgFV4zk55P6UEzXu6m5LIzl+dygfN/j/AEphAHG5vRScVBJc/JnJVR3HU060LhnV1ByCSO4NTc52RSsEUAA8t27VTnyG3nPPtnJq7PsCMvc9fl4H0qDaSpbIUZ4z3oEYF1ESQ5wGx0bn/wDVXG6zblmZhtDF9hz6DjNd5qKttwvGQQSeQa4/VUfYw6KRkHtuq6bs9BbnmeuW7Rq2eOScY6YOP6VzGCGIA5BrtfESMHyCDkdvpXHzoVnOB3z/AI17+GleJ42LilPQdbMwRsEjIOSKtT7uBg4I/CqMLbHJ446/4Gr2Sykkk4yAT6VrJamMdVY7r4W5EGoHHden412x3DsPQcdK4v4XDdZagSeUkTP5E9K7Js57575rkqfEw6D1zwwyO/4U6Lf5i+uOfaowdxAwCO+B+tSxhjKOD75P6VAFxuenPv61E5Of4fyJqU53ZAwenvUTZGOccetCQHzljPWnlSCTnvzTR17U8jrzXpGRJGDgYzwO1WFVsZ59KrR59atRcgc/zrORrA0dPZg6gEY9K7PRXYsnI2gHPPbFcPbZBGOO/Wuk0t3jdW3nPoG6/wCeK4cRG6PVwsuh6PpBkwWDAEj05Hp/n3roYJnbKhgP/wBf/wBeuN0aZypJfoPvZ6Ed/cV1FnIWKlDhlGeOO1eS9Gdr3Okt5iNwY+Xk8Anv/k1ds33AryoAJZgMEHrx+INZVvJ5gQkgEYyOf8+tW7dx0DEknjqexqRG5FKxicc4yOOv+e/506dZWtiiMUZlPJ64Of6Y5+tZSTqQjRgKu7IJbkeoz/npVqSXHIbPHQjoaQ9jmLyKW1IR4yAnyqTyp/H0+tVjdHaUGSuc5HT/AOvXS3JimhZHO5W4Oec+1YOpWywuxVdkYwMjkfjV3ubwqKW5nSSkIxJbJ/hzU2l3TqyW652sC3HX86gDbo9sOC7vgHHtVi2sHjm3CTfuBwF4Ht9f/rUGk7ctmaiJlshicjdkHoe+KtwL5cZUkbT+Gc//AK6htIo0VgzBB1U/0xStK4jUdVXjOcAf55rM5WhkhCgFyOOuPftj0qCR2GMkKuME+pqOUsZt5fCnjBPf/Cmm3cA+vrjt607ksrToZctg5HQHrmua1qHazKuAvU5PU8c8/wCetdN5fyKFYgA+ucCuf1RGlDFVDEckE+nWmnZiR55rlswAIAxgDIGBmuKv7cjJ7ivQtWiZ97A7cnGBzXHXkB3SBu3v2r2cLPTc8/GQuYKqwJ6DsatJny+D1APXpUMy+W53Hr70+3OSF7ZrvequeZFtM7j4XS41PUrdmA8yFZVHqVYj+TV6AVOc46cnmvJ/BNyLfxbYFj8srNCSDj7ykD9cV61IO+ckcH5sVyVfiLI8EHnoT09alt1zIozz+X+e1M6KBu5HXB7fSpLbiUDPXnOazuIuODgA59iOajOeuAc+makfJPX8fWomBHVh9cgUKw9j5yxkYDdu/wBadjI65+tN6dDn0pyKDkA816Jkhwz1yfyqzEWA4zzVYLyCTk1PGoxxn6VMi47l+DpkH8K3tNL71IOSOvHOPWuegAHQ/jWtYggpz0bnjPFctVXR6GHlZndaZucqI2GT/D/Suv0lyw+bBA7cj61wGlS7dpRsE4OfQ+v4V2WmyDcu1+QB8vr/AJxXj1VZnpt3R1VuGZUIYYUZIPPbpj8qtMuRkkZIJO09fb9Kz7Rg20sxJ4K46Hj1rXgcMGzsynTccYx6f571ixIgVplJVsFTkZ56mh7kxqFf5VPcZ59c+tSTAtkBt6lhjHAz/nNRNA5UjB4bJ9QOnT16UXKHpOcqQTjqCvQY9fxFR3YP2fb1PQDHWpHg3IVZWJIznHJ7UeRuJJIZGJPHOf8AGi+pOvQqwwxhW8sYHClR1x6Zq9HZIsa/Jwc47EelTx2YYh9jZzjOP0+tXlRFIOw7yeo6Zxnmk2aXKN6ggsDsO2RuVc9Sen9Olczh4ZoWRfkMmdjtuxntn04rqr2AT28kXyls7gG5Hr0rnRbNBdlbkbf4okU559eaa9TSm1ysu/ZywQAEhjnI5Ip7kFNvB69M8HpS6WxuYWL7Vyx4zgc9CR+I4p0oCt2APUZwMUtjB3uUbmCQADAYZOPz/wA/gKwtRi2r2L9veunuVGzduLYJUZ5P4kf0rB1HDI6E/KTz9eP/AK9AjgtVtXTcXZuR06GuNvbYidlyxAOOe3416PqUIdZOdwxjnggiuN1K1JZigOemAOp9P8969DDVPMxrR5lc43VIShDH61VtshiRkY5zWzqkCFGKMT+X51hJlWPOa9anLmieNVXLIvW8xt7uC5UkCKZJB7YYH+le4ykGRipyGJK85z6fpXhBUPGVHQLz9a9m0Vzc6Fp1w5zvtkPI6cc1lW6El9QcDklh+eKntVPmjJz74qBQDgcdOMipLVQJh6AcjrWDAuSHn0GKgfdn5R9ef8amYkAgHGfT+tROJCcptI9x/hTTB6HzrjFSIO/ambRk9SR6U5cA9cV6DMx2Oeh9cVLEMcA8VER3BxT1Hfj1qWUnqX4Fz3rUtYzv+Uj34rHt8ZHIz9a2LNQf4lGBkdq5qmh3UHqjodNByCuSO3GP89K6XTZTG/yk889OlczYLhlLcMfQda6HTohvUnG1zwvTnt+VeXWPXjsdXp1wSQzD1YBjg59Mf561vxTjIVuCp74yPf8A+tXJ2SmMFF5wcHBAx9fb+tbELBxhs5P4HsfzrjYHQW4UJkqcgYXHv6/571YLpgIeV/2uMds/pWPBOyjdkgA5GTyOcnH6VOJd4LH5SQSAR9MD8qA3NnaoTeoyoGc5xu6U6JF8gBmVj0GOD/nNZ8bvGx8tgVBJCuO3ufw/GpoJ4yqnezufvDjpwe9FmNJ7GgsaomSx2gAjDY/Ee9IT8wxnI4J9PofT/GsnUy0k4I/1QTAUZGMd/wAKrWt7IoSM7Cm3ar8AEjr/AF607XRahpdGw8mWYspdSeh4z6/5+lVLi3in8qV8F16Hvj3qJpGyu1uVB4HUjoP8/Wqu9mUA5LKv4D2P50loTZrY0YjbxoVjYrz908YI6896imyMMCMNwD25waorcjb8w5yRgHj/AD1pxbDnHEZ529RRczJbrGxd3y8feU5/yawLuPbG6DdkkHHp71szTbhsBYjODx/Ssm+RNjHcVwT05/X35pNgjmL1fmdSQGA5Ofz4rmNQgEhYLzjk89PeuwuIVCBgmAR16dj0rAvYxyoyM8Anj3xXRSlZha+hw+pwAK6pwgyBjj8K5eRNszD05zXaavEpjckLwcjaK5C9ULISDkV7WGldHj4yHLIcnEeCe/Feo+Bp/P8AC9spOGhDQ7iPQnpXlUWAoI5r0j4a5fRbhSzALcEqpPfA5/z71VZe6cqZ16LwpOeQAD61PaKDMDyvTkmq6/eB5Jz0xVi2GZc56Z4/rXM2MsyA92yMYpm1T1I/KnuCQT+HbmmErgbjg47UID52GDwPWg9fw69KOCaTAx1+leiQScYGTzUkYUg1EMbeOfanxkA/WkxotQ4GOcVrWLKGUhiPcDOayIcZ/wDr1pWjBSoB/H1rnqLQ66DSZ1ulhSyEk5PQqc4/Ouo09UkKYPbuMkg8/wAq4/TGClRjJI/hOK6rS5lBXyyckda8iutT2o6o6K1QEpgY6AgkfhWpBGGj++N3UnGP1rHi2jAJUHAOQeB/n3rQgdgAEOVBwSe1cbA0olzsHAUZUY5/Lt1q9aeVnDhSNvBbuT2z+tZIlQ8IduOueP5/jVqNEcK/UDIz0I9M0AkaVwqfYpzGqoNuDj+E89Py/U1jW2HCCSTaufmZTn8M/StWOdkRQCCR2JAHp+PWm/YIZZnmidYcj/VgArnPPamuxtTmloyKWUxYdY8sRtLsMjHXp3qrDBHcXW0MEXO4jbweeQPxpn2iRT5VxFJGQfmJUkHqD296Ffz1Cou8YxwMDOPboe9O5s1ZaG7NCmGIARfu4yM9ef8A9VV5IAJWO3evQk8+nap0fMESs+HCjJPQ9sflUMhOzehyCcsoHXHapRyO5XRAVHXliTxzTMqFIZWBzg46596sPhwp6AjggnOPp2qG4YK+GCqx5A3cEe/60iWUy+cEHYeh9QPaqspBByoBHQ1JPIdoLEAnuOfxqi8nQKSxHrxn3+lDEZl8jOXwfkQ5GOQPw9Kw9Qj+V+STt6g9D9PrXQlFEvGCCcjI4rBu5BJuLZVgxXLdOvX6YrWmykjkdZHDYwc9MH9D/OuP1BcN0AA967HUwpaRIztAOdrdvb2rlNRRWww4yORzXs4V2PMx0exmxkAAe9eh/DYI+mXpMrI6zfMBjoVXHX3FednAJ6da7/4ZAGG/Pyj96ik/VTn+VdVb4TzEdwjYGNwdc43dPw/+vVy1X5t3JBHA6YqogB56t9at2YUMxGeoHrXEyyZ8diMj36UwyAfxCnP6ZqE7s5Ujnk85oQPQ+fMDJzzSjaaOO+aOPp7V6RmPBUcd/alG33z7Zpg25z14qQYxyOlIaLEWCBjOav24CnuR064/Cs+Bhnv14rRhKkYwc9cisZnVS1N3TnUbck4z1IrqtOlLAKHQL161x1q4VcFWx6rx/k+9dDpOoRIoBjzx97oa8yvC+p7VG7VkdVaupYKjZbGcjgGtCGfkKeVAzuHJPtntWRaSROhZT8nBPOMelaEZVyGLYyBn/wDUa8+S1NDVi4Y5Yc9Ce1XIJCrKDswDyM4z/jWTFNgxmVC2TuyB/n2/zxWtDsdDsAYAduQR61ItiUYbDx5Uj09D1H6itCNxuKuzHHGOmeen1IrOiAi+UjIxxxzn3Pr7VaBVkAlOc8ZXuc+vYUIDQaZDMiuFD55JHUEc/wCfep/Oi4WIrtUHbxjoep9Ov41m2x3ELtBzhlBPI64/Gll1CONwqQoz/d2456/Xg9zTKUXLYknlVZQN31CjpTc7U+VuucleOelK7RyFjsxJnlT1H4fjVW4dc7eAgGBt7H696BLsyy7DaSF25GAPX/AVj6tfpBHghC+3JyeD706W5ZsY7c8jpn3rB1iWFrw+Vl3ZQWB5BzQlqOKV9RU1RLl5I5BiRRx8xAYd/wAanJ+85P13enpgVz0sAdS8aOWJHA7d+a2bVCmnhNxkkA++frkj9cU5JJXQ5xitUEp3tkuQpP3lyOvQVg6sypMgyoJz0zxxzmtl2AQg7gx7H255NYWpmADzHX5unGR706e5Bzl+EMjHsO56cd65a/Ch3x90Nn0rrb5IyCOeFyeB3/p1rmNQVNzBeAeox3r1sOzgxaujAmwJMda7D4Z3Cx6heRMSVljB+hU/4GuRuNoxjt7VveA5AmvLtPzbTwep/Gu+avA8d6M9VQDjgDnjnp/+qrdmcFiM/TrxWfDIr/eXaAeR7/T/AD0q9ZEHdjofQfzrhZZM2N2eQc4PNRc9lJ+pp5YAkjg44qBvK43ZPHYU0DZ4HkE9Dk0EgdOKTjJ/rQCB7DHpXomY4EbsYNSIc+vNRA8jn86lXBIx1qWUiRflP1q7ayAYGOnUVDGqvEO/uKE+Rhxis3qbxvFm/ZujKVbgEYHGcVf06VFAEg7/AIH/AD6Vi2Uqhhg5PHStyKWJbYuUDjdgj1riqqx7GGn1N21kJDLDlscknt/hW3BKNgZkwDjcDxk1zlndxRBY402owGcnP+e9akbHzQzEeo4B46dO1efUTud+r6HR208bAKCFI6j8OKuS3TQwiWDYZDyVHXGMZxWLFh2AOUYY68g/5z1q+q7cspDZ+Yc+tc9rEONmaen6mZJI45mKkck9M+/Fa1qUuHPlsu8dRt7ev05FcvHs2F3RenAz254/z6VcsbiO2meUMSSpVSOhI7EEc8UNXKcE9kdLCB5gJ+YIN3Az165/z61WeAQ38kgKMnIO3Pb39P5VW1OQyW8KxKQxYchv4cZ6/jzmlScopEwyT/D9On8z9aEiUrK5PIQHARVMg746dMGq0txjIccE4AHUe+PwqKS4XGWYsFGdud3Q4xVKedQGcANng88fgKNSJK464nUEgDkn5R0zxWdMrHDRnIIxkDPPvUdzIXkO3qcENnn8qke5AuUhCkA4GRznnn+VFieVvYdBDGowAxOSSeuafhY1A2YCkHPQZqR4nVVwQcj5yBx7/wCfeoJGyoVsAHpxzj/PapYlqVLnYh2jORkg46D1/lWHeMpU5ALDvzya3ZSPmBKlSM/WsudIlVyxIcNtzwOTz+X+FawY1tqcxemMR7ju3DsPy/OsDUwAxBYEA9cdfWun1RI1RiAEy2duM4+tc3qUShQVDE4xgnp7+nNelQZyYlXWhzVzsyQueD3FaPhCVU1613HapOCc4xj61RvQARn7wPIx0pumyCDULaUZLJKrZ49a9PeJ4s1ZntIPJZQevQjA7Zq5aFcOeSM559KpLKrHA5I5xjGKt2eCrYJrhaAnL85OO/AqEsAAAjH6D/69KSNwxgdSe+Kg34/+sf8A64oGeE5GTnFAPHTIo3DnjvzQD3wORXoGdhQw71PGRjkDHXioQ3PuKsxNzyO4+tTIuG5YhwPbPSrLQh1BxkjrTI+m7bV+1PA2gZAyR0Nc8m1qd9KCloytEm3qOPetbT7oKwUhSOnzd6kiiVlHyj0qRbYD5gADjGSa5pzUtGd1OjKGqNCYiSBREhBXkqoHIx1FT2l2yhSD9Dnqfeo7HqB0OeM4FaSqHJV+SecZwQfX271xyaWh305W3NbTbxZCCCoOcAZxitCK4TeQpwR3GMfX+VZdpB5PzCMllOTnHP6UQz72PmYPJBB9cmuZxXQtKMndGubg/NtU4OG+tJH++kWNFAZscZ6cj/8AVVQT7Iw80Y2k4Ldqu2DtNcrtYF24+YcAe/5UrWLtZaG5dyf8S/ZDCRIhHycZ+uf8PWqymURZd2QqpAViOPQ/zq66+ZAyI6KzfxEjg9jWK0r28xSchHXDYHr+PalYxgrqxLKx3kbSVAyAP881UlcqSdi5Df3f6VaFyjAiQoVI5weD/nmq1tO094VyCrITuz931oSuglHS7K8amNCzEZ681f8As8ZZbh1JkGOW7Z7j0pIbWFIxsZnIfrJ6/QelWfM3DaGwuPXrQ30MJPXQgllVsgkN/eBIOffiqrtlGwThD68E1alIRsn5kAxwBx/nmqtxhVBOzI6hjxjPU0muxKZm6jiWKSPeqg/Lnbxj096zrhwoVSCcDqepArRnclznG71PA98/r+VZ93J5RbaMkdCDxk/56+9aw7GieljH1OXzw6KPnQnPTAH0/r+Haud1PKDhQcZ24wBj6GukvlRUKMdqnr0HQdM1zd9IxJCgEHgtnGP8a76HkcmI+E567IIySAfTjiqlu6pPGxGQrAkDHPNXrvkDPOPw5rOY4btXqw1R4lRanstnPHIqvCAFl5QLgjFatm/yscDP8qx9JcGwt3DHlQecZrYtWyrbsc+vWuGSEhzE55GPY/1qP5W5Cyt/1zOBUjEgcDgDAqEsoPJT8cU0DPCx0PGP60ZOehP4UoJ9/bNHr6V3kCg4I4zVmA8D6/lVZeucYPvVmAnripkXDc0YOQAM9OO9aFsWyCBkg+/FZsDfICQfXrWza7gVJGBnPP8ASuSpoenQtJmnZEugUINwI65GavwrlSCuw4HzDJyKrWqyKwO0lRyCT17/AJ/4VtQpuT/VgAjPBxkf5NebUlY9SJUSJlkXjGDjoWxWhA/aSL5sdyc/55qe2TadrDCg+vNJNeBZ9kMPmtkjeTx0HesHLm0saRXM7JGlasHVMgg9DnnNWZLaO5WN9pjkDffXjPtjv0qG3iV8ugIGcMG5K/hWlFBIE3bthAxnH9KxJ2ZDcWsUNq8ozI/3WZhxgnk4qO0Vgw8kbdzE4Bxz7f4GtWVhFbPLOWePIyPr/k/lTIAo8zyVbaxxgeg6CmmzWD0K+xi2SQF7sCePatK0uFu2KXCI0yDuMbx6/wD1qilXf2x3HPI69/xqjK/2aeN4wSAQCB3BP/6qNwklJWLE+kRSjcJmRRkbUHGf/wBXaq0dmlq8jAySOw2EEYA59K1LiQjls5zgAjGOvGapyfK2537enX86Lsxcm1ZshU7QMgkdBzk5qLzUO0gk9yCDmnyFnB+QlQR7cf570gY/cxkdj7dqLeRmIG3KdwCnHpxVV5MYV0Ugg8tnt/n9an85jIybT/u9due/86oXUrrkbG2AHdn3otrsFrlO8AU/IhOTz1wcjHT8BWbPcbnOR8y9AvIHvmtC8lcAuUdl3fw8k8gYH0rKnZjLhtqo33iBg4raCH6mfeOhQBACS2FBzjbk8fSufndlztUgA9CSD7/St+9fzfkVVMWOSBnPH6/59a5/UC5fB3SJjkbiOnv29K76KOau9DFvGxH9zkn1/wA81m5JYk/nV+5Xvk57j29/WqHJY5GRXpw2PEqbnq3he6Nzolk/cRhGA4BI4zXQ2rEIxORg81x/gGVm0Uq2flmOBzxwD/Wuwttxj+7zn61yVFZslCO3JI+8O3rUTMOOg+tSOcZ4wfrTQWI4VQPdqFYGeGc4peRnilbJzxSDIOQPwIruJQqg+mf1qxFnnjvUSg4AAyB2qeEMOgH4/WpZcdy5bg4A/A8Vt6ezBNpA2jnGDWPahhkhfzzWzaM4COATgY571yVj08No7m/bfKQoxgkcc8n1/wDrVfFwsMxiP3lGc/579azLVihXepPPHpWpLbyzqjRkCVM4zxkd+a8yaV9T1I2vqaUUgaPCIzA8nI/nTFgIXcjKzcfLg8571Dbm4Qt+4JZDk5PX/Gr0MyYUAdcjk4/P9K52rbGyVtia1DxuNq88YxzityzdlVXdWTjjJ6n/APV2rKR1AU8MvbI6c9v0q7p4uGeRwp2jlsg4x06/WpFOPMtSa7uZP3iLGSjHjbz17Gq1rc7AixtuYDafz4NXpIxLhWYB1GMDuB/SlEQEZDKjgZJOAPzp2QozSVipNdkAKVTaeuRzUcEnm3cLrGXBP8IPB7dPSrCrDudnjVQc/wCs5/CrMVwpiSNYgCSflBxkfTtSeg3PshzsV2nIYZxwc5FVpCSWVjnPTvT2IO4qcDnr0qs6tuf5Rk+vT/6wpIxsEi5+QhcDn5f8frUQfamQvzAdQOD7Y/rT9rbAxGD1Oehqu75OEGeMEben0pkg0zKwwoy3ULx36Cq8pbhtoOO69BS3LkkZILMvB7D/ADx+VQzSvg5ILjoV54/zmiwWKryFnJBJIGen4YrMv9/lhxlRnIbjj/HpV1ncgsq4zyD6D6fn+dVnOEYyAneeR1+n+NbR0Bo5+YiUEGPYx+9GO47jP9azZi7u/wB5VxhQDjPHTj8eK2biItOzumSxxtLYPtisfUlkBLEEKencnocnvjjrXfS1OarsYOoAhdzx7GPQH/PNZeDnAPTrxWpeB9nUshJIYgj69azOc7h64r0qex41b4jvfAcv+h/Zz1DeYq9c5xnntjmu4t2xETxmuJ8AMTYOFVsq5BI6c9Px6flXaW28xEcjPXjBrlqL3mZoHYgg45xTSSOAFH160PuPY5xz/hTGL5yoUg+9JJDdzxHmgBuRjOeOO9PwR0PH9KmggZ1yOp4AJ646/wD667SURJng1ZQHr0B/nUSKwYKc/n196soCOCfwqZM1gWbcPke9bNiJAyhjwOOKx4twI5IPWtW0Dh8cjJ5we1clXY9Cg7G/bKd4MbHZkY4yRzW1ADIgIGD1z71h2TPvX5sgj16j/Oa37ckKdhCuvc9M15lXc9JMv2jybgj8o2CQx/UUrabPHeSPAFaNskhiBg+mDSWz/Nu29OSP7p9v0rTtiTsIJ6g544/D8q527DjNrYbY2col3ySIViBPXJ9f/r4rTEjN975FPcHt71XjY5x99l5yD1/TpUrMXBDsh3EDHpUvzDmb3JIog6qzsMv1I7+lLc3O392pVuT833SDnqcdsUxSvl/IB1BB9+tUrm2LM7wzMu4ZIPPP8/SmtyotX1C5+ZVxgKCM8c+/HPWlVwSCoIbbgNnPH0pkMEynNzMpU9ADzketVpTd+c+zZ5ZO4NnjHr607XK5lcs3V+8KBQqSS5GMDINF7K6KGQhmOMn04qlCk28vKVCbSQoPXOOv6VJ5jBHJ555GR/KhImTV9Bkk1z58WzcU2c7h8o/HpmmzzMX+ZyvGMD/PSkDMwIPyZ56/jVabc7LtyCfQ/e9/509yW7kkhYguhBJ/iP8AOq7lugJOcA84xUsqORguA2364qhc71k+eQ+QzfMBwe3SmlcSEdZPLLKq7iMHpx7fhVKd5QFj2u5HPA5H4emKueYWUbCCuc56DI+n1qpO7GFpZW+TcckfeA9R9a1ihtmZdfv9xVvmGODjr7f41k3l66hiyjax25KE+3B6EfSte73bC0iMm3jIIAP+B757VhXczICfMIbGCpOT9Bn+ldtFXOOtLlRhXwkDPu2gk/dH8PtVA52jI5NXr6R2BYkBj/dPSqgBIwuPSvShsePN+8d/4DBSxuF27CXBx6naK7GAHyjxnsfrXO+GLY21gjFyJHAYdmrooQwhwWzx+GK5JvVszQxySR06/r3qNt5PCg/U09t2clvc9Of88VE7sD97H4UIdzxwRbmUN0PJx6e1alupCtuAA+7tAzvP8KAdx7dO5zwKgaBkKkljlemP88/41ftIN8hLMFSBWMhU9AMFyPc5CjHYV0yeg4rUZLZiSImUjecsCrBtvr9SScfn7GqJjkhfZMNpyAD2P0NbEDtJEhCLvdgI4VJIOOOvoBke5JPYVa+zeen2fPmhsyPxwuSMYPbJHX+6tZ89tGaLyMqFGIHX04q9ao67CDk9gD1qCSwkgzJbs01upHB++OcDjv34HPrV2zZZ1wHCEAnqfpjFZ1HpdHZQkm7GhaOXfcWJA6kHJrbtGliBYHMeAMelYiQvG4cEAexNa1tGXXcr5B/hya4KiTPSi+hvWTkvkuBkDhhj1x0rSgVTJhHVAeuX4xWJaRu2T1Bxghj/AC/pVuF5IWK9ecDHXj/PSuRoo2NjouGY7gfUgn8PpUe+RhwwUZI59fT2NRRSySMTlQBxyetAYgDY2c9STn360gJI8553DGQVx19Men0oRyUKqQPXJHB+v51FlnA3xgc55brTRmMnDMVOeMnP4U0O4/5+RuAXvlskj/D/AAqOYOHUBsjGDjnH+NMebJBGe5OOe3NQtIWDjkcDpmhIGybLo/PzegyDxTQ7YPJHBCj1/wA5qtI2UO2VhjOB6g+9RO0hyDkKBkYPNCiK9yxIzLEEGd2c5z09qgeUom4Jliu3tn/61VWmfCkE5yeCf/rUGWSR2LON2OQD/wDWq+VoRIk+45YkZB4Yj/PNQyt5kzAKxA4we3H+eaQowdtzAKM455GO2KjcyupK7Qq8AYxkU+XsFxHZlTylyQRzjmqc7gshieOMg4Xecnp/hViTcseJGAUAkgZz+P8A9as6XKJmIRqOuXPU4zxmtYRJcindiTPzJkL820cED65x+BrHvwyhg2cngZByfUD2q1fCTDKBCEyTnecHPXnHP19qyp49gJJYHpnOa76UDz61TdIz7sBW4PfuaXTLR7q7WMEAAZJ9qZKBwBj1rb8JWAnvA7pvC4IU8A+nP1HT2rsbtE82T1O+tl8uKMBVTAACBsnH1rQQN5OSeKpQxlEwG49auKpEY5+X1BrkZKYxyeTxj1pj8HG/GP8AaxTn3K2e38qgcEEfMvT604oGf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticaria is characterized by circumscribed, raised, erythematous, and extremely pruritic lesions. They typically appear in one area, resolve over the course of several hours, and then reappear elsewhere. Individual lesions may enlarge and develop central pallor before fading.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Very large erythematous annular lesion of the shoulder with central clearing. This patient had several large lesions of this type which could be confused with erythema migrans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11380=[""].join("\n");
var outline_f11_7_11380=null;
var title_f11_7_11381="Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Pediatric drug information";
var content_f11_7_11381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26181?source=see_link\">",
"    see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/59/5044?source=see_link\">",
"    see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F744563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naglazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1015974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Enzyme",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1015996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26181?source=see_link\">",
"      see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with antihistamines with or without antipyretics 30-60 minutes prior to infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      MPS VI:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: Limited data available: I.V: 1 or 2 mg/kg/dose once weekly has been used in four infants (3-12 months); similar safety results to those of older patients were reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children, Adolescents, and Adults: I.V.: 1 mg/kg/dose once weekly",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F744597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naglazyme&reg;: 5 mg/5 mL (5 mL) [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F744565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1015999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Parenteral: I.V.: Without the use of a filter needle, slowly withdraw calculated dose from vial and dilute in NS to a final volume of 250 mL or 100 mL (if patient weight &lt;20 kg); do not shake. Infuse via an infusion pump via in-line, low-protein-binding 0.2 micrometer filter over at least 4 hours. Infuse 250 mL solution at 6 mL/hour for the first hour; if well-tolerated, increase rate to 80 mL/hour for the remaining 3 hours. For 100 mL infusion, use a lower rate to ensure infusion over at least 4 hours. Infusion time may be extended up to 20 hours if infusion reactions occur. If hypersensitivity or infusion-related reaction occurs, discontinue immediately. pH: 5.8",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1015991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Stable in NS",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1015988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not shake or freeze; protect from light. Allow vials to reach room temperature prior to dilution; however, do not keep vials at room temperature longer than 24 hours. Following dilution, administer immediately. May store diluted solution under refrigeration; storage after dilution should not exceed 48 hours from the time of preparation to completion of infusion. Room temperature storage of diluted preparation is not recommended except during infusion. Do not infuse with other medication products.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1015975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Treatment of mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) for improvement of walking and stair-climbing capacity [FDA approved in pediatric patients (age not specified) and adults &le;29 years]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F744581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Angioedema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, gastroenteritis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, areflexia",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis, corneal opacification increased",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear pain, hearing impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Dyspnea, pharyngitis, nasal congestion, laryngeal edema",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Antigalsulfase antibodies, infusion reactions, umbilical hernia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, bradycardia, bronchospasm, cyanosis, erythema, hypotension, hypoxia, membranous nephropathy, pallor, paresthesia, respiratory failure, shock, tachycardia, tachypnea, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1015980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to galsulfase or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F11253112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with compromised respiratory function or acute respiratory disease; there may be a higher risk of serious complications from infusion reactions. Use with caution in patients who are at risk of fluid overload; may cause heart failure; patients particularly at risk include those with weight &lt;20 kg, underlying respiratory disease, or compromised cardiopulmonary function; monitor patients closely including prolonged observation times postinfusion. Use with caution in patients with sleep apnea; antihistamine pretreatment may increase the risk of apneic episodes; consider use of nonsedating antihistamine and have apneic treatment options (supplemental oxygen, CPAP) readily available. Consider delaying the galsulfase infusion in patients with febrile illness or with acute respiratory illness.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1015981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions, including anaphylactic reactions and anaphylactic shock, have been reported during and within 24 hours after infusion; immediate treatment for hypersensitivity reactions should be available during administration; discontinue treatment immediately if signs or symptoms occur; use caution with readministration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune-mediated reactions (Type III) have been reported (including membranous glomerulonephritis); monitor patients closely and consider discontinuation of treatment if signs or symptoms occur; use caution with readministration; in some cases rechallenge with treatment has been successful.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Infusion-related reactions including angioneurotic edema, hypotension, dyspnea, bronchospasm, respiratory distress, apnea, urticaria, fever, chills, rigors, headache, rash, nausea, vomiting, increased blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain have been reported and may be severe; reactions may occur as late as week 146 of treatment. Predisposing factors for infusion-related reactions have not been identified. Patients should be premedicated with antihistamines with or without antipyretics 30-60 minutes prior to start of the infusion; evaluate airway prior to therapy (due to possible effects of antihistamine use). Despite pretreatment, infusion-related reactions have been reported in up to 56% of patients (ie, 33 of 59 pretreated patients); and 70% experienced recurrent reactions during multiple infusions although not necessarily consecutive treatments. In case of reaction, decrease the rate of infusion, temporarily discontinue the infusion, and/or administer additional antihistamines, antipyretics, and possibly corticosteroids. In patients who experience an infusion-related reaction, subsequent doses may be managed by using a lower infusion rate. For severe reactions, the risks and benefits of readministering should be evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F744571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Fetal harm was not reported in animal studies. There are no studies in pregnant women. Pregnant women are encouraged to enroll in the Clinical Surveillance Program.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1016001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Vital signs; presence of infusion-related reactions (chills, pruritis, urticaria, dyspnea, rash, shortness of breath, nausea, abdominal pain); in clinical studies, tests of mobility and physical function were monitored at baseline and every 6 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1015992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Galsulfase is a recombinant enzyme produced in Chinese hamster cells, which provides exogenous N-acetylgalactosamine 4-sulfatase [arylsulfatase B (ASB)] to patients with mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome); deficiency of this enzyme leads to accumulation of the glycosaminoglycan dermatan sulfate in various tissues, causing progressive disease which includes decreased growth, skeletal deformities, upper airway obstruction, clouding of the cornea, heart disease, and coarse facial features.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1015994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Data based on mixed patient population of children &ge;5 years and adults &lt;29 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Week 1: Median: 9 minutes (range: 6-21 minutes); Week 24: Median: 26 minutes (range: 8-40 minutes)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F11253858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/59/5044?source=see_link\">",
"      see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report immediately any swelling of face, tongue, or lips; difficulty swallowing; difficulty breathing; chills; rash that occurs during infusion; or any redness, burning, or swelling at infusion site. Inform prescriber if you experience nausea, vomiting, or diarrhea; headache; pain in joints or muscles; ear pain; cough; or other adverse reactions between infusions.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1016002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     In order to better understand MPS VI disease progression and to monitor long-term effects of galsulfase, a voluntary Clinical Surveillance Program has been established. Monitoring also includes the effect of galsulfase on pregnant women and their offspring, and during lactation. For more information, visit www.naglazyme.com/en/clinical-resources/surveillance-program.aspx or call (800) 983-4587.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11381/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11381/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Medicines Agency, Nalgazyme Product Information. Available at file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000640/WC500024289.pdf. Date accessed: May 23, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giugliani R, Harmatz P, and Wraith JE, \"Management Guidelines for Mucopolysaccharidosis VI,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(2):405-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11381/abstract-text/17671068/pubmed\" id=\"17671068\" target=\"_blank\">",
"        17671068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmatz P, Giugliani R, Schwartz IV, et al, \"Long-Term Follow-Up of Endurance and Safety Outcomes During Enzyme Replacement Therapy for Mucopolysaccharidosis VI: Final Results of Three Clinical Studies of Recombinant Human N-Acetylgalactosamine 4-Sulfatase,\"",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2008, 94(4):469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11381/abstract-text/18502162/pubmed\" id=\"18502162\" target=\"_blank\">",
"        18502162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmatz P, Ketteridge D, Giugliani R, et al, \"Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(6):e681-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11381/abstract-text/15930196/pubmed\" id=\"15930196\" target=\"_blank\">",
"        15930196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmatz P, Whitley CB, Waber L, et al, \"Enzyme Replacement Therapy in Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome),\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 144:574-80.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hendriksz CJ, Giugliani R, Harmatz P, et al, \"Design, Baseline Characteristics, and Early Findings of the MPS VI (Mucopolysaccharidosis VI) Clinical Surveillance Program (CSP),\"",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11381/abstract-text/22127392/pubmed\" id=\"22127392\" target=\"_blank\">",
"        22127392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16064 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11381=[""].join("\n");
var outline_f11_7_11381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744563\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015974\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015996\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744597\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744565\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015999\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015991\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015988\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015975\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744581\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015980\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11253112\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015981\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299385\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220567\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744571\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744572\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016001\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015992\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015994\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11253858\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016002\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16064|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26181?source=related_link\">",
"      Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/59/5044?source=related_link\">",
"      Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_7_11382="Probenecid: Pediatric drug information";
var content_f11_7_11382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Probenecid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"    see \"Probenecid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36756?source=see_link\">",
"    see \"Probenecid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benuryl&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adjuvant Therapy, Penicillin Level Prolongation",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antigout Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Uric Acid Lowering Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Uricosuric Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"      see \"Probenecid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prolongation of penicillin serum levels:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dosing per manufacturer; some indication-specific dosing may vary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &le;50 kg: Oral: Initial: 25 mg/kg/dose or 700 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose as a single dose; maintenance: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 1200 mg /",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      /day",
"     </b>",
"     in 4 divided doses; maximum dose: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &gt;50 kg: Oral: 500 mg 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gonorrhea, uncomplicated infections of cervix, urethra, and rectum:",
"     </b>",
"     Adolescents &gt;45 kg: Oral: 1000 mg as a single dose with cefoxitin (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     Adolescents &gt;50 kg: 1000 mg as a single dose with cefoxitin in combination with doxycycline with/without metronidazole (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Neurosyphilis:",
"     </b>",
"     Adolescents &gt;50 kg: Oral: 500 mg 4 times daily with procaine penicillin for 10-14 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of cidofovir nephrotoxicity:",
"     </b>",
"     Limited data available; various regimens have been reported (Anderson, 2008; Bhadri, 2009; Cesaro, 2005; Doan, 2007; Williams, 2009): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-directed dosing:  25-40 mg/kg/dose (maximum dose: 2000 mg) administered 3 hours before cidofovir infusion and 10-20 mg/kg/dose (maximum dose: 1000 mg) at 2-3 hours and 8-9 hours after cidofovir infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Body surface area (BSA)-directed dosing: 1000-2000 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose administered 3 hours prior to cidofovir, followed by 500-1250 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose 1-2 hours and 8 hours after completion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gonorrhea, uncomplicated infections of cervix, urethra, and rectum:",
"     </b>",
"     Oral: 1000 mg as a single dose with cefoxitin (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hyperuricemia with gout:",
"     </b>",
"     Oral: Initial: 250 mg twice daily for 1 week; may increase to 500 mg twice daily; if needed, may increase in 500 mg increments every 4 weeks; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"     . If serum uric acid levels are within normal limits and gout attacks have been absent for 6 months, daily dosage may be reduced by 500 mg increments every 6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prolongation of penicillin serum levels:",
"     </b>",
"     Oral:   500 mg 4 times daily;",
"     <b>",
"      Note:",
"     </b>",
"     Dosing per manufacturer, some indication-specific dosing may vary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or antacids to minimize GI effects",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15674208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjuvant to therapy with penicillins to prolong serum concentrations (FDA approved in ages &ge;2 years and adults); treatment of hyperuricemia associated with gout and gouty arthritis (FDA approved in adults); has also been used with cephalosporin therapy to prolong serum concentrations and to prevent nephrotoxicity associated with cidofovir therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Probenecid may be confused with Procanbid",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dyspepsia, gastroesophageal reflux, nausea, sore gums, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, aplastic anemia, hemolytic anemia (in G6PD deficiency), leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Costovertebral pain, gouty arthritis (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotic syndrome, renal colic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to probenecid or any component; pediatric patients &lt;2 years of age; individuals with blood dyscrasias or uric acid kidney stones; initiation during an acute gout attack; concurrent aspirin therapy (regardless of dose)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage requirements may be increased; monotherapy may not be effective if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute; concurrent use with penicillin in patients with renal insufficiency is not recommended. Use with caution in patients with peptic ulcer disease. In gouty patients, probenecid may cause  hematuria, renal colic, costovertebral pain, and development of uric acid stones; may be prevented by liberal fluid intake and alkalinization of urine. Use caution in patients with G6PD deficiency; may increase risk for hemolytic anemia.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3948934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salicylates may diminish the therapeutic effect of probenecid; this effect may be more pronounced with high, chronic doses; however, the manufacturer recommends the use of an alternative analgesic even in place of small doses of aspirin; probenecid may increase the half-life of acetaminophen and some NSAIDS (eg, ketoprofen, naproxen); consider dosage reductions. Probenecid may increase the serum concentration of methotrexate; avoid concomitant use of probenecid and methotrexate if possible; if concurrent use necessary, consider lower methotrexate doses and monitor for methotrexate toxicity. Therapy with probenecid should not be initiated until an acute gouty attack has subsided; may cause exacerbation of acute gouty attack; if an acute attack occurs during probenecid therapy, usage may continue but other appropriate agents (eg, colchicine) should be used to control the acute attack; the frequency of acute gouty attacks may increase during the first 6-12 months of therapy. Use has been associated with rare, severe hypersensitivity reactions, including anaphylaxis; discontinue therapy if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), UGT1A6",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefotaxime: Probenecid may increase the serum concentration of Cefotaxime.  Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid.  Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins: Probenecid may increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Probenecid may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doripenem: Probenecid may increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ertapenem: Probenecid may increase the serum concentration of Ertapenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Probenecid may increase the serum concentration of Ganciclovir-Valganciclovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemifloxacin: Probenecid may decrease the excretion of Gemifloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: Probenecid may increase the serum concentration of Imipenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoprofen: Probenecid may increase the serum concentration of Ketoprofen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): Probenecid may increase the serum concentration of Ketorolac (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): Probenecid may increase the serum concentration of Ketorolac (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Probenecid may enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.  Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LORazepam: Probenecid may increase the serum concentration of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meropenem: Probenecid may increase the serum concentration of Meropenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Probenecid may increase the serum concentration of Methotrexate.  Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Probenecid may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: Probenecid may increase the serum concentration of Nitrofurantoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oseltamivir: Probenecid may increase serum concentrations of the active metabolite(s) of Oseltamivir.  Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: Probenecid may enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Probenecid may increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Probenecid may increase the serum concentration of PRALAtrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Probenecid may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Benzoate: Probenecid may increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phenylacetate: Probenecid may increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Probenecid may decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Probenecid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aminophylline; Theophylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Probenecid may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13108713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Probenecid crosses the placenta; adverse fetal events have not been reported.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uric acid, renal function, CBC",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels; increases plasma levels of weak organic acids (penicillins, cephalosporins, or other beta-lactam antibiotics) by competitively inhibiting their renal tubular secretion",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Penicillin concentrations: After 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Uric acid renal clearance: 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36756?source=see_link\">",
"      see \"Probenecid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause GI upset; take with food. Drink plenty of fluids to reduce the risk of uric acid stones. The frequency of acute gouty attacks may increase during the first 6-12 months of therapy; do not start during a gout flare; after starting therapy, continue medication if a flare occurs. Avoid taking large doses of aspirin or other salicylates; avoid alcohol.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al, \"High-Risk Adenovirus-Infected Pediatric Allogeneic Hematopoietic Progenitor Cell Transplant Recipients and Preemptive Cidofovir Therapy,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2008, 12(2):219-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11382/abstract-text/18307672/pubmed\" id=\"18307672\" target=\"_blank\">",
"        18307672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhadri VA, Lee-Horn L, and Shaw PJ, \"Safety and Tolerability of Cidofovir in High-Risk Pediatric Patients,\"",
"      <i>",
"       Transpl Infect Dis",
"      </i>",
"      , 2009, 11(4):373-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11382/abstract-text/19392729/pubmed\" id=\"19392729\" target=\"_blank\">",
"        19392729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11382/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cesaro S, Zhou X, Manzardo C, et al, \"Cidofovir for Cytomegalovirus Reactivation in Pediatric Patients After Hematopoietic Stem Cell Transplantation,\"",
"      <i>",
"       J Clin Virol",
"      </i>",
"      , 2005, 34(2):129-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11382/abstract-text/16157264/pubmed\" id=\"16157264\" target=\"_blank\">",
"        16157264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doan ML, Mallory GB, Kaplan SL, et al, \"Treatment of Adenovirus Pneumonia With Cidofovir in Pediatric Lung Transplant Recipients,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2007, 26(9):883-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11382/abstract-text/17845926/pubmed\" id=\"17845926\" target=\"_blank\">",
"        17845926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams KM, Agwu AL, Dabb AA, et al, \"A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral infection,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2009, 31(11):825-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11382/abstract-text/19801951/pubmed\" id=\"19801951\" target=\"_blank\">",
"        19801951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12730 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11382=[""].join("\n");
var outline_f11_7_11382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213409\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061363\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061356\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213388\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213373\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061366\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15674208\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061365\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213449\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213447\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061370\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061355\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3948934\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213438\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213382\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108713\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061362\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061354\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061368\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061369\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061361\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12730\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12730|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=related_link\">",
"      Probenecid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36756?source=related_link\">",
"      Probenecid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_7_11383="Clonazepam: Pediatric drug information";
var content_f11_7_11383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clonazepam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"    see \"Clonazepam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22197?source=see_link\">",
"    see \"Clonazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      KlonoPIN&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clonazepam&reg;;",
"     </li>",
"     <li>",
"      Clonapam;",
"     </li>",
"     <li>",
"      Clonazepam-R;",
"     </li>",
"     <li>",
"      CO Clonazepam;",
"     </li>",
"     <li>",
"      Dom-Clonazepam;",
"     </li>",
"     <li>",
"      Dom-Clonazepam-R;",
"     </li>",
"     <li>",
"      Mylan-Clonazepam;",
"     </li>",
"     <li>",
"      Novo-Clonazepam;",
"     </li>",
"     <li>",
"      PHL-Clonazepam;",
"     </li>",
"     <li>",
"      PHL-Clonazepam-R;",
"     </li>",
"     <li>",
"      PMS-Clonazepam;",
"     </li>",
"     <li>",
"      PRO-Clonazepam;",
"     </li>",
"     <li>",
"      ratio-Clonazepam;",
"     </li>",
"     <li>",
"      Riva-Clonazepam;",
"     </li>",
"     <li>",
"      Rivotril&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Clonazepam;",
"     </li>",
"     <li>",
"      ZYM-Clonazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"      see \"Clonazepam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Seizure disorders:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;10 years or 30 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial daily dose: 0.01-0.03 mg/kg/day (maximum initial dose: 0.05 mg/kg/day) given in 2-3 divided doses; increase by no more than 0.5 mg every third day until seizures are controlled or adverse effects seen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 0.1-0.2 mg/kg/day divided 3 times/day; not to exceed 0.2 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;10 years (&gt;30 kg) and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial daily dose not to exceed 1.5 mg given in 3 divided doses; may increase by 0.5-1 mg every third day until seizures are controlled or adverse effects seen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 0.05-0.2 mg/kg/day; do not exceed 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Panic disorder: Adolescents &ge;18 years and Adults: Initial: 0.25 mg twice daily; increase in increments of 0.125-0.25 mg twice daily every 3 days; target dose: 1 mg/day; maximum dose: 4 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     KlonoPIN&reg;: 0.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     KlonoPIN&reg;: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F153428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10815684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225680.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225680.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food or water to decrease GI distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally-disintegrating tablet: Open pouch and peel back foil on the blister; do not push tablet through foil. Use dry hands to remove tablet and place in mouth. May be swallowed with or without water. Use immediately after removing from package.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 80&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alone or as an adjunct in the treatment of absence (petit mal), petit mal variant (Lennox-Gastaut), infantile spasms, akinetic, and myoclonic seizures; panic disorder with or without agoraphobia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ClonazePAM may be confused with cloBAZam, cloNIDine, clorazepate, cloZAPine, LORazepam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       KlonoPIN&reg; may be confused with cloNIDine, clorazepate, cloZAPine, LORazepam",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F153433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions reported in patients with seizure and/or panic disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema (ankle or facial), palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, ataxia, behavior problems, coma, confusion, coordination impaired, depression, dizziness, drowsiness, emotional lability, fatigue, fever, hallucinations, headache, hysteria, insomnia, intellectual ability reduced, memory disturbance, nervousness; paradoxical reactions (including aggressive behavior, agitation, anxiety, excitability, hostility, irritability, nervousness, nightmares, sleep disturbance, vivid dreams); psychosis, slurred speech, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hair loss, hirsutism, skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, libido increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased/decreased, coated tongue, constipation, dehydration, diarrhea, encopresis, gastritis, gum soreness, nausea, weight changes (loss/gain), xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Colpitis, dysuria, ejaculation delayed, enuresis, impotence, micturition frequency, nocturia, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, eosinophilia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (transient), hepatomegaly, transaminases increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Choreiform movements, coordination abnormal, dysarthria, hypotonia, muscle pain, muscle weakness, myalgia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, eye movements abnormal, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, chest congestion, cough, hypersecretions, pharyngitis, respiratory depression, respiratory tract infection, rhinitis, rhinorrhea, shortness of breath, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, aphonia, dysdiadochokinesis, &ldquo;glassy-eyed&rdquo; appearance, hemiparesis, flu-like syndrome,  lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Apathy, burning skin, chest pain, depersonalization, dyspnea, excessive dreaming, hyperactivity, hypoesthesia, hypotension postural, infection, migraine, organic disinhibition, pain, paresthesia, paresis, periorbital edema, polyuria, suicidal attempt, suicide ideation, thick tongue, twitching, visual disturbance, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clonazepam, any component, or other benzodiazepines; severe liver disease, acute narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with chronic respiratory disease, hepatic disease, or impaired renal function; abrupt discontinuance may precipitate withdrawal symptoms, status epilepticus or seizures (withdraw gradually when discontinuing therapy); worsening of seizures may occur when clonazepam is added to patients with multiple seizure types",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7802664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clonazepam was shown to be teratogenic in some animal studies. Clonazepam crosses the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. Epilepsy itself, the number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines, including clonazepam.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to clonazepam during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of suicidality (eg, anxiety, depression, behavior changes). Long-term use: CBC with differential, platelets, liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relationship between serum concentration and seizure control is not well established; measurement at random times postdose may contribute to this problem; predose concentrations are recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proposed therapeutic levels: 20-80 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic concentration: &gt;80 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex; depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and young children: Up to 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Up to 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.5-4.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized in the liver; undergoes nitroreduction to 7-aminoclonazepam, followed by acetylation to 7-acetamidoclonazepam; nitroreduction and acetylation are via cytochrome P450 enzyme system; metabolites undergo glucuronide and sulfate conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 22-33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Usual: 30-40 hours; range: 19-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites excreted as glucuronide or sulfate conjugates; &lt;2% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22197?source=see_link\">",
"      see \"Clonazepam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use (withdrawal symptoms or an increase in seizure activity may occur). May cause dry mouth. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Report excessive drowsiness, CNS changes (eg, confusion, depression, headache) or changes in cognition; respiratory difficulty or shortness of breath; muscle tremors; visual disturbances; excessive GI symptoms (constipation, vomiting, anorexia); worsening of seizure activity, or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethosuximide or valproic acid may be preferred for treatment of absence (petit mal) seizures. Clonazepam-induced behavioral disturbances may be more frequent in mentally handicapped patients. When discontinuing therapy in children, the clonazepam dose may be safely reduced by &le;0.04 mg/kg/week and discontinued when the daily dose is &le;0.04 mg/kg/day. When discontinuing therapy in adults treated for panic disorder, the clonazepam dose may be decreased by 0.125 mg twice daily every 3 days, until the drug is completely withdrawn. Treatment of panic disorder for &gt;9 weeks has not been studied; long-term usefulness of clonazepam for the treatment of panic disorder should be re-evaluated periodically.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F153360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.1 mg/mL oral suspension may be made with tablets and one of three different vehicles (cherry syrup; a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush six 2 mg tablets in a mortar and reduce to a fine powder. Add 10 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 60 days when stored in amber prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,\" Am",
"     <i>",
"      J Health Syst Pharm",
"     </i>",
"     , 1996, 53(16):1944-9.",
"     <span class=\"pubmed-id\">",
"      8862208",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sugai K, &ldquo;Seizures With Clonazepam: Discontinuation and Suggestions for Safe Discontinuation Rates in Children,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1993, 34(6):1089-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11383/abstract-text/8243361/pubmed\" id=\"8243361\" target=\"_blank\">",
"        8243361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walson PD and Edge JH, &ldquo;Clonazepam Disposition in Pediatric Patients,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1996, 18(1):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/7/11383/abstract-text/8848810/pubmed\" id=\"8848810\" target=\"_blank\">",
"        8848810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13170 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11383=[""].join("\n");
var outline_f11_7_11383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051776\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051769\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153353\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153338\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153428\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10815684\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051782\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051772\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051781\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153435\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153433\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051787\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051768\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7802664\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153421\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153347\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153348\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153366\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051775\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051780\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051767\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051785\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051786\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051774\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051788\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153360\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13170\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13170|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=related_link\">",
"      Clonazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22197?source=related_link\">",
"      Clonazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_7_11384="Adjuvant medical therapy for HER2-positive breast cancer";
var content_f11_7_11384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant medical therapy for HER2-positive breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11384/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11384/contributors\">",
"     Harold Burstein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11384/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11384/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/7/11384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1352263895\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females. In the United States, breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 49 years. The lifetime probability of developing invasive breast cancer is one in eight.",
"   </p>",
"   <p>",
"    Breast cancer is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behavior. Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene is present in approximately 18 to 20 percent of primary invasive breast cancers. Women with early stage breast cancer that meet criteria for HER2 positivity are treated with chemotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    as adjuvant treatment.",
"   </p>",
"   <p>",
"    This topic review will cover the use of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus chemotherapy in patients with HER2-positive early stage breast cancer (stage I to III (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )). Principles of testing for HER2 expression on breast cancer tumor tissue is discussed elsewhere, as is adjuvant chemotherapy in other populations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"       \"HER2 and predicting response to therapy in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"       \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17650?source=see_link&amp;anchor=H12702676#H12702676\">",
"       \"Treatment protocols for breast cancer\", section on 'Regimens for HER2-positive breast cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7901849\">",
"    <span class=\"h1\">",
"     PATIENT ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All newly diagnosed breast cancers are tested for HER2 overexpression because HER2-directed therapy is a critical component of the adjuvant treatment of HER2 positive breast cancer. Testing algorithms for tumor HER2 status were developed by a joint consensus panel convened by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) (",
"    <a class=\"graphic graphic_table graphicRef75536 \" href=\"UTD.htm?6/56/7054\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are eligible for adjuvant HER2-directed treatment if they have HER2-positive breast cancer defined as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunohistochemical (IHC) stain of 3+, defined as uniform intense membrane staining for HER2 in 30 percent or more of tumor cells, or",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       HER2/CEP17",
"      </span>",
"      (chromosome enumeration probe 17) fluorescent in situ hybridization (FISH) amplification ratio &ge; 2.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations from the joint panel regarding optimal performance, interpretation, and reporting of individual assays are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link&amp;anchor=H6#H6\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Assays for HER2 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the trials establishing the benefit of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    limited eligibility to women with either node-positive or node-negative high-risk breast cancer (usually defined as tumor size &gt;1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] or &gt;2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/6\">",
"     6",
"    </a>",
"    ]). However, at least three studies from the pre-trastuzumab era suggest a higher risk of recurrence for patients with HER2-positive node-negative tumors &le;1 cm compared to those with HER2-negative tumors of the same size [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 2026 women with node-negative disease who underwent tissue microarray, 206 women (10 percent) were HER2-positive [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/9\">",
"       9",
"      </a>",
"      ]. Ten percent of the HER2-positive group and 17 percent in the HER2-negative group had a tumor size &lt;10 mm. The majority of women in this subset (82 percent) did not receive chemotherapy. Although there was a trend towards worse relapse-free survival in women with HER2-positive disease, there was no difference in breast cancer specific survival.",
"     </li>",
"     <li>",
"      In another study of 965 patients with T1a (&gt;1 mm but &le;5 mm) or T1b (&gt;5 mm but &le;10 mm) (",
"      <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"       table 1",
"      </a>",
"      ) node-negative breast cancer, those with HER2-positive tumors had significantly worse five-year rates of recurrence-free survival (77 versus 94 percent) and distant recurrence-free survival (86 versus 97 percent) when compared with HER2-negative disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/8\">",
"       8",
"      </a>",
"      ]. In this cohort, 86 percent of the women had hormone receptor-positive tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the benefit of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in women with tumors &le;1 cm has not been directly addressed in clinical trials, it is widely believed that trastuzumab and chemotherapy would lower the recurrence risk by approximately 50 percent compared to baseline. Most clinicians feel these benefits outweigh the risk of side effects and administer trastuzumab plus chemotherapy to this group of patients. We agree with the guidelines from the National Comprehensive Cancer Network (NCCN) that suggest trastuzumab and chemotherapy be used for women with HER2-positive node-negative tumors measuring 0.6 to 1.0 cm (ie, T1b) and for smaller tumors that have &le;2 mm axillary node metastases (pN1mi) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517953067\">",
"    <span class=\"h1\">",
"     HER2-DIRECTED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are candidates for adjuvant HER2-based therapy, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . Trastuzumab is the only HER2-directed agent to result in a survival benefit when administered (with chemotherapy) in the adjuvant treatment. The administration of other HER2-directed agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"     ado-trastuzumab emtansine",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00490139\">",
"     lapatinib",
"    </a>",
"    , and",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT01358877\">",
"     pertuzumab",
"    </a>",
"    in the adjuvant setting is being evaluated on clinical trials. (See",
"    <a class=\"local\" href=\"#H517953427\">",
"     'Trastuzumab-based therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H330927470\">",
"     'Lapatinib'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    requires IV infusion, a 2012 clinical trial suggests that a subcutaneous (SQ) formulation may be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/12\">",
"     12",
"    </a>",
"    ]. If validated, this would represent a more convenient modality of treatment for patients, particularly in the maintenance setting. However, the SQ formulation is not available and its use requires further evaluation before being adopted in clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link&amp;anchor=H541773077#H541773077\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\", section on 'HER2-directed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517953645\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend adjuvant chemotherapy plus HER2-directed treatment for all women with HER2-positive, node-positive breast cancer and for women with HER2-positive, node-negative tumors &gt;1 cm in size. We also suggest adjuvant chemotherapy plus HER2-directed therapy in women with HER2-positive breast cancers smaller than 1.0 cm (ie, T1a or T1b) with no nodal involvement.",
"   </p>",
"   <p>",
"    We suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    be administered concomitantly with chemotherapy rather than sequentially. Following completion of chemotherapy plus trastuzumab, we recommend trastuzumab as a single agent (ie, maintenance treatment) for a total treatment duration of 52 weeks. (See",
"    <a class=\"local\" href=\"#H361579099\">",
"     'Choice of chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no data to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus endocrine therapy (instead of chemotherapy) for women with ER-positive, HER2-positive breast cancer, and we consider this approach investigational. We recommend endocrine therapy concurrently with trastuzumab during maintenance treatment (following completion of adjuvant chemotherapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H659778#H659778\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Patients with HER2-positive tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517953427\">",
"    <span class=\"h1\">",
"     TRASTUZUMAB-BASED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to adjuvant chemotherapy in patients with HER2-positive tumors was confirmed in a 2012 meta-analysis of eight trials of chemotherapy plus trastuzumab versus chemotherapy alone involving nearly 12,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in disease-free survival (DFS, hazard ratio [HR] for recurrence 0.60, 95% CI 0.50-0.71), regardless of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      treatment duration or the administration schedule (ie, concurrent with chemotherapy or sequentially following chemotherapy).",
"     </li>",
"     <li>",
"      Improvement in overall survival (OS, HR for mortality 0.66, 95% CI 0.57-0.77).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      administered for 12 months in the adjuvant setting was associated with an improvement in OS (HR 0.67, 95% CI 0.57-0.80). While trastuzumab treatment for &le;6 months also showed a trend towards an improvement in OS, it did not reach statistical significance (HR 0.55, 95% CI 0.27-1.11).",
"     </li>",
"     <li>",
"      The benefit in OS was associated with concurrent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      with chemotherapy (HR 0.64, 95% CI 0.53-0.76) but not with sequential treatment of chemotherapy followed by single agent trastuzumab (HR 0.85, 95% CI 0.43-1.67).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the survival benefits, adjuvant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    appears to also increase the risks of cardiac toxicities, including congestive heart failure and left ventricular ejection fraction declines. These risks and monitoring for cardiac function for patients on trastuzumab are discussed in detail below (see",
"    <a class=\"local\" href=\"#H2718616\">",
"     'Assessing risks and benefits of treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133979075\">",
"    <span class=\"h2\">",
"     Treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 meta-analysis discussed above supports the use of one year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    treatment given with adjuvant chemotherapy rather than for shorter periods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Results from two studies presented at the 2012 European Society of Medical Oncology (ESMO) meeting appear to confirm this recommendation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Herceptin Adjuvant (HERA) trial, 5090 women with HER2-positive breast cancer who had completed adjuvant chemotherapy were randomly assigned to observation or to the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for one or two years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/4,15-17\">",
"       4,15-17",
"      </a>",
"      ]. With eight years follow-up, there was no difference in disease-free survival between women treated with one versus two years of trastuzumab (76 percent in both arms) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/17\">",
"       17",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In the PHARE trial, 3380 women were randomly assigned to treatment with 6 or 12 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/18\">",
"       18",
"      </a>",
"      ]. As presented, with a median follow-up of 43 months, four year disease-free survival was lower among women who received six months of treatment compared to 12 months (85 versus 88 percent; HR 1.28, 95% CI 1.05-1.56).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these results, we recommend one year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in the adjuvant setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361579099\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several chemotherapy regimens used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    have been evaluated in large prospective studies. We prefer the use of anthracycline-based chemotherapy regimens followed by combinations of taxane and trastuzumab treatment due to the greater experience with this combination and limited data to suggest greater efficacy for non-anthracycline containing regimens. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Anthracycline-based therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, the non-anthracycline regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (TCH) is an appropriate and effective alternative treatment. We suggest TCH for women with true contraindications to anthracyclines (eg, preexisting cardiac conditions, borderline ejection fraction at baseline, or prior anthracycline exposure), or personal preferences to receive non-anthracycline-based therapy. (See",
"    <a class=\"local\" href=\"#H1352264107\">",
"     'Non-anthracycline based therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The studies that form the basis of this recommendation are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anthracycline-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the combination of anthracycline-based chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    come largely from two North American Cooperative Group trials that were initially designed as parallel clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/3\">",
"     3",
"    </a>",
"    ]. In both randomized studies, all patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    given every three weeks for four cycles. Otherwise, the specific eligibility and taxane-based schema was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Surgical and Breast and Bowel Project 31 trial (NSABP B-31) - In the",
"      <strong>",
"      </strong>",
"      NSABP B-31, women with HER2-positive, node-positive disease received either four courses of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      given every three weeks (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over three hours) with or without weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (initial loading dose 4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      then 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      weekly for one year), beginning with the first dose of paclitaxel.",
"     </li>",
"     <li>",
"      North Central Cancer Treatment Group (NCCTG)-coordinated Intergroup trial N-9831 - In N-9831, women with HER2-positive node-positive or high-risk node-negative disease (&gt;1 cm ER-negative or &gt;2 cm ER-positive) were then treated with one of three regimens: weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for 12 weeks, followed by no further treatment; weekly paclitaxel followed by sequential",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for 52 weeks; or weekly paclitaxel with concurrent trastuzumab for 12 weeks followed by trastuzumab alone for 40 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With a median follow-up of 3.9 years, chemotherapy plus adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    resulted in significantly superior rates of DFS (86 versus 74 percent, HR 0.52) and OS (93 versus 86 percent, HR 0.61) at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352264107\">",
"    <span class=\"h3\">",
"     Non-anthracycline based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    with a nonanthracycline-containing chemotherapy regimen was evaluated in the Breast Cancer International Research Group 006 (BCIRG-006) trial of 3222 women with HER2-positive, node-positive or high-risk, node-negative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with negative lymph nodes (no evidence of involvement in review of a minimum of six axillary nodes or a negative sentinel node biopsy) were eligible if they had at least one high risk feature (ie, age &lt;35 years; tumor &gt;2 cm;",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    negative; or histologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nuclear tumor grade 2 or 3).",
"   </p>",
"   <p>",
"    All patients were randomly assigned to adjuvant treatment with one of the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ACT &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every three weeks for four cycles, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every three weeks for four cycles",
"     </li>",
"     <li>",
"      ACTH &mdash; ACT plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for one year (weekly during chemotherapy, then every three weeks) (ACTH)",
"     </li>",
"     <li>",
"      TCH &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (area under curve 6) every three weeks for six cycles, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (weekly during chemotherapy, then every three weeks) for one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With a median follow-up of 65 months, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    containing arms (ACTH or TCH) resulted in the following outcomes when compared to ACT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant improvement in estimated DFS at five years &mdash; ACTH (84 versus 75 percent with ACT) and TCH (81 versus 75 percent with ACT).",
"     </li>",
"     <li>",
"      Significant improvement in estimated OS at five years &mdash; ACTH (92 versus 87 percent) and TCH (91 versus 87 percent).",
"     </li>",
"     <li>",
"      The differences in DFS and OS between ACTH and TCH were not statistically significant, although the study was not powered to detect equivalence between ACTH and TCH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When compared with ACTH, TCH resulted in the following differences in adverse events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly lower rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (66 versus 63 percent) and leukopenia (48 versus 60 percent), but significantly higher rates of severe anemia (6 versus 3 percent) and thrombocytopenia (6 versus 2 percent).",
"     </li>",
"     <li>",
"      A significantly lower incidence of congestive heart failure (2 versus 0.4 percent, respectively). By comparison, congestive heart failure was seen in 0.7 percent of women receiving ACT alone.",
"     </li>",
"     <li>",
"      A significantly lower incidence of subclinical and sustained loss of mean left ventricular ejection fraction (LVEF, 18.6 versus 9.4 percent). By comparison, this incidence was 11.2 percent among women treated with ACT. In 33 percent of cases, the decrease in LVEF persisted for at least four years after randomization. The long term significance of these changes in LVEF is not known.",
"     </li>",
"     <li>",
"      Significantly lower rates of sensory neuropathy (36 versus 50 percent), motor neuropathy (4 versus 6 percent), nail changes (29 versus 44 percent), and myalgias (39 versus 56 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with the other trials that demonstrate improved DFS and OS when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is added to combination chemotherapy. Compared to TCH, ACTH demonstrated a trend towards improved DFS and OS that did not reach statistical significance, but was associated with a small but significantly greater toxicity than TCH. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Anthracycline-based therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330927470\">",
"    <span class=\"h1\">",
"     LAPATINIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    should not be administered in the adjuvant setting. The apparent lack of benefit of lapatinib was shown in a phase III trial of 3147 women with stage I to III HER2-positive breast cancer who had previously received systemic chemotherapy (without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients were randomly assigned treatment with lapatinib or placebo. The median follow-up was 47 and 48 months the lapatinib and placebo arms, respectively. Compared to placebo, lapatinib resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No difference in mortality (6 percent in each arm, HR 0.99, 95% CI 0.74-1.31).",
"     </li>",
"     <li>",
"      No differences in local (2 versus 3 percent), regional (2 percent in each arm), or distant (8 versus 10 percent) recurrences. There was also no difference in the rate of primary CNS recurrences (&lt;1 versus 1 percent, HR 0.65, 95% CI 0.33-1.28).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data indicate there is no role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    as a single agent following adjuvant chemotherapy. Whether the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus lapatinib improves survival compared to trastuzumab alone in the adjuvant setting is being evaluated in the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00490139\">",
"     Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study",
"    </a>",
"    , which has completed accrual. The results of this trial are eagerly anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361579294\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361579310\">",
"    <span class=\"h2\">",
"     Male breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is a rare diagnosis in men but decisions regarding adjuvant chemotherapy do not differ by gender. The prognosis for men and women with breast cancer is similar. Male breast cancer is covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361579318\">",
"    <span class=\"h2\">",
"     Breast cancer in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    during pregnancy is contraindicated. The agent has not been studied in pregnancy, and there are theoretical concerns that exposure to trastuzumab in utero could result in fetal abnormalities or neonatal death. Mothers are advised to either discontinue nursing if they wish to receive trastuzumab or to discontinue trastuzumab if they want to continue nursing.",
"   </p>",
"   <p>",
"    Most chemotherapy agents for breast cancer are United States Food and Drug Administration (FDA) pregnancy category D, meaning they carry a risk of teratogenicity in humans. However, chemotherapy administered outside of the first trimester has a low-risk profile. Breast cancer during pregnancy is covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2718654\">",
"    <span class=\"h2\">",
"     Patients with cardiac risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential risk factors associated with the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity include previous or concurrent anthracycline use, age greater than 50, pre-existing cardiac dysfunction, high body mass index, and treatment with antihypertensive agents. For patients with cardiac risk factors who are candidates for adjuvant HER2-directed treatment, we recommend careful monitoring of cardiac function during and after treatment. However, the presence of cardiac risk factors alone should not exclude HER2-positive patients from HER2-targeted therapy. (See",
"    <a class=\"local\" href=\"#H2718616\">",
"     'Assessing risks and benefits of treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2718616\">",
"    <span class=\"h1\">",
"     ASSESSING RISKS AND BENEFITS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    improves survival outcomes in women with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/13\">",
"     13",
"    </a>",
"    ]. However, treatment is associated with a fivefold higher risk for congestive heart failure (CHF) and a twofold higher risk of left ventricular ejection fraction declines [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/13,21\">",
"     13,21",
"    </a>",
"    ]. These cardiac risks should not prevent HER2-positive patients from receiving adjuvant trastuzumab. The overall incidence of cardiac toxicity was low in prospective clinical trials, ranging from 1 to 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/3-5,14-16,19,22\">",
"     3-5,14-16,19,22",
"    </a>",
"    ]. In addition, trastuzumab-related cardiac toxicity is also reversible, especially if detected early, and responds well to medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H517953427\">",
"     'Trastuzumab-based therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    A discussion of the benefits of therapy should be balanced with the risk for cardiac toxicity, particularly in patients at a lower risk of recurrence (ie, tumor size &lt;1 cm). The survival benefit and the risk of congestive heart failure (CHF) associated with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus chemotherapy can be estimated as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11384/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with high risk HER2-positive breast cancer,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      is associated with an absolute risk reduction (ARR) of death of 13.3 percent (mortality rate, 36.7 versus 50 percent in controls). The number of patients needed to treat (NNT) to save one life is eight. For patients with low risk disease, the ARR is 3.3 percent (10 versus 6.7 percent, respectively). The NNT is 31.",
"     </li>",
"     <li>",
"      For patients at high risk for CHF prior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      treatment, the absolute risk increase (ARI) of CHF associated with trastuzumab is 21 percent (26 versus 5 percent in controls). The number of patients needed to harm (NNH) is five. However, for patients at low risk for CHF, the ARI is 2.1 percent (2.6 versus 0.5 percent, respectively). The NNH in this group is 48.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , routine cardiac monitoring is suggested. (See",
"    <a class=\"local\" href=\"#H2718654\">",
"     'Patients with cardiac risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"       \"Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"       \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amplification or overexpression of the HER2 oncogene is present in approximately 18 to 20 percent of primary invasive breast cancers. Women with early stage breast cancer that meet criteria for HER2 positivity are treated with chemotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    as adjuvant treatment. Our approach is consistent with the guidelines of two leading expert panels, the National Comprehensive Cancer Network (NCCN) and the International Consensus Panel on the Primary Treatment of Early Breast Cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is essential that all patients with newly diagnosed breast cancer be tested for HER2 overexpression because HER2-directed therapy (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      ) is a critical component of the adjuvant treatment of HER2 positive breast cancer. (See",
"      <a class=\"local\" href=\"#H7901849\">",
"       'Patient eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are eligible for adjuvant HER2-directed treatment if they have HER2-positive breast cancer, if their tumors are: HER2-positive by immunohistochemical stain of 3+ (defined as uniform intense membrane staining of 30 percent or more of tumor cells) or have a",
"      <span class=\"nowrap\">",
"       HER2/CEP17",
"      </span>",
"      fluorescent in situ hybridization (FISH) amplification ratio &ge;2.0. (See",
"      <a class=\"local\" href=\"#H7901849\">",
"       'Patient eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -containing adjuvant regimen to all women with HER2-positive node-positive breast cancer with trastuzumab administered for one year (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also recommend this approach for women with HER2-positive node-negative tumors &gt;1 cm in size (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7901849\">",
"       'Patient eligibility'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H517953427\">",
"       'Trastuzumab-based therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the benefit of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      in women with HER2-positive breast cancers smaller than 1.0 cm (ie, T1a or T1b) with no nodal involvement has not been directly addressed in clinical trials, we suggest trastuzumab plus chemotherapy in patients with subcentimeter, HER2-positive tumors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When administering adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -based therapy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for four cycles, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      weekly for 12 weeks with concurrent trastuzumab and then trastuzumab alone to complete a total of 52 weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus trastuzumab (TCH) is an appropriate and effective alternative treatment for women without evidence of poor prognostic factors (eg, node negative) and those with true contraindications to anthracyclines (eg, preexisting cardiac conditions, borderline ejection fraction at baseline, or prior anthracycline exposure). (See",
"      <a class=\"local\" href=\"#H517953427\">",
"       'Trastuzumab-based therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      have an increased risk for cardiac toxicity (ie, congestive heart failure or left ventricle fraction declines). These risks should be taken into account when prescribing trastuzumab. All patients receiving adjuvant trastuzumab should undergo routine cardiac monitoring. (See",
"      <a class=\"local\" href=\"#H2718654\">",
"       'Patients with cardiac risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"       \"Cardiotoxicity of trastuzumab\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/1\">",
"      Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/2\">",
"      Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011; 29:e458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/3\">",
"      Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/4\">",
"      Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/5\">",
"      Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/6\">",
"      Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/7\">",
"      Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27:5693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/8\">",
"      Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27:5700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/9\">",
"      Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26:5697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/10\">",
"      Livi L, Meattini I, Saieva C, et al. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 2012; 118:3236.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/12\">",
"      Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/13\">",
"      Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4:CD006243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/14\">",
"      Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27:5685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/15\">",
"      Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/16\">",
"      Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/17\">",
"      Goldhirsch A, Piccart M, Procter M, et al. HERA Trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow-up. Ann Oncol 2012; 23:ixe2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/18\">",
"      Pivot X, Romieu G, Bonnefoi H, et al. Phare trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Ann Oncol 2012; 23:ixe2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/19\">",
"      Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29:3366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/20\">",
"      Goss PE, Smith IE, O'Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/21\">",
"      Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/22\">",
"      Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11384/abstract/23\">",
"      Mart&iacute;n M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 773 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11384=[""].join("\n");
var outline_f11_7_11384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1352263895\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7901849\">",
"      PATIENT ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H517953067\">",
"      HER2-DIRECTED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H517953645\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H517953427\">",
"      TRASTUZUMAB-BASED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1133979075\">",
"      Treatment duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361579099\">",
"      Choice of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anthracycline-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1352264107\">",
"      - Non-anthracycline based therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H330927470\">",
"      LAPATINIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361579294\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361579310\">",
"      Male breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361579318\">",
"      Breast cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2718654\">",
"      Patients with cardiac risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2718616\">",
"      ASSESSING RISKS AND BENEFITS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/56/7054\" title=\"table 2\">",
"      ASCO summary guideline recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17650?source=related_link\">",
"      Treatment protocols for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_7_11385="Role of radiation therapy in breast conservation therapy";
var content_f11_7_11385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of radiation therapy in breast conservation therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11385/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/7/11385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with invasive breast cancer may now preserve their breast(s) without sacrificing oncologic outcome. Radiation therapy (RT) is an essential component of BCT. Whole breast irradiation provides adequate control of microscopic residual disease, permits the preservation of a cosmetically satisfactory breast, and improves survival.",
"   </p>",
"   <p>",
"    The radiation treatment volume for whole breast irradiation often includes the lower axilla and some of the internal mammary (IM) lymph nodes. Whether all of the IM nodes, the supraclavicular area, and the upper axilla should be included in the radiation treatment volume (regional nodal irradiation) in patients undergoing BCT has been controversial. However, randomized trials have shown that locoregional irradiation after mastectomy reduces locoregional recurrence and improves survival. There is now evidence to support a benefit for regional nodal irradiation in patients undergoing BCT as well, although these benefits come at the cost of modestly greater toxicity.",
"   </p>",
"   <p>",
"    This topic review will cover the benefits of whole breast RT and the contribution of regional nodal irradiation when added to whole breast RT in patients undergoing BCT. Techniques and complications of breast irradiation, surgical techniques of mastectomy and BCT, surgical management of the axillary lymph nodes, and postmastectomy radiation therapy (RT) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=see_link\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the equivalence in overall survival with modified radical mastectomy and BCT, breast conservation would have limited appeal if high local recurrence rates resulted in a significant number of subsequent mastectomies. The degree of residual disease in the breast after lumpectomy alone is significant. This is best illustrated by a detailed evaluation of mastectomy specimens using radiography of thin (5 mm) sections and histologic examination of an average of 20 blocks per specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/1\">",
"     1",
"    </a>",
"    ]. Residual microscopic cancer &gt;2 cm from the tumor was found in 41 percent of patients (two-thirds of which was intraductal and one-third invasive); this disease would be left behind after a standard lumpectomy. The percentage of women with residual cancer (either invasive or intraductal) &gt;2 cm from the reference tumor corresponds well to the local failure rate in women with invasive breast cancer undergoing excision alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. RT is an essential component of BCT to eradicate these subclinical deposits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8489445\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern RT techniques that deliver between 45 to 50 Gy to the entire breast over 4.5 to 5 weeks provide adequate control of microscopic residual disease, permit the preservation of a cosmetically satisfactory breast, and improve survival.",
"   </p>",
"   <p>",
"    The impact of radiation therapy (RT) after breast-conserving surgery (BCS) on recurrence, survival, and mortality was evaluated in a 2011 meta-analysis from the Early Breast Cancer Trialists&rsquo; Collaborative Group (EBCTCG) that involved 10,081 women (known to be either pathologically node negative [pN0] or positive [p+]) participating in one of 17 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with BCS alone, the addition of RT after BCS resulted in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in the 10-year risk of recurrence by nearly half (relative risk [RR] 0.52, 95% CI 0.48-0.56), which translates into an absolute risk reduction (ARR) of 15.7 percent.",
"     </li>",
"     <li>",
"      A significant reduction in the 15-year risk of breast cancer death by almost 20 percent (RR 0.82, 95% CI 0.75-0.90), which translates into an ARR of 3.8 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This suggests that with RT about one death from breast cancer is avoided for every four recurrences avoided.",
"   </p>",
"   <p>",
"    A subset analysis of women with pN0 disease (n=7287) demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in the 10-year risk of recurrence (RR 0.46, 95% 0.41-0.51), which translates into an ARR of 15.4 percent.",
"     </li>",
"     <li>",
"      A significant reduction in 15-year risk of breast cancer death (RR 0.83, 95% CI 0.73-0.95), which translates into an ARR of 3.3 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar benefits were seen among women with pN+ disease (n=1050):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in 10-year risk of recurrence (RR 0.53, 95% CI 0.44-0.64), which translates into an ARR of 21.2 percent.",
"     </li>",
"     <li>",
"      A significant reduction in 15-year risk of breast cancer death (RR 0.79, 95% 0.65-0.95), which translates into an ARR of 8.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results confirm the benefit of RT after BCS not only with a reduction in the risk of an in-breast recurrence, but also in the reduction of distant recurrence and risk of death. First recurrence patterns differed depending on whether or not RT was used. For women treated with BCS alone, the majority of first recurrences were locoregional and not distant (25 versus 10 percent). For women treated with RT after BCS, the first recurrence was distal more commonly than locoregional (12 versus 8 percent). However, several points deserve emphasis regarding local recurrence with BCS and the role of RT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the National Surgical Breast and Bowel project (NSABP) B-06 trial of lumpectomy with or without RT, there was no significant survival difference among women who had lumpectomy alone and those who had lumpectomy and RT, despite a significant difference in local recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/2\">",
"       2",
"      </a>",
"      ]. This is often misinterpreted as meaning that higher local recurrence rates will not impact overall survival. However, the trial was not large enough to detect a small survival advantage from the addition of RT, which was noted in the meta-analysis above. In addition, the morbidity and mortality attributed to RT has greatly decreased as the technology for the delivery of radiation has improved.",
"     </li>",
"     <li>",
"      A local recurrence can represent either a true recurrence of the initial cancer or a second primary. The risk of developing a second, new ipsilateral breast cancer following BCS is similar to the risk of developing a contralateral breast cancer either after BCS or mastectomy (about 0.5 to 1 percent per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8489570\">",
"    <span class=\"h2\">",
"     Alternate approaches to RT in women undergoing breast conserving therapy (BCT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the data discussed above regarding the benefits of whole breast RT as a component of BCT were derived in women receiving conventional fractionation external beam RT (45 to 50 Gy in 1.8 to 2 Gy daily fractions to the entire breast over 4.5 to 5 weeks) after breast conserving surgery. Conventional RT as a component of BCT is inconvenient for many patients, increases costs, and provides a serious strain on resources in countries with limited RT facilities (eg, Canada, United Kingdom) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, it is reasonable to consider alternate approaches to RT so as to improve convenience and decrease costs while maintaining excellent rates of local control, without increasing local recurrence rates. Attempts have been made to streamline RT by using more rapid fractionation schedules, by the use of accelerated partial breast irradiation, or by identifying subgroups of patients with a sufficiently low risk of local recurrence as to warrant the omission of whole breast RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600305411\">",
"    <span class=\"h3\">",
"     Shorter fractionation schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shorter fractionation schedules have gained in popularity as a treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. A meta-analysis of four randomized trials involving a total of 7095 women concluded that compared to conventionally scheduled whole breast RT, shorter fractionation was associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant difference in ipsilateral local recurrence at five years (relative risk [RR] for recurrence 0.93, 95% CI 0.73-1.19) and at 10 years (RR 0.99, 95% CI 0.77-1.29)",
"     </li>",
"     <li>",
"      No significant difference in overall survival (RR for mortality 0.89, 95% CI 0.77-1.04)",
"     </li>",
"     <li>",
"      A significant decrease in acute radiation toxicity (RR for toxicity 0.21, 95% CI 0.07-0.64)",
"     </li>",
"     <li>",
"      No significant difference in late skin or subcutaneous toxicity, ischemic heart disease, or rib fractures",
"     </li>",
"     <li>",
"      No difference in breast cosmesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The meta-analysis provides further evidence to support a shorter duration of RT as a reasonable alternative to five weeks of therapy using standard fractionation for patients with node-negative favorable disease. However, the following caveats apply [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional long-term results are needed to completely assure comparable efficacy and minimal toxicity.",
"     </li>",
"     <li>",
"      The toxicity risks of shorter fractionation schedules for women with large breasts (ie, breast width of more than 25 cm at the posterior border of the medial and lateral tangential beams) are unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/14\">",
"       14",
"      </a>",
"      ]. In the meta-analysis, 87 percent of patients whose breast size was reported had small or medium breasts and comprised 60 percent of the total population included in the analysis. &nbsp;",
"     </li>",
"     <li>",
"      Women with T3 tumors (T-size &gt;5 cm) made up less than 2 percent of the entire study population and 0.33 percent of the population in the analysis.",
"     </li>",
"     <li>",
"      There are insufficient data to evaluate the tolerability of shorter fractionation with other therapies (ie, chemotherapy or monoclonal antibodies). The potential for complications when chemotherapy is added to RT is well described. Caution should be used when applying these fractionation schemes to women who have received adjuvant chemotherapy, since the results from these trials may not adequately represent the potential long-term complications of RT in the presence of chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H1404371166#H1404371166\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Sequencing chemotherapy and radiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is not known whether shorter course RT is equivalent to standard longer course therapy in patients for whom a boost has been shown to be of greatest benefit (ie, patients &lt;50 years of age, positive axillary nodes, lymphovascular space invasion,",
"      <span class=\"nowrap\">",
"       close/positive",
"      </span>",
"      resection margins). Approximately 80 percent of patients in this analysis were node-negative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link&amp;anchor=H15#H15\">",
"       \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'RT boost'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although not reported with short-term follow-up of the START trials, treatment-related toxicity may be a concern with shorter duration of RT if applied to regional lymph node regions [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/9\">",
"       9",
"      </a>",
"      ]. In one retrospective study from the United Kingdom, the incidence of treatment-related brachial plexopathy in women receiving 1.8 versus 3.7 Gy daily fractions was 1 and 6 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link\">",
"       \"Complications of peripheral nerve irradiation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=see_link&amp;anchor=H949706089#H949706089\">",
"       \"Complications of breast and chest wall irradiation for early stage breast cancer\", section on 'Rib fracture and brachial plexopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A task force convened by ASTRO to address fractionation for whole breast irradiation concluded that a shorter dose fractionation schedule of 42.5 Gy in 16 fractions was an excellent alternative to standard fractionation schedules in patients aged 50 years or older who had disease stage pT1-2, pN0 breast cancer, who did not receive chemotherapy, and who were not receiving a radiation boost [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/17\">",
"     17",
"    </a>",
"    ]. We consider this to be an acceptable approach for patients that meet these criteria. Application to other patient populations is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543132\">",
"    <span class=\"h3\">",
"     Partial breast irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated partial breast irradiation (APBI) refers to the use of limited focused adjuvant radiation therapy (RT) as an alternative to conventional whole breast irradiation for patients with early breast cancer following breast conserving surgery. Compared with whole breast irradiation, APBI delivers RT to a limited volume of tissue (partial breast irradiation), and a higher dose can be delivered in a shorter period of time.",
"   </p>",
"   <p>",
"    Although promising, the follow-up duration in all trials evaluating APBI is short, and all studied highly selected patients with relatively favorable disease. It is unclear which patients are at sufficiently low risk for local recurrence so that the advantages of APBI (short treatment duration, decreased cost, reduced toxicity) outweigh the possibility of an increased risk of local recurrence. Longer follow-up and confirmation of local control, survival, and toxicity with APBI will be needed before concluding that APBI is an acceptable substitute for conventional whole breast irradiation in women undergoing BCT for early breast cancer.",
"   </p>",
"   <p>",
"    APBI is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12728?source=see_link\">",
"     \"Accelerated partial breast irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611293\">",
"    <span class=\"h3\">",
"     Breast conserving therapy (BCT) without radiation therapy (RT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, multiple trials have directly compared surgery versus surgery plus whole breast RT in women with early stage breast cancer. All demonstrate a significant reduction (average 75 percent) in local recurrence rate with RT (eg, 10 versus 35 percent at twelve years in NSABP trial B-06 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/3\">",
"     3",
"    </a>",
"    ]). While none of the individual trials shows an absolute improvement in survival, at least two pooled analyses support a survival benefit for RT as a component of BCT. Coupled with the dramatic reduction in breast cancer recurrence associated with RT, these data suggest that RT should be considered a standard component of BCT except in selected circumstances. (See",
"    <a class=\"local\" href=\"#H8489445\">",
"     'Benefits'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Investigators have attempted to identify a subgroup of patients (based upon clinical and histologic features) with a low enough risk of local recurrence after surgery alone to justify eliminating RT; however, identification of such a subgroup has not been possible in many trials. As an example, local recurrence rates are generally lower with more extensive surgery (eg, quadrantectomy compared to lumpectomy) and in older compared to younger women. Despite these general associations, older women who undergo quadrantectomy still derive benefit from the addition of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further data from the Joint Center for Radiation Therapy (JCRT) support the concept that there may not exist a subset of women with a low enough risk to justify the elimination of RT. In this prospective single-arm study, women with favorable prognostic features (tumor size &le;2 cm, histologically negative axillary nodes, absence of both lymphatic vessel invasion and extensive intraductal component (EIC) and no cancer cells within 1 cm of inked margins) were offered the option of surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/19\">",
"     19",
"    </a>",
"    ]. The median pathologic tumor size was 9 mm, and all but one patient had a negative surgical margin at reexcision. This trial was stopped shortly before it reached its accrual goal of 90 patients; at a median follow-up time of 86 months, the crude rate of local recurrence in this highly selected group was 23 percent.",
"   </p>",
"   <p>",
"    Thus, there appears to be no subset of women undergoing BCT for whom the risk of recurrence is sufficiently low after surgery alone to justify the omission of whole breast RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729991\">",
"    <span class=\"h3\">",
"     Can RT be omitted in patients receiving adjuvant systemic therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant systemic therapy appears to provide additional local control benefit beyond that achieved with RT in women undergoing BCT. Randomized trials provide support for a lower rate of recurrence in the treated breast in women who receive systemic therapy in addition to BCT compared to those treated with BCT alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In NSABP trial B-13, women with node-negative, estrogen receptor (ER)-negative invasive tumors were randomly assigned to chemotherapy or a no treatment control group following local treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/20\">",
"       20",
"      </a>",
"      ]. Among the 235 women undergoing BCT, the eight-year local recurrence rate was significantly less in the chemotherapy group (2.6 versus 13.4 percent).",
"     </li>",
"     <li>",
"      In NSABP trial B-14, women with node-negative, ER-positive tumors were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or placebo for at least five years following definitive local therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/21\">",
"       21",
"      </a>",
"      ]. Among the 1062 women who underwent BCT, the rate of local recurrence at ten years was significantly less in women receiving tamoxifen (4.3 versus 14.7 percent).",
"     </li>",
"     <li>",
"      Similar data were noted in the Stockholm Breast Cancer Study Group among women with node-negative breast cancer who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or placebo following local therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/22\">",
"       22",
"      </a>",
"      ]. Among the 432 women treated with BCT, the ten-year rate of local recurrence was significantly less in women receiving tamoxifen (3 versus 12 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although adjuvant systemic therapy (chemotherapy, endocrine therapy, or both) substantially reduces the rate of local recurrence in patients treated with breast-conserving surgery with RT, it is unclear whether it can replace the need for RT after conservative surgery alone. The data from randomized trials are mixed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In NSABP protocol B-06, women with node-positive invasive cancer underwent lumpectomy and adjuvant chemotherapy with or without RT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/3\">",
"       3",
"      </a>",
"      ]. Despite the use of chemotherapy in all women in both groups, the women who did not receive RT had a significantly higher rate of breast cancer recurrence at 20 years (39 versus 14 percent); this did not adversely impact survival.",
"     </li>",
"     <li>",
"      The British Association of Surgical Oncology (BASO)-II trial randomly assigned women with histologically low-grade primary tumors &lt;2 cm and negative axillary nodes to wide excision with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , or wide excision plus RT with or without tamoxifen [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/23\">",
"       23",
"      </a>",
"      ]. In the latest preliminary report, with a median follow-up of 26 months, the ipsilateral breast tumor recurrence rate was similar among the 521 women who did not receive RT compared to the 525 women who did, and it was low in both groups (0.8 versus 0.6 percent). This abstract was presented in the year 2000, and a final peer-reviewed manuscript has not been published.",
"     </li>",
"     <li>",
"      In the German Breast Cancer Study Group (GBSG)-V trial, 361 low-risk patients (&lt;2 cm, hormone receptor positive, grade 1 or 2) undergoing breast conserving surgery were randomly assigned, using a 2 x 2 factorial design, to RT or not, and to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use or not [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/24\">",
"       24",
"      </a>",
"      ]. There was a benefit with both RT and tamoxifen in reducing local recurrence rates (9.7 and 7.5 percent for RT and tamoxifen, respectively, versus 34 percent with BCT alone). However, in the group receiving tamoxifen, the local recurrence rates were not substantially lower in women who received RT compared to those who did not (5.3 versus 7.5 percent, respectively). This trial was small and likely underpowered to detect small differences in the four groups.",
"      <br/>",
"      <br/>",
"      This issue is also being addressed in the PRIME II trial, in which 1000 women over the age of 65, with ER positive, node-negative tumors &lt; 3 cm in size, who undergo breast-conserving surgery and receive adjuvant endocrine therapy are randomly assigned to RT or no RT; accrual is complete and the data are maturing [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Older women receiving adjuvant endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The avoidance of RT is of particular interest for older women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective series of conservative surgery alone, with or without adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , have produced varying results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. In general, local recurrence rates appear higher in women who do not receive RT, but distant recurrence and mortality rates appear similar. This has prompted several randomized trials, all of which show a reduction in local recurrence with RT, but no impact on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. The three most mature trials are described in detail:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In NSABP B-21, which included 1009 women (of any age, approximately 50 percent over the age of 60) undergoing lumpectomy for invasive breast cancer &le;1 cm in size, the rate of ipsilateral breast local recurrence was significantly higher in women receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      alone compared to those undergoing radiation alone or with tamoxifen (16.5 versus 9.3 and 2.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/33\">",
"       33",
"      </a>",
"      ]. Overall survival rates at eight years were similar in all three groups (93, 94, and 93 percent, respectively).",
"     </li>",
"     <li>",
"      A Canadian trial randomly assigned 769 women age 50 or older to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      with or without RT following lumpectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/34\">",
"       34",
"      </a>",
"      ]. Women with tumors as large as 5 cm were eligible, and ER-positivity was not required. A preliminary report of the most recent analysis at eight years demonstrated a significantly higher local failure rate among nonirradiated patients (12.2 versus 4.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/37\">",
"       37",
"      </a>",
"      ], but no difference in overall survival (89 percent in both groups) or freedom from distant relapse (76 versus 82 percent in the tamoxifen and RT groups, respectively). Death rates from non-breast cancer causes far exceeded those from breast cancer in this low-risk (node-negative, ER-positive) population.",
"     </li>",
"     <li>",
"      The Cancer and Leukemia Group B (CALGB) conducted CALGB 9343 in 636 women 70 years or older who had ER-positive tumors no larger than 2 cm, all of whom were treated with endocrine therapy and randomly assigned to treatment with or without RT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/35\">",
"       35",
"      </a>",
"      ]. Assessment of cosmetic results and adverse events uniformly rated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      plus RT inferior to tamoxifen alone. At a median follow-up of 10.5 years, however, there was a significant difference in the risk of local recurrence in women treated with tamoxifen alone compared to RT plus tamoxifen (9 versus 2 percent; p=0.015) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/39\">",
"       39",
"      </a>",
"      ]. However, compared to tamoxifen treatment alone, there were no significant differences in metastasis-free survival (95 versus 93 percent) or breast cancer specific survival (98 versus 96 percent) with the addition of RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the survival outcomes reported from CALGB 9343, RT had no statistically significant impact on the rate of mastectomy to treat a local recurrence (4 versus 2 percent without versus with RT, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/39\">",
"     39",
"    </a>",
"    ]. The need for a subsequent mastectomy was evaluated in a 2012 Surveillance, Epidemiology and End Results (SEER) study that included women between 70 and 79 years with T1N0 breast cancer (less than 10 percent of whom received adjuvant chemotherapy) who received (n=6484) or did not receive (n=919) adjuvant RT. With a median follow-up of seven years, the main results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant RT reduced the risk of a subsequent mastectomy (3 versus 6 percent, HR 0.33, 95% CI 0.22-0.48). This reduction in risk was higher among women who underwent a surgical evaluation of the axilla (HR 0.21, 95% CI 0.11-0.37) compared to those who did not (HR 0.49, 95% CI 0.27-0.87).",
"     </li>",
"     <li>",
"      Among patients who did not undergo a surgical axillary assessment, RT resulted in a significant reduction in the ten year risk of undergoing a mastectomy (2 versus 7 percent, p&lt;0.001).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data support the view that for women over the age of 70 with small (&lt;2 cm) ER-positive, clinically node-negative breast cancer, endocrine therapy alone (and omission of RT) is a reasonable option. However, patients should be counselled that rates of in-breast recurrence tend to increase over time and the risk of subsequently requiring a mastectomy is higher in women who do not receive adjuvant RT. Physicians should also take into account a patient&rsquo;s performance status and presence of comorbid conditions when estimating the benefit from treatment. A nomogram that may estimate the five- and ten-year probability of mastectomy free survival has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/40\">",
"     40",
"    </a>",
"    ]. However, prospective validation of this tool is required before it should be used in routine clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Factors that affect treatment decisions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H730200\">",
"    <span class=\"h1\">",
"     BENEFITS OF REGIONAL NODAL IRRADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three anatomic regions must be considered when planning the radiation target volume for women undergoing breast conservation therapy (BCT): the breast, the internal mammary (IM) lymph node region, and the supraclavicular fossa and axilla. Depending on the clinical situation, one, two, or all three areas will require treatment in an individual patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link&amp;anchor=H5#H5\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'The intact breast or chest wall'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like the axillary lymph nodes, the IM nodes receive lymph drainage from all quadrants of the breast; however, medial tumors have a significantly higher rate of IM nodal metastases. The IM nodes will be found to contain regional metastases in about 8 to 10 percent of patients with axillary node-negative disease. Pathologic involvement of the IM nodal chain has been reported in up to 37 percent of axillary node-positive breast cancers that are located in the inner or central breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Internal mammary lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, whether the IM nodes should be included in the RT field, particularly among patients with axillary node-negative disease, is controversial (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link&amp;anchor=H6#H6\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'The IM nodes'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several series report a less favorable outcome for inner as compared to outer quadrant lesions, suggesting a need for treatment of the IM nodes in these women.",
"     </li>",
"     <li>",
"      On the other hand, clinical evidence of recurrence at this site is uncommon, although detection of an IM recurrence is difficult and as a result, recurrences at this site may be underreported. More importantly, a survival benefit for routine resection of the IM nodes has not been shown in at least four randomized trials, supporting the view that radiating these nodes may not influence survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of the regional lymph nodes in breast cancer\", section on 'Internal mammary lymph nodes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The question of whether the IM nodes should be treated has again been brought to the forefront with the publication of data from randomized trials testing the value of postmastectomy RT, which suggest that enhanced local-regional tumor control (perhaps as a result, in part, of including the IM nodes in the radiation treatment volume) is associated with long-term survival benefits among patients who are receiving adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H14#H14\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Modern clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women undergoing BCT differ from those undergoing mastectomy only by the presence of intact breast tissue. Thus, in theory, the survival benefit realized in the postmastectomy trials for women with node-positive breast cancer should be applicable to those undergoing locoregional RT to an intact breast. In fact, the similarity in the benefits of RT on survival among women undergoing mastectomy or BCT has now been shown by the EBCTCG [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rationale'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefit of regional nodal irradiation in women undergoing BCT was directly addressed in the NCIC-CTG MA.20 trial, in which 1832 women with node-positive (90 percent, 85 percent with one to three positive nodes) or high-risk node-negative (tumor size &ge;5 cm, or &ge;2 cm and fewer than 10 axillary nodes in the specimen, ER-negative, grade 3, or lymphovascular invasion) breast cancer undergoing BCT were randomly assigned to whole breast irradiation (50 Gy in 25 daily 2 Gy fractions) with or without regional nodal irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/42\">",
"     42",
"    </a>",
"    ]. The group receiving regional nodal irradiation received concurrent treatment (45 Gy in 25 daily 2-Gy fractions) to a field that included the high axillary, supraclavicular, and upper IM nodal chain (the first three upper intercostal spaces). Boost irradiation (10 Gy in 5 fractions) was allowed. Adjuvant chemotherapy was received by 91 percent of the patients in both arms, and in &gt;90 percent of cases, was anthracycline-based.",
"   </p>",
"   <p>",
"    A preliminary report of a planned interim analysis was presented at the 2011 meeting of the American Society of Clinical Oncology (ASCO). At a median 62 months of follow-up, regional nodal irradiation was associated with a significant improvement in five-year disease-free survival (DFS), with significant decreases in both isolated locoregional (96.8 versus 94.5 percent, hazard ratio [HR] 0.58, 95% CI 0.37 to 0.92) and distant DFS (92.4 versus 87 percent, HR 0.64, 95% CI 0.47 to 0.85). There was also a trend toward better survival that also favored the addition of regional nodal irradiation (five-year overall survival 92.3 versus 90.7 percent, p = 0.07).",
"   </p>",
"   <p>",
"    Radiation dermatitis (50 versus 40 percent, any grade) and radiation pneumonitis (1.3 versus 0.2 percent, any grade) were modestly but significantly more common in the group receiving regional nodal irradiation. Long-term, rates of lymphedema were also significantly higher with regional nodal irradiation (7 versus 4 percent), and cosmetic outcomes were described as fair or poor in a significantly higher percentage of patients as well (36 versus 29 percent). &nbsp;",
"   </p>",
"   <p>",
"    Based upon these data, the risks and benefits of regional nodal irradiation should be discussed with all patients with positive nodes who are undergoing BCT. Whether the risk to benefit ratio is favorable in all such women is uncertain. There may be subgroups of women with low-volume regional nodal disease (eg, women found to have fewer than three sentinel nodes or axillary nodal micrometastases on a sentinel node biopsy) whose risk of locoregional recurrence is so low that regional nodal irradiation would provide no benefit, but at present, it is not clear where the cutpoint is. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H5456194#H5456194\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'When should completion axillary dissection be performed?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32573033\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY IN BRCA MUTATION CARRIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 6 percent of breast cancers are associated with germline (inherited) genetic mutations, of which the majority involve the breast and ovarian cancer susceptibility genes, BRCA1 and 2. In women who have inherited BRCA1 or BRCA2 mutations, the lifetime risk of breast cancer is as high as 85 percent by age 70. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H410336733#H410336733\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Hereditary breast and ovarian cancer syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the normal function of the BRCA genes is incompletely understood, preclinical data suggest that they participate in the normal mechanisms that repair double-strand DNA breaks, thus maintaining genomic stability. The BRCA genes colocalize with Rad 51, the human homologue of the yeast DNA damage checkpoint gene, and together, they are thought to represent a common DNA damage response pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Because of this association, concern has been raised that cells that carry a",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    mutation may be exquisitely sensitive to agents that cause DNA damage, such as RT and certain chemotherapy agents.",
"   </p>",
"   <p>",
"    Despite these data, at least two studies that directly compared differences in radiation sensitivity between breast cancer patients with",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    mutations with patients not at risk for having a",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    mutation and failed to show greater radiation-related toxicity in women who harbor BRCA mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11385/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the increased risk for breast cancers in patients known to harbor",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    mutations, rates of in-breast recurrence after breast conservation therapy (BCT) have also been studied in carriers. The available data support an increase in the incidence of ipsilateral (and contralateral) second primary breast cancers but not true local recurrences in affected women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H27#H27\">",
"     \"Breast conserving therapy\", section on 'Inherited susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"       \"Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610393\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the emergence of breast conservation therapy (BCT), women with invasive breast cancer may now preserve their breast(s) without sacrificing oncologic outcome. Radiation therapy (RT) is an essential component of BCT. Compared with no radiation therapy, whole breast RT provides adequate control of microscopic residual disease, permits the preservation of a cosmetically satisfactory breast, and improves survival. (See",
"      <a class=\"local\" href=\"#H8489445\">",
"       'Benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women undergoing BCT, we recommend whole breast external beam radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H611293\">",
"       'Breast conserving therapy (BCT) without radiation therapy (RT)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H729991\">",
"       'Can RT be omitted in patients receiving adjuvant systemic therapy?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected women age 70 and older with small (&lt;2 cm) ER-positive, clinically node-negative breast cancer, treatment with adjuvant endocrine therapy alone after breast conserving surgery is reasonable. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Older women receiving adjuvant endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who will be receiving whole breast RT, conventional fractionation RT schedules (46 to 50 Gy to the entire breast over 4.5 to 5 weeks followed by a boost to the lumpectomy cavity) or the shorter Canadian fractionation schedule (42.5 Gy in 16 fractions over 22 days) are acceptable. We prefer standard fractionation RT for women who are 50 years of age or younger, those who have received chemotherapy, and those with high grade",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ER negative disease (ie, clinical characteristics unlike the majority of the patients on the Canadian trial).",
"     </li>",
"     <li>",
"      For patients who opt for shorter course RT, we provide a boost although there are limited data regarding outcomes and cosmesis using the Canadian or similar fractionation protocol plus a boost.",
"     </li>",
"     <li>",
"      We do not offer shorter course RT to women with node-positive disease who will receive regional nodal irradiation due to concerns of brachial plexopathy. (See",
"      <a class=\"local\" href=\"#H600305411\">",
"       'Shorter fractionation schedules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H730200\">",
"       'Benefits of regional nodal irradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with node-positive disease, we suggest the addition of regional nodal RT to whole breast RT (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H730200\">",
"       'Benefits of regional nodal irradiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BRCA mutation carriers should be managed similarly to those without BRCA mutations. Studies that directly compare differences in radiation sensitivity between breast cancer patients with and without",
"      <span class=\"nowrap\">",
"       BRCA1/2",
"      </span>",
"      mutations failed to show greater radiation-related toxicity in women who harbor BRCA mutations. (See",
"      <a class=\"local\" href=\"#H32573033\">",
"       'Radiation therapy in BRCA mutation carriers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/1\">",
"      Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985; 56:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/2\">",
"      Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/3\">",
"      Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/4\">",
"      Lagios MD, Richards VE, Rose MR, Yee E. Segmental mastectomy without radiotherapy. Short-term follow-up. Cancer 1983; 52:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/5\">",
"      Montgomery AC, Greening WP, Levene AL. Clinical study of recurrence rate and survival time of patients with carcinoma of the breast treated by biopsy excision without any other therapy. J R Soc Med 1978; 71:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/6\">",
"      Freeman CR, Belliveau NJ, Kim TH, Boivin JF. Limited surgery with or without radiotherapy for early breast carcinoma. J Can Assoc Radiol 1981; 32:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/7\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/8\">",
"      Obedian E, Fischer DB, Haffty BG. Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 2000; 18:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/9\">",
"      Harris JR. Notes on the Ontario trial in the context of breast-conserving therapy for early-stage breast cancer. J Clin Oncol 2000; 18:43S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/10\">",
"      Shelley W, Brundage M, Hayter C, et al. A shorter fractionation schedule for postlumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys 2000; 47:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/11\">",
"      Olivotto IA, Weir LM, Kim-Sing C, et al. Late cosmetic results of short fractionation for breast conservation. Radiother Oncol 1996; 41:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/12\">",
"      Schomberg PJ, Shanahan TG, Ingle JN, et al. Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study. Radiology 1997; 202:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/13\">",
"      Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006; 7:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/14\">",
"      Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/15\">",
"      James ML, Lehman M, Hider PN, et al. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev 2010; :CD003860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/16\">",
"      Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 1990; 18:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/17\">",
"      Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 81:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/18\">",
"      Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 1995; 31A:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/19\">",
"      Lim M, Bellon JR, Gelman R, et al. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys 2006; 65:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/20\">",
"      Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/21\">",
"      Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/22\">",
"      Dalberg K, Johansson H, Johansson U, Rutqvist LE. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group. Cancer 1998; 82:2204.",
"     </a>",
"    </li>",
"    <li>",
"     Blamey RW. British Association of Surgical Oncology (BASO) II trial: comparing wide local excision alone with wide local excision plus radiotherapy in small well differentiated breast cancers. Eur J Cancer. 2000;36(suppl 5):S93. Abstract 253. Presented at the 2nd European Breast Cancer Conference. September26-30, 2000; Brussels, Belgium.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/24\">",
"      Winzer KJ, Sauerbrei W, Braun M, et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2010; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/25\">",
"      Kunkler I. PRIME II breast cancer trial. Clin Oncol (R Coll Radiol) 2004; 16:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/26\">",
"      Nemoto T, Patel JK, Rosner D, et al. Factors affecting recurrence in lumpectomy without irradiation for breast cancer. Cancer 1991; 67:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/27\">",
"      Kantorowitz DA, Poulter CA, Sischy B, et al. Treatment of breast cancer among elderly women with segmental mastectomy or segmental mastectomy plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1988; 15:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/28\">",
"      Reed MW, Morrison JM. Wide local excision as the sole primary treatment in elderly patients with carcinoma of the breast. Br J Surg 1989; 76:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/29\">",
"      Martelli G, DePalo G, Rossi N, et al. Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen. Br J Cancer 1995; 72:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/30\">",
"      Lee KS, Plowman PN, Gilmore OJ, Gray R. Tamoxifen in breast conservation therapy. Int J Clin Pharmacol Ther 1995; 33:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/31\">",
"      Shin E, Takatsuka Y, Okamura Y, et al. A Retrospective Study of Breast Cancer Patients Treated with Quadrantectomy without Radiation Therapy. Breast Cancer 1999; 6:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/32\">",
"      Benhaim DI, Lopchinsky R, Tartter PI. Lumpectomy with tamoxifen as primary treatment for elderly women with early-stage breast cancer. Am J Surg 2000; 180:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/33\">",
"      Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20:4141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/34\">",
"      Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/35\">",
"      Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/36\">",
"      P&ouml;tter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/37\">",
"      Fyles AW, Manchul L, McCready D, et al. Long-term results of a randomized trial of tamoxifen with or without radiation in women over 50 years of age with T1/2 breast cancer (abstract). Int J Radiat Oncol Biol Phys 2006; 66:S4.",
"     </a>",
"    </li>",
"    <li>",
"     Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up (abstract). Data presented at the 29th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14, 2006. (Abstract available online at www.sabcs.org/SymposiumOnline/index.asp#abstracts, accessed January 5, 2007).",
"    </li>",
"    <li>",
"     Hughes, KS, Schnaper, LA, Cirrincione, C, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer (abstract 507). J Clin Oncol 2010; 28:69s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=50014 (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/40\">",
"      Albert JM, Liu DD, Shen Y, et al. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol 2012; 30:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/41\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer (abstract LBA1003). J Clin Oncol 2011; 29:779s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=79126 (Accessed on June 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/43\">",
"      Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/44\">",
"      Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/45\">",
"      Pellegrini L, Yu DS, Lo T, et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002; 420:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/46\">",
"      Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000; 18:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11385/abstract/47\">",
"      Shanley S, McReynolds K, Ardern-Jones A, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006; 12:7025.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 739 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-3EC3620203-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11385=[""].join("\n");
var outline_f11_7_11385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H610393\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8489445\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8489570\">",
"      Alternate approaches to RT in women undergoing breast conserving therapy (BCT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H600305411\">",
"      - Shorter fractionation schedules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H543132\">",
"      - Partial breast irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H611293\">",
"      - Breast conserving therapy (BCT) without radiation therapy (RT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H729991\">",
"      - Can RT be omitted in patients receiving adjuvant systemic therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Older women receiving adjuvant endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H730200\">",
"      BENEFITS OF REGIONAL NODAL IRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32573033\">",
"      RADIATION THERAPY IN BRCA MUTATION CARRIERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H610393\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12728?source=related_link\">",
"      Accelerated partial breast irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=related_link\">",
"      Complications of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=related_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_7_11386="Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults";
var content_f11_7_11386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11386/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11386/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/7/11386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/7/11386/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/7/11386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis is characterized by recurring episodes of inflammation limited to the mucosal layer of the colon. It commonly involves the rectum and may extend in a proximal and continuous fashion to involve other parts of the colon.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations, diagnosis, and natural history of ulcerative colitis. The definition, epidemiology, pathogenesis, and treatment of ulcerative colitis are discussed in detail, separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844647392\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative colitis usually present with diarrhea which may be associated with blood. Bowel movements are frequent and small in volume as a result of rectal inflammation. Associated symptoms include colicky abdominal pain, urgency, tenesmus, and incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with mainly distal disease may have constipation accompanied by frequent discharge of blood and mucus.",
"   </p>",
"   <p>",
"    The onset of symptoms is usually gradual and symptoms are progressive over several weeks. Symptoms may be preceded by a self-limited episode of rectal bleeding that occurred weeks or months earlier.",
"   </p>",
"   <p>",
"    The severity of symptoms may range from mild disease with four or fewer stools per day with or without blood to severe disease with more than 10 stools per day with severe cramps and continuous bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients may have systemic symptoms including fever, fatigue, and weight loss. Patients may also have dyspnea, and palpitations due to anemia secondary to iron deficiency from blood loss, anemia of chronic disease, or autoimmune hemolytic anemia (AIHA). The presence and severity of systemic symptoms depends on the clinical severity of the intestinal disease. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link&amp;anchor=H14#H14\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Iron'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1844647817\">",
"     'Extraintestinal manifestations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination is often normal, especially in patients with mild disease. Patients with moderate to severe ulcerative colitis may have abdominal tenderness to palpation, fever, hypotension, tachycardia, and pallor. Rectal examination may reveal evidence of blood. Patients with prolonged diarrhea symptoms may have evidence of muscle wasting, loss of subcutaneous fat, and peripheral edema due to weight loss and malnutrition. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H596557654\">",
"    <span class=\"h3\">",
"     Disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of disease in patients with ulcerative colitis is important in guiding clinical management and can predict long-term outcomes. The severity of disease activity can be objectively measured using a clinical disease activity index. The Montreal classification of severity of ulcerative colitis is one such index that stratifies ulcerative colitis severity into mild, moderate, and severe based on the frequency and severity of diarrhea, and the presence of systemic symptoms and laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      &ndash; Patients with mild clinical disease have four or fewer stools per day with or without blood, no signs of systemic toxicity, and a normal erythrocyte sedimentation rate (ESR). Mild crampy pain, tenesmus, and periods of constipation are also common, but severe abdominal pain, profuse bleeding, fever, and weight loss are not part of the spectrum of mild disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      &ndash; Patients with moderate clinical disease have frequent loose, bloody stools (&gt;4 per day), mild anemia not requiring blood transfusions, and abdominal pain that is not severe. Patients have minimal signs of systemic toxicity, including a low-grade fever. Adequate nutrition is usually maintained and weight loss is not associated with moderate clinical disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      &ndash; Patients with a severe clinical presentation typically have frequent loose bloody stools (&ge;6 per day) with severe cramps and evidence of systemic toxicity as demonstrated by a fever (temperature &ge;37.5&ordm;C), tachycardia (HR &ge;90",
"      <span class=\"nowrap\">",
"       beats/minute),",
"      </span>",
"      anemia (hemoglobin &lt;10.5",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      or an elevated ESR (&ge;30",
"      <span class=\"nowrap\">",
"       mm/hour).",
"      </span>",
"      Patients may have rapid weight loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with ulcerative colitis present with an attack of mild severity at presentation, approximately 27 percent of patients have moderate disease, and 1 percent have severe disease at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Mayo scoring system can also be used to assess disease severity and monitor patients during therapy (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?8/46/8929?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/5\">",
"     5",
"    </a>",
"    ]. Scores range from 0 to 12 with higher scores indicating more severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25425471\">",
"    <span class=\"h3\">",
"     Acute complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe bleeding",
"      </strong>",
"      &ndash; Bleeding may be severe in up to 10 percent of patients. Massive hemorrhage occurs in up to 3 percent of patients with ulcerative colitis at some time in their disease course and may necessitate urgent colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fulminant colitis and toxic megacolon",
"      </strong>",
"      &ndash; Patients with ulcerative colitis may develop fulminant colitis with more than 10 stools per day, continuous bleeding, abdominal pain, distension, and acute, severe toxic symptoms including fever and anorexia. Patients with fulminant colitis are at high risk of developing toxic megacolon as the inflammatory process extends beyond the mucosa to involve the muscle layers of the colon.",
"      <br/>",
"      <br/>",
"      Toxic megacolon is characterized by colonic diameter &ge;6 cm or cecal diameter &gt;9 cm and the presence of systemic toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link&amp;anchor=H7#H7\">",
"       \"Toxic megacolon\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H527391245#H527391245\">",
"       \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Avoidance of contributing factors and assessment of compliance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Perforation",
"      </strong>",
"      &ndash; Perforation of the colon most commonly occurs as a consequence of toxic megacolon [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/3\">",
"       3",
"      </a>",
"      ]. However, it may also occur in the absence of toxic megacolon in patients with the first episode of ulcerative colitis due to lack of scarring from prior attacks of colitis. Perforation with peritonitis has been associated with 50 percent mortality in patients with ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H165136853#H165136853\">",
"       \"Surgical management of ulcerative colitis\", section on 'Types of surgical procedures based upon clinical setting'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844647817\">",
"    <span class=\"h2\">",
"     Extraintestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ulcerative colitis primarily involves the bowel, it is associated with manifestations in other organ systems. Although less than 10 percent of patients with inflammatory bowel disease (IBD) have an extraintestinal manifestation (EIM) at initial presentation, 25 percent of patients have an EIM in their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/10\">",
"     10",
"    </a>",
"    ]. With the exception of primary sclerosing cholangitis and ankylosing spondylitis, EIMs tend to follow the clinical course of the colitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Musculoskeletal",
"      </strong>",
"      &ndash; Arthritis is the most frequent EIM of IBD. IBD is associated with both a nondestructive peripheral arthritis, which primarily involves large joints, and ankylosing spondylitis. Other musculoskeletal manifestations of IBD include osteoporosis, osteopenia, and osteonecrosis. The musculoskeletal manifestations of IBD are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link&amp;anchor=H3#H3\">",
"       \"Arthritis associated with gastrointestinal disease\", section on 'Ulcerative colitis and Crohn's disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eye",
"      </strong>",
"      &ndash; The most frequent ocular manifestations of IBD include uveitis and episcleritis (",
"      <a class=\"graphic graphic_picture graphicRef75384 graphicRef76962 \" href=\"UTD.htm?35/16/36097\">",
"       picture 1A-B",
"      </a>",
"      ). Scleritis, iritis, and conjunctivitis have also been associated with IBD. Affected patients may be asymptomatic or complain of burning, itching, or redness of the eyes. The eye manifestations of IBD and their management are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H7#H7\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Eye'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin",
"      </strong>",
"      &ndash; The most frequent skin lesions associated with IBD include erythema nodosum and pyoderma gangrenosum (",
"      <a class=\"graphic graphic_picture graphicRef71344 graphicRef53733 graphicRef52528 \" href=\"UTD.htm?26/5/26712\">",
"       picture 2A-C",
"      </a>",
"      ). The skin manifestations of IBD and their management are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H3#H3\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Skin manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatobiliary",
"      </strong>",
"      &ndash; Primary sclerosing cholangitis, fatty liver, and autoimmune liver disease have been associated with IBD. Patients with primary sclerosing cholangitis are usually asymptomatic and identified only due to an isolated elevation in the serum alkaline phosphatase concentration. Patients may present with fatigue, pruritus, fevers, chills, night sweats, and right upper quadrant pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Hematopoietic/coagulation",
"       </strong>",
"      </span>",
"      &ndash; Patients with IBD are at an increased risk for both venous and arterial thromboembolism (",
"      <a class=\"graphic graphic_table graphicRef68675 \" href=\"UTD.htm?32/51/33595\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/11-17\">",
"       11-17",
"      </a>",
"      ]. In one prospective cohort study, for example, the risk for development of venous thromboembolism was increased in both hospitalized and ambulatory patients with an IBD flare as compared with controls (hospitalized patients absolute risk",
"      <span class=\"nowrap\">",
"       37.5/1000",
"      </span>",
"      person-years versus",
"      <span class=\"nowrap\">",
"       13.9/1000",
"      </span>",
"      person-years, ambulatory patients with IBD flare",
"      <span class=\"nowrap\">",
"       9.0/1000",
"      </span>",
"      person-years versus",
"      <span class=\"nowrap\">",
"       0.6/100",
"      </span>",
"      person-years) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of acute pulmonary embolism\", section on 'Symptoms / Signs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"       \"Management of severe ulcerative colitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Autoimmune hemolytic anemia (AIHA) has been associated with IBD. Patients with anemia may be asymptomatic or have nonspecific symptoms including dyspnea, fatigue, and palpitations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary",
"      </strong>",
"      &ndash; Pulmonary complications of IBD, although rare, include airway inflammation, parenchymal lung disease, serositis, thromboembolic disease, and drug-induced lung toxicity. Symptoms range in severity from asymptomatic decreases in diffusion capacity to disabling bronchiectasis with cough and mucopurulent sputum production. The pulmonary manifestations of IBD and their management are discussed in detail, separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=see_link\">",
"       \"Pulmonary complications of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844648462\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe ulcerative colitis may have anemia, an elevated erythrocyte sedimentation rate (ESR)",
"    <span class=\"nowrap\">",
"     (&ge;30mm/hour),",
"    </span>",
"    low albumin, and electrolyte abnormalities due to diarrhea and dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with ulcerative colitis and primary sclerosing cholangitis may have an elevation in serum alkaline phosphatase concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fecal calprotectin or lactoferrin may be elevated due to intestinal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\", section on 'Fecal calprotectin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844648373\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal imaging is not required for the diagnosis of ulcerative colitis but may be performed in patients who present with symptoms of colitis.",
"   </p>",
"   <p>",
"    Abdominal radiography is usually normal in patients with mild to moderate disease, but may identify proximal constipation, mucosal thickening or &ldquo;thumbprinting&rdquo; secondary to edema, and colonic dilation in patients with severe or fulminant ulcerative colitis. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema may be normal in mild ulcerative colitis. Findings on barium enema may include a diffusely reticulated pattern with superimposed punctate collections of barium in microulcerations (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60508 \" href=\"UTD.htm?26/3/26687\">",
"     image 1",
"    </a>",
"    ). In more severe disease, there may be spiculated collar button ulcers, shortening of the colon, loss of haustrae, narrowing of the luminal caliber, pseudopolyps, and filiform polyps (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56793 graphicRef63353 graphicRef65953 \" href=\"UTD.htm?13/55/14198\">",
"     image 2A-C",
"    </a>",
"    ). Barium enema should be avoided in patients who are severely ill since it may precipitate ileus with toxic megacolon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link&amp;anchor=H7#H7\">",
"     \"Toxic megacolon\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Computed tomography (CT) and magnetic resonance imaging (MRI) may demonstrate marked thickening of the bowel wall, but this finding is nonspecific (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70898 \" href=\"UTD.htm?42/23/43377\">",
"     image 3",
"    </a>",
"    ). CT and MRI have lower sensitivity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema for the detection of subtle early mucosal disease but are equivalent in patients with established and severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound with Doppler may demonstrate a thickened hypoechoic mucosal layer in patients with active ulcerative colitis. More severe cases may be associated with transmural bowel wall thickening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59627 \" href=\"UTD.htm?11/0/11269\">",
"     image 4",
"    </a>",
"    ). However, these sonographic findings are not specific for ulcerative colitis and may be seen in colitis due to other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32154?source=see_link&amp;anchor=H10#H10\">",
"     \"Transabdominal ultrasonography of the small and large intestine\", section on 'Ulcerative colitis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1492761672\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25426712\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient with suspected ulcerative colitis serves to exclude other causes of colitis, establish the diagnosis of ulcerative colitis, and to determine the extent and severity of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25426526\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ulcerative colitis is based on the presence of chronic diarrhea for more than four weeks and evidence of chronic colitis on endoscopy and biopsy. Since these features are not specific for ulcerative colitis, establishing the diagnosis also requires the exclusion of other causes of colitis by history, laboratory studies, and by biopsies of the colon obtained on endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266085607\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of risk factors for other causes of colitis should be sought. This includes a history of recent travel to areas endemic for parasitic infections including amebiasis, recent antibiotic use that might predispose to an infection with Clostridium difficile, a history of or risk factors for sexually transmitted diseases (eg, Neisseria gonorrhea and herpes simplex virus (HSV)) that are associated with proctitis. Atherosclerotic disease or prior ischemic episodes are suggestive of chronic colonic ischemia. A history of",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    radiation and",
"    <span class=\"nowrap\">",
"     NSAID/medication",
"    </span>",
"    exposure should be sought as these may also be associated with colitis. In an immunocompromised patient, cytomegalovirus (CMV) can mimic ulcerative colitis. (See",
"    <a class=\"local\" href=\"#H1492761672\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"     \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42313?source=see_link\">",
"     \"Colonic ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844649662\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool studies should include stool Clostridium difficile toxin, routine stool cultures (Salmonella, Shigella, Campylobacter, Yersinia), and specific testing for E. coli 0157:H7. Microscopy for ova and parasites (three samples) and a Giardia stool antigen test should also be performed, particularly if the patient has risk factors such as recent travel to endemic areas.",
"   </p>",
"   <p>",
"    In addition, specific serologic testing for sexually transmitted diseases including Neisseria gonorrhea, HSV, and Treponema pallidum should be considered, particularly in patients with severe rectal symptoms including urgency and tenesmus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a complete blood count, electrolytes, albumin, and markers of inflammation erythrocyte sedimentation rate and C-reactive protein (CRP) should be obtained to assess disease severity. (See",
"    <a class=\"local\" href=\"#H1844648462\">",
"     'Laboratory findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of autoantibodies have been detected in patients with inflammatory bowel disease (IBD). Perinuclear anticytoplasmic antibody (pANCA) may be elevated in patients with ulcerative colitis. However, the accuracy of antibody tests in differentiating ulcerative colitis from Crohn&rsquo;s disease in patients with &ldquo;indeterminate colitis&rdquo; on biopsy, is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Antibody testing is therefore not part of the diagnostic evaluation of patients with suspected IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689197#H12689197\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Antibody tests'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25426712\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H596557081\">",
"    <span class=\"h3\">",
"     Endoscopy and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic findings in patients with ulcerative colitis are nonspecific. Biopsies of the colon obtained on endoscopy are necessary to establish the chronicity of inflammation and to exclude other causes of colitis. An ileocolonoscopy allows for evaluation of the terminal ileum for inflammation that would be suggestive of Crohn&rsquo;s disease and to determine the endoscopic extent and severity of colonic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, a colonoscopy should be avoided in hospitalized patients with severe colitis because of the potential to precipitate toxic megacolon. In such patients, a flexible sigmoidoscopy should be performed and evaluation limited to the rectum and distal sigmoid colon. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The endoscopic findings in patients with ulcerative colitis include loss of vascular markings due to engorgement of the mucosa, giving it an erythematous appearance. In addition, granularity of the mucosa, petechiae, exudates, edema, erosions, touch friability, and spontaneous bleeding may be present. More severe cases may be associated with macroulcerations, profuse bleeding, and copious exudates (",
"    <a class=\"graphic graphic_picture graphicRef81755 \" href=\"UTD.htm?17/50/18213\">",
"     picture 3",
"    </a>",
"    ). Nonneoplastic pseudopolyps may be present in areas of disease involvement due to prior inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H3#H3\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Endoscopic findings in ulcerative colitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biopsy features suggestive of ulcerative colitis include crypt abscesses, crypt branching, shortening and disarray, and crypt atrophy. Epithelial cell abnormalities including mucin depletion and Paneth cell metaplasia may be seen. Inflammatory features of ulcerative colitis include increased lamina propria cellularity, basal plasmacytosis, basal lymphoid aggregates, and lamina propria eosinophils. Although none of these features are specific for ulcerative colitis, the presence of two or more histologic features is highly suggestive of ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Basal plasmacytosis may also be a predictor of relapse in patients with seemingly well-controlled ulcerative colitis with complete mucosal healing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H28#H28\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inflammation usually involves the rectum and extends proximally in a continuous and circumferential pattern (",
"    <a class=\"graphic graphic_picture graphicRef76332 \" href=\"UTD.htm?43/47/44786\">",
"     picture 4",
"    </a>",
"    ). The initial episode of ulcerative colitis is limited to the rectum or sigmoid colon in 30 to 50 percent of patients, 20 to 30 percent have left-sided colitis, and only approximately 20 percent of patients have pancolitis with disease extending proximal to the splenic flexure and involving the cecum. Occasionally a subset of patients with ulcerative colitis have focal inflammation around the appendiceal orifice that is not contiguous with disease elsewhere in the colon (a \"cecal patch\") [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/20,34,35\">",
"     20,34,35",
"    </a>",
"    ]. Ileal inflammation (&ldquo;backwash&rdquo; ileitis) may occasionally be seen in patients with ulcerative colitis with active right-sided colitis. Unlike the ileitis associated with Crohn&rsquo;s disease which is patchy, backwash ileitis associated with ulcerative colitis is diffuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Backwash ileitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with CMV colitis, conventional hematoxylin and eosin stains reveal enlarged (cytomegalic) cells that are often two- to fourfold larger than surrounding cells, usually with large eosinophilic intranuclear inclusions, sometimes surrounded by a clear halo, and smaller cytoplasmic inclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/36\">",
"     36",
"    </a>",
"    ]. Immunoperoxidase staining should be done to confirm suspected CMV. Cultures for Neisseria gonorrhea and HSV should be performed in patients with severe rectal symptoms of urgency and tenesmus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492761672\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ulcerative colitis includes other causes of chronic diarrhea.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Crohn's disease",
"      </strong>",
"      &ndash; Crohn&rsquo;s disease that involves the colon may have a similar clinical presentation to ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/35\">",
"       35",
"      </a>",
"      ]. However, features that are suggestive of Crohn&rsquo;s disease include absence of gross bleeding, presence of perianal disease (eg, anal fissures, anorectal abscess), and fistulas. The absence of rectal inflammation and the presence of ileitis, focal inflammation, and granulomas on endoscopy and biopsy are also suggestive of Crohn&rsquo;s disease.",
"      <br/>",
"      <br/>",
"      Although ileal inflammation (&ldquo;backwash&rdquo; ileitis) may occasionally be seen in ulcerative colitis, these patients have active right-sided colitis. In addition, backwash ileitis associated with ulcerative colitis is diffuse and not patchy as seen in Crohn&rsquo;s disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689029#H12689029\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689148#H12689148\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Infectious colitis",
"      </strong>",
"      &ndash; Infectious colitis may have a similar clinical presentation and endoscopic appearance to ulcerative colitis (",
"      <a class=\"graphic graphic_table graphicRef67648 \" href=\"UTD.htm?14/62/15340\">",
"       table 2",
"      </a>",
"      ). Infectious colitis must be excluded with stool and tissue cultures, stool studies, and on biopsies of the colon. (See",
"      <a class=\"local\" href=\"#H1844649662\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Radiation colitis",
"      </strong>",
"      &ndash; Radiation colitis may be seen weeks to years after abdominal or pelvic irradiation. Radiation colitis involving the rectum or sigmoid colon has a similar appearance to ulcerative colitis on endoscopy. Although not specific for radiation colitis, histologic findings suggestive of radiation colitis include eosinophilic infiltrates, epithelial atypia, fibrosis, and capillary telangiectasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link&amp;anchor=H11872693#H11872693\">",
"       \"Clinical features, diagnosis, and treatment of radiation proctitis\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features, diagnosis, and treatment of radiation proctitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diversion colitis",
"      </strong>",
"      &ndash; Individuals with diversion colitis have a history of a surgically excluded bowel loop and prominent lymphoid hyperplasia on histology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9414?source=see_link&amp;anchor=H6#H6\">",
"       \"Diversion colitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Solitary rectal ulcer syndrome",
"      </strong>",
"      &ndash; Patients with solitary rectal ulcer syndrome may have bleeding, abdominal pain, and altered bowel habits. Mucosal ulceration may be seen on endoscopy similar to ulcerative colitis but solitary rectal ulcer syndrome has a characteristic appearance on histology with a thickened mucosal layer and distortion of crypt architecture. The lamina propria is replaced with smooth muscle and collagen leading to hypertrophy and disorganization of the muscularis mucosa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21125?source=see_link&amp;anchor=H4#H4\">",
"       \"Solitary rectal ulcer syndrome\", section on 'Histology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Graft versus host disease",
"      </strong>",
"      &ndash; Graft versus host disease (GVHD) of the colon can cause chronic diarrhea in patients with a history of bone marrow transplantation. Patients may have symptoms due to involvement of the proximal gastrointestinal tract (eg, dysphagia, painful ulcers) or other organs (eg, liver involvement as suggested by elevated liver tests, skin involvement resembling lichen planus or scleroderma). There are no endoscopic features of chronic GVHD of the colon that distinguish it from ulcerative colitis. However, histologic examination in chronic GVHD is characterized by the presence of crypt cell necrosis with the accumulation of degenerative material in the dead crypts (",
"      <a class=\"graphic graphic_picture graphicRef61225 \" href=\"UTD.htm?40/55/41845\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1844647392\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Clinical and histologic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diverticular colitis",
"      </strong>",
"      &ndash; Diverticular colitis is characterized by inflammation in the interdiverticular mucosa without involvement of the diverticular orifices. In contrast, in patients with IBD and diverticulosis, the inflammation involves the colonic area harboring diverticula, as well as the diverticular orifices [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/38\">",
"       38",
"      </a>",
"      ]. In addition, the distribution of the colitis in patients with diverticular colitis (ie, limitation to a segment of diverticular disease, sparing the rectum, terminal ileum, and other portions of the colon) also assist in differentiating it from ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20324?source=see_link&amp;anchor=H3#H3\">",
"       \"Diverticular colitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Medication associated colitis &ndash;",
"      </strong>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) can cause chronic diarrhea and bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/40\">",
"       40",
"      </a>",
"      ]. Other drugs that may cause a similar clinical presentation include retinoic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      , and gold. The diagnosis is established by a history of medication use and the presence of non specific mucosal inflammation or mucosal erosions on biopsy that resemble ischemic changes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"       \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492762071\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative colitis usually present with attacks of bloody diarrhea that last for weeks to months. With treatment, the course of ulcerative colitis typically consists of intermittent exacerbations alternating with long periods of complete symptomatic remission. However, a small percentage of patients have continuing symptoms and are unable to achieve complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Overall, patients who present initially with proctitis have a more benign disease course and frequently respond to topical therapy, whereas those who present with more extensive disease require systemic therapy and have a higher risk of colectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1575040140\">",
"    <span class=\"h2\">",
"     Disease course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 67 percent of patients have at least one relapse 10 years following the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The risk of relapse depends on the age at initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In an observational study of 295 patients with ulcerative colitis, patients with late-onset ulcerative colitis (diagnosed at age 50 years or older) had a higher likelihood of steroid free clinical remission (64 versus 49 percent) at one year as compared with those with early onset ulcerative colitis (diagnosed between ages 18 and 30 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/44\">",
"     44",
"    </a>",
"    ]. A disease flare within two years of the diagnosis, the presence of fever or weight loss at diagnosis, and active disease in the preceding year increase the risk of subsequent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extension of colonic disease is seen in up to 20 percent of patients within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/42,46-48\">",
"     42,46-48",
"    </a>",
"    ]. Patients with proctitis have a 50 percent chance of extension and those with disease proximal to the sigmoid colon have a 9 percent chance of progression to pancolitis.",
"   </p>",
"   <p>",
"    Approximately 20 to 30 percent of patients with ulcerative colitis will require colectomy for acute complications or for medically intractable disease. The likelihood and timing of colectomy depends on the extent of the disease and severity at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/42,43,49,50\">",
"     42,43,49,50",
"    </a>",
"    ]. As an example, for patients with pancolitis, the rate of colectomy is approximately 19 percent after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, 5 percent of patients who present with proctitis alone have undergone colectomy after 10 years. Patients with left-sided ulcerative colitis and a cecal patch have a similar course as those with isolated left-sided ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucosal healing in response to treatment is also important in predicting long-term clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In an analysis of two multicenter, randomized controlled trials (ACT-1 and ACT-2) in which patients with moderate to severe ulcerative colitis were randomized to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or placebo, early mucosal healing as defined by a Mayo endoscopy subscore of zero or one at week eight in patients treated with infliximab was associated with a lower risk of colectomy through 54 weeks and higher rates of symptomatic remission, steroid free remission, and subsequent mucosal healing at weeks 30 and 54 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H596557654\">",
"     'Disease severity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link&amp;anchor=H3#H3\">",
"     \"Anti-tumor necrosis factor therapy in ulcerative colitis\", section on 'ACT 1 and ACT 2 trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266085790\">",
"    <span class=\"h2\">",
"     Chronic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term complications of ulcerative colitis include strictures, dysplasia, and colorectal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266086647\">",
"    <span class=\"h3\">",
"     Stricture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign strictures can occur due to repeated episodes of inflammation and muscle hypertrophy in about 10 percent of cases with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/55\">",
"     55",
"    </a>",
"    ]. Strictures are most frequently seen in the rectosigmoid colon and may cause symptoms of obstruction. Strictures in ulcerative colitis should be considered malignant until proven otherwise by endoscopic evaluation with biopsy. Surgery is indicated for strictures that cause continued symptoms of obstruction or that cannot be fully evaluated to exclude malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H165136853#H165136853\">",
"     \"Surgical management of ulcerative colitis\", section on 'Types of surgical procedures based upon clinical setting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1844648639\">",
"    <span class=\"h3\">",
"     Dysplasia or colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative colitis are at increased risk for colorectal cancer (CRC) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63411 \" href=\"UTD.htm?9/60/10191\">",
"     image 5",
"    </a>",
"    ). The extent of colitis and duration of disease are the two most important risk factors for CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of CRC appears to be highest in patients with pancolitis, while those with proctitis and proctosigmoiditis are probably not an increased risk of CRC, regardless of the duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/57\">",
"     57",
"    </a>",
"    ]. The CRC risk begins to increase 8 to 10 years following the onset of symptoms in patients with pancolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In one prospective study, the cumulative incidence of CRC was 2.5 percent after 20 years and 7.6 percent after 30 years of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/61\">",
"     61",
"    </a>",
"    ]. Patients with left-sided colitis have almost the same risk of CRC and dysplasia as those with pancolitis but the risk of CRC increases only after 15 to 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that are associated with an increased risk of CRC include endoscopic and histological severity of inflammation, positive family history of sporadic colorectal cancer (twofold increased risk), postinflammatory pseudopolyps (twofold increased risk), and the presence of primary sclerosing cholangitis (fourfold increased risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/19,64-67\">",
"     19,64-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link&amp;anchor=H2#H2\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H2#H2\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79249606\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative colitis may have a slightly higher overall mortality compared with the general population (HR 1.2, 95% CI 1.22���1.28) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. The overall mortality appears to be highest in the first year after ulcerative colitis diagnosis (HR 2.4, 95% CI 2.3���2.6). Long-term, cause-specific mortality may also be increased in patients with ulcerative colitis (infectious disease HR 1.6, 95% CI 1.2���2.2; gastrointestinal disorders other than ulcerative colitis HR 1.3, 95% CI 1.1���1.5; and colorectal cancer HR 1.5, 95% CI 1.2���1.8). However, mortality rates appear to have decreased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/7/11386/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcerative colitis is characterized by recurring episodes of inflammation limited to the mucosal layer of the colon. It commonly involves the rectum and may extend in a proximal and continuous fashion to involve other parts of the colon. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ulcerative colitis usually present with diarrhea which is frequently associated with blood. Associated symptoms include colicky abdominal pain, urgency, and tenesmus. Patients may also have fever, fatigue, and weight loss. Ulcerative colitis primarily involves the intestine but may be associated with several extraintestinal manifestations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Colitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1844647817\">",
"       'Extraintestinal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ulcerative colitis should be suspected in patients with chronic diarrhea for more than four weeks. The clinical presentation, including laboratory features, endoscopic appearance, and radiology findings, is not specific for ulcerative colitis, and may be seen in a number of other causes of colitis including Crohn's disease, radiation colitis, ischemic colitis, infectious colitis, and colitis related to medications (",
"      <a class=\"graphic graphic_table graphicRef67648 \" href=\"UTD.htm?14/62/15340\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1492761672\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ulcerative colitis is based on the presence of chronic diarrhea for more than four weeks and evidence of chronic colitis on endoscopy and biopsy. Since these features are not specific for ulcerative colitis, establishing the diagnosis also requires the exclusion of other causes of colitis by history, laboratory studies, and by biopsies of the colon obtained on endoscopy. (See",
"      <a class=\"local\" href=\"#H25426526\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ulcerative colitis usually present with attacks of bloody diarrhea that lasts for weeks to months. The course of ulcerative colitis typically consists of intermittent exacerbations alternating with periods of complete symptomatic remission. However, a small percentage of patients have continuing symptoms and are unable to achieve remission. Overall, patients who present initially with proctitis have a more benign disease course and frequently respond to topical therapy, whereas those who present with more extensive disease require systemic therapy and have a higher risk of colectomy. (See",
"      <a class=\"local\" href=\"#H596557654\">",
"       'Disease severity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1575040140\">",
"       'Disease course'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"       \"Management of mild to moderate ulcerative colitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"       \"Management of severe ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extension of colonic disease is seen in up to 15 percent of patients within five years. Approximately 67 percent of patients have at least one relapse 10 years following the diagnosis. The risk of relapse depends on the age at initial diagnosis. The likelihood and timing of colectomy depends on the extent of the disease and severity at presentation. Mucosal healing in response to treatment is an important predictor of long-term clinical outcomes. (See",
"      <a class=\"local\" href=\"#H1575040140\">",
"       'Disease course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications associated with ulcerative colitis include severe bleeding, toxic megacolon, perforation, strictures, and the development of dysplasia and colorectal cancer. Patients with ulcerative colitis may have a slightly higher mortality as compared with the general population. (See",
"      <a class=\"local\" href=\"#H2266085790\">",
"       'Chronic complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/1\">",
"      Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/2\">",
"      Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749.",
"     </a>",
"    </li>",
"    <li>",
"     Yamada. Textbook of Gastroenterology, 4,  Vol 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/4\">",
"      Langholz E, Munkholm P, Nielsen OH, et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/5\">",
"      Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625.",
"     </a>",
"    </li>",
"    <li>",
"     Becker JM. Surgical management of ulcerative colitis. In: Inflammatory Bowel Disease, MacDermott RP, Stenson WF (Eds), Elsevier, New York 1992. p.599.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/7\">",
"      Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilatation in ulcerative and Crohn's colitis. J Clin Gastroenterol 1985; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/8\">",
"      Jalan KN, Sircus W, Card WI, et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 1969; 57:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/9\">",
"      Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am 1989; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/10\">",
"      Mons&eacute;n U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990; 85:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/11\">",
"      Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/12\">",
"      Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/13\">",
"      Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/14\">",
"      Spina L, Saibeni S, Battaglioli T, et al. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005; 100:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/15\">",
"      Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008; 6:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/16\">",
"      Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/17\">",
"      Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/18\">",
"      Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/19\">",
"      Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/20\">",
"      Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/21\">",
"      Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/22\">",
"      van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/23\">",
"      Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/24\">",
"      Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/25\">",
"      Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/26\">",
"      Sandborn WJ, Loftus EV, Colombel JF. Utility of perinuclear anti-neutrophil cytoplasmic antibodies (PANCA), anti-saccharomyces cerevesiae (ASCA), and anti-pancreatic antibodies (APA) as serologic markers in a population based cohort of patients with Crohn's disease (CD) and ulcerative colitis (UC) (abstract). Gastroenterology 2000; 118:A106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/27\">",
"      Boon N, Hanauer SB, Kiseil J. The clinical significance of pANCA and ASCA in indeterminate colitis (abstract). Gastroenterology 1999; 116:A671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/28\">",
"      Sandborn WJ, Loftus EV Jr, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001; 7:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/29\">",
"      Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/30\">",
"      Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013; 11:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/31\">",
"      Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007; 133:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/32\">",
"      Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/33\">",
"      Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012; 107:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/34\">",
"      D'Haens G, Geboes K, Peeters M, et al. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997; 92:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/35\">",
"      Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol 1999; 94:3258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/36\">",
"      Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/37\">",
"      Woodruff JM, Hansen JA, Good RA, et al. The pathology of the graft-versus-host reaction (GVHR) in adults receiving bone marrow transplants. Transplant Proc 1976; 8:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/38\">",
"      Tursi A, Elisei W, Giorgetti GM, et al. Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease. Aliment Pharmacol Ther 2011; 33:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/39\">",
"      Lamps LW, Knapple WL. Diverticular disease-associated segmental colitis. Clin Gastroenterol Hepatol 2007; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/40\">",
"      Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/41\">",
"      Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/42\">",
"      Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/43\">",
"      H&ouml;ie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/44\">",
"      Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol 2010; 8:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/45\">",
"      Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology 1983; 85:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/46\">",
"      Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/47\">",
"      Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/48\">",
"      Ayres RC, Gillen CD, Walmsley RS, Allan RN. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol 1996; 8:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/49\">",
"      Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/50\">",
"      Allison J, Herrinton LJ, Liu L, et al. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol 2008; 6:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/51\">",
"      Mutinga ML, Odze RD, Wang HH, et al. The clinical significance of right-sided colonic inflammation in patients with left-sided chronic ulcerative colitis. Inflamm Bowel Dis 2004; 10:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/52\">",
"      Fr&oslash;slie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/53\">",
"      Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/54\">",
"      Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/55\">",
"      De Dombal FT, Watts JM, Watkinson G, Goligher JC. Local complications of ulcerative colitis: stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J 1966; 1:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/56\">",
"      Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-analysis of Population-based Cohort Studies. Inflamm Bowel Dis 2013; 19:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/57\">",
"      Levin B. Inflammatory bowel disease and colon cancer. Cancer 1992; 70:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/58\">",
"      Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/59\">",
"      Lennard-Jones JE. Cancer risk in ulcerative colitis: surveillance or surgery. Br J Surg 1985; 72 Suppl:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/60\">",
"      Collins RH Jr, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med 1987; 316:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/61\">",
"      Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/62\">",
"      Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991; 100:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/63\">",
"      Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/64\">",
"      Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998; 115:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/65\">",
"      Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/66\">",
"      Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/67\">",
"      Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006; 130:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/68\">",
"      Jess T, Gamborg M, Munkholm P, S&oslash;rensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007; 102:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/69\">",
"      Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013; 11:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/7/11386/abstract/70\">",
"      Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013; 19:599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4067 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11386=[""].join("\n");
var outline_f11_7_11386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1844647392\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H596557654\">",
"      - Disease severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25425471\">",
"      - Acute complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1844647817\">",
"      Extraintestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1844648462\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1844648373\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25426712\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25426526\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2266085607\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1844649662\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H596557081\">",
"      - Endoscopy and biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492761672\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492762071\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1575040140\">",
"      Disease course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2266085790\">",
"      Chronic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2266086647\">",
"      - Stricture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1844648639\">",
"      - Dysplasia or colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79249606\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4067|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/3/26687\" title=\"diagnostic image 1\">",
"      Acute ulcerative colitis BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/39/639\" title=\"diagnostic image 2A\">",
"      Pseudopolyps in UC BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/36/41551\" title=\"diagnostic image 2B\">",
"      Filiform polyps in UC BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/4/24655\" title=\"diagnostic image 2C\">",
"      Chronic ulcerative colitis BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/23/43377\" title=\"diagnostic image 3\">",
"      Ulcerative colitis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/0/11269\" title=\"diagnostic image 4\">",
"      Ulcerative colitis US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/60/10191\" title=\"diagnostic image 5\">",
"      Sigmoid cancer in UC BE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4067|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/3/33854\" title=\"picture 1A\">",
"      Anterior uveitis in a patient with IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/25/16799\" title=\"picture 1B\">",
"      Diffuse episcleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/28/463\" title=\"picture 2A\">",
"      Erythema nodosum IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39187\" title=\"picture 2B\">",
"      Pyoderma gangrenosum early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/47/7920\" title=\"picture 2C\">",
"      Pyoderma gangrenosum cribriform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/50/18213\" title=\"picture 3\">",
"      Ulcerative colitis endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/47/44786\" title=\"picture 4\">",
"      Continuous lesions UC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/55/41845\" title=\"picture 5\">",
"      Rectal biopsy in acute GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4067|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/51/33595\" title=\"table 1\">",
"      Hypercoagulability in IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/62/15340\" title=\"table 2\">",
"      Infectious mimics of IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?8/46/8929?source=related_link\" title=\"calculator 1\">",
"      Calculator: Mayo score for assessing ulcerative colitis activity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=related_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9414?source=related_link\">",
"      Diversion colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20324?source=related_link\">",
"      Diverticular colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28872?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=related_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21125?source=related_link\">",
"      Solitary rectal ulcer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32154?source=related_link\">",
"      Transabdominal ultrasonography of the small and large intestine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_7_11387="Utah criteria for ADHD";
var content_f11_7_11387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F70999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F70999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Utah criteria for attention deficity hyperactivity disorder (AD/HD) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Childhood history consistent with AD/HD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adult symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperactivity and poor concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Two of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Affective lability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Hot temper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Inability to complete tasks and disorganization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Stress Intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Impulsivity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wender PH. Attention-deficit hyperactivity disorder in adults. Copyright &copy; 1995 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11387=[""].join("\n");
var outline_f11_7_11387=null;
var title_f11_7_11388="Lifestyle changes in CVS";
var content_f11_7_11388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifestyle changes in CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lifestyle changes (for one to two months or one to two cycles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Reassurance",
"        </strong>",
"        (eg, episodes are not self-induced) and anticipatory guidance (eg, natural history)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Avoidance of triggers",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keep a \"vomiting diary\" of potential precipitating factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid fasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recognize the potential role of excitement as a trigger (eg, downplay big events)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maintain good sleep hygiene (eg, avoid sleep deprivation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid triggering foods: chocolate, cheese, monosodium glutamate, antigenic foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid excessive energy output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Supplemental carbohydrate: for fasting-induced episodes",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide fruit juices, other sugar-containing drinks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide extra snacks between meals, before exertion, or at bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Migraine headache lifestyle interventions",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regular aerobic exercise (avoid overexercising)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regular meal schedules (ie, avoid skipping meals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderation in consuming or avoidance of caffeine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11388=[""].join("\n");
var outline_f11_7_11388=null;
var title_f11_7_11389="Methacholine test in pregnancy";
var content_f11_7_11389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Improvement in bronchial responsiveness during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 212px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchial responsiveness, as measured by the dose of methacholine required to produce a 20 percent fall in FEV1 (PC20) before, during, and after pregnancy in 16 women with asthma. The PC20 increased 1.5 to 2-fold during pregnancy, indicating improved bronchial responsiveness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Juniper, EF, Daniel, EE, Roberts, RS, et al. Am Rev Respir Dis 1989; 140:924.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11389=[""].join("\n");
var outline_f11_7_11389=null;
var title_f11_7_11390="Superficial hemangioma";
var content_f11_7_11390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 157px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial hemangiomas consist of a bright red papule, nodule, or plaque raised above clinically normal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11390=[""].join("\n");
var outline_f11_7_11390=null;
var title_f11_7_11391="Retinal ischemia in Behcets";
var content_f11_7_11391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal ischemia in Behcet's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAopQCSABk12vhfw2qxpeaipL9Y4SP1NY168aEeaR04XCVMVPkh832Kfhvww12Y7nUMx2x5VP4n/+tXdxIqKIoFCovRRwBTEJZu5AqYHbgqOtfPYjETryvL7j7zLcDSwsbQ36vqx6RNnPam7WDYxnNSo5zjipgilTjr61yOTW569k9iMDauSMCpFCnnGD60xTlgvOB61ITjG0CpZa13JQO3X0qRR8+e1Mi6cjmpkXIyelYyZdh4yckdKTGfb1zTkXkKDwaeyAYGelZXC+okXbBwe1SSp5p4b5h+tROCTxximI5R1I655zStfVF8xI0eSOmT1pDHgVfEYlhJQgNVfYxJGOlSpleRAyDv1pyRHqOakVCTzinj5DweKHIhqwxUwemc96nRvkwO1C9OcZpoXI461Dd9yWi9EpZRzkVaQ7VwV68VBZKrAK1WJCEwq8jsa5ZvWwm+hUQ7tyFunrVaZMyjoPWrEgCTE+tQPkuMVrHuNrsV70qQMckDis0WrlC5bGe1bt1AAiF1wxHWs1lw2PSt6U9NDKcbspsgDAyDKAVVZowCME56EVrvt8twfTms5I0VSSOK6YSvuJ02jjfE3hqC/R7ixVYrsdU6B//r159cQSW0zRToUkU4INew3n8RUd6wtc0e21WPccpcqMK47+xr3sFjXBctTVfkfK5vlVOterRVpfg/8Agnm1FT3dtNaTNFPGyOOxFQV7aaauj46UXF2e4UUUUxBRRRQAUUUUAFFFFABRRRQAUtJXYeD/AA8biMajdqPJU/ukP8R9fpWNetGhDnkbUKEq81CI/wAL6MLQJe36DeRmOMjp7mutSQOeuSaiZfMbL4JpUjAPyjB/lXz1aq60uaW59dhKUaMeSGxbhXGWzwKkC5IIHFQRRkLlm5zVpD14yPSuaR7OHTsIqDPUgmpFfapXGMd/WgOm3HG6ngBiDnis2+51xdtBIBtYllyO1S7gzggVGAW+7xg9KeDgc1LN47E7KMA5pwYcdcVHncox0qVVOBjp2rJ+ZqiRHHGOtTFGxnggdRUKAlhwOOtWFJ5IPBrKWmwrJkZYLyc1FgF896mbJOCuaWJGYknGBQnZXNEkSxHHI6VbgxIegDVDEQIyoALU+M4kyxC46Vzy1HIWeHyx83ektbRr2dYUZUJySzcDitNXguoiCPmUVnyKVzt4NZxm2rbMzvzKxHGIt+12O1TgkUFcEYzmiKMKemWPrT2TBDK2T6elXfUVixbyoi5I5qXyy5Gzv6VTRf3qkjitMFWA8rGPWsZ6O6JloVLyLYmT681XEY2q2SRV1kaRXB+aonhYogHQ9KcZWVmJPuQ3EpmATJIXjNZ7RnzGORkdq2DbCNSp61QuY/m4Fa05LZE37GbLlULEZFU2bIwK1nIK7SBVGXYpwEIx3x1rrpyIcn0MW9Jb7qZ9SKbHHt5I4I/KtDBcHIAHr6CmzyDaFTG3v712KeljjnS5nzNnM67pSararFu2zIco5H6GvOru3ktLmSCYYkQ4Ir1mTiYHHSsnxPo0GpWMk8KAXqDKkfxj0Nerg8Z7JqE/hf4Hz2ZZZ7eLq0/iX4r/ADPNaKcylWKsCCOCD2pte6fIhRRRQAUUUUAFFFFABRRUkMTzSpHGCzuQoA9aNg3NXwvpI1bUQkpZbdBukZR+lejGRYUSGJQkaDaqjsKi0yxXS9Mitogu8cyNj7zd6juA24sDgdq+cxNf6zUv0W3+Z9HhaDw8NtXuLJMA/vUQuSJeoNVGkwxzRtyNwBz60o011PRoO5sRSs+MjmrUU+0bSvJrEs3cN3NaZcOozwKxq07Ox60ZuEdC4EUOWJ5NWFUlA1VIei85q8oynXBrknodFKXMGAvIyDUAOepOas7cD2qNlVnG3ipiztgPjchemBU8Um7GaiVcjHpUgT5eM5qJWNSwpBOB1qRVJbB7VXQYdQanDnd8vSsZLsLYk8v5utSsdijjBxUasAOp3CmtMWHIyP5VnZstMtIFEQIbD96gebdJjHzdAaYGO3JHBp6Ku7I60rW1YMnt2kTOzg96vWqLco0kmRjqPWq9u4JIOOlS2W6OUKynaTWE+vczeg2cZG6MHGeBSxxAblc4ccgVfuIuMR/ePUgcCqVxGRGuDlg2c1EZ3VhRlccI2iHmEDA7GprWZJBlgBg8gVSDsQfMPU9KY/ysccCm4X0YNX3NRpEVJChB9qhM+SoC8DnNVefLJBxTklKhUIxkdalQsS1ZEtwxbkct7VmOzmQjHbvV3zzFIQgBJ71Supl8xgDW1NNaElCdykmO9GTK+GO0EYqKfDXSkZz69qJ5E/gByO9dqjtYS1G3e1EKJz71nMrMeRhRViabPbFQB29crXRTi0iZpFS5dQPm4HrUPAUBScHvVu6RWXkc+9VWwkfHeumDTRxzhrqcf4x0na3223QkH/WgDp71yVesOSytlcqRgg9xXm+tWElheMrD923zIfUV7eBr8y9nLdHyGdYFU5+3prR7/wCfzM+iiivRPACiiigAooooAK7j4f6YoSbUp48lTshJHQ9zXIabam9voLdTjzGC59B3NevQJDa20dnbriGJdoz3968vM6/JD2cd3+R6WXUOeftHsvzIZXyTnmoZcMpq0VURgnrVSUgE+teNE96Oi1KrRIQeMGmbCAABVtUDEFutOePBxng9a3U7aHfQ5UtBsEWyIEEdeamRMnpToIQDjk1p2tnuGawqVVHVnZyplONGXHNXEcnhqt/ZgMZHSnvbKynb0rllVTOmklEFjymevFQeWA5JqzbD5SrH6VJLCCmR1FY89nY6oyIYkOMkcVI0ZyNvSpIANozzUpILDbUOTuVe5WRCT83Jp6fKOM9etSsecbRijJzjHFLmuNNCuE2BlI3HrQqBh14qGQgZ64pFkCqQBwKVnbQu5eZUEfyjHvUBbZ8wpEuA8e0jmkfGNuKlRa3E5aF2L7gdBlj+lXY9xZWkzwKp2K7UDM2ENWZMxuChLE8gGuee9iG7l2N33Mij3GazS08UrbwfTBq9azmaVHmO3b2FR6wzNMHC4BHGKyhpLlaITs7EDKCoO3nuajKMyFuoB6UiSsYwnappHURgAcgdq11Rpci3fKoI709grcnoO1V3mBYAche9Rm4y5HT3quRikyZtu4seQBWXyz5bkZ5q4HYo2OrGqzoF3BOvetqehDKd65DFEPyVRZnBGDVqdWKn0qJVDZ2g8da7YWSC2pGygr82d1QjK5Aq2YcR7i3emNCEQM3Q+tWpImSbZTm46ZJ96qzIzcqv1NXyA56HaKdIgEZGOK1jPlMp01K5npyu1jWR4lsPt1gyRrmWP5k9/UVvTLtIwv1NQO2T8oHA7VvSqOMlOJx4mhGpTcJ7M8kIKsQRgjgg02t7xhYm11PzlXEU43j2PcVg19LSqKpBTXU/O8RRdCpKm+gUUUVZiFFFKASQB1NAHZ+ANOUeZqdxjYuUjHfPc12DyK/CH8ayNOg+xaRbW+MOE3MPc9afFcOG5r5rEN1qkp/cfTYWMaNOMfv9TUlbCYI/Gqr4LZFSxzLKmMgGmyBAMkjPpXPHTQ627q6GQ/NJ6Gra2xkGOfrVKEruKk8etbdmUIChue1KrJx1R04ddWR20DqMFa3bBBCmXAIx0qGBdg28Ed6uQkLJh/lU151ao5aHepWRKYA2HC/Ke1MltHXqBzyKurcALiNR7VK80kiDcnHc4rj55IuEmZSxrgYHPQ0rw8bVNStgAt2zUEknHB/CtU2zsi2QCJkk+U5FWEVQDg81Akh9QBT1ZcMQferd2bomaMspwOKjjUrnd+FIkjHlj8tMmd1bA5zSSew0uoxlyxwenamsQABj6+9XY4cwGTH4d6rOhcFlXbj1qoyT0LY2MBh+7HNSRowPzdO9JCxXA6HpVxIZDyASuKU5WMyewDEbduVq3bxOLgvMDt7Cm6WSJAHjyuegrppLN7naPLZUxxgdK86vW5JWZjUqqLszKt7ZWBOPmJ4FV7y2fnDZ7YrobfR3HzEsOadNpMpYsck1yrExUtzn+sRT3OWS2QxfMDvFQ7RG0m85ArXvLGeFgoDAHrxWPqQUSbEJCr19zXZTnzvc6IVbmfJHtOTjnnFQKuXwBz71a5aM5GT2pDsijyR+9rsUjR7jZXKIFGM1UPLHLYpLjJBINQLkqMnGa1hDQYS4Rto+ZT3NMWGRydvCjrVgRAgEkkCrD8RAAcHtV89thPyMu4BCMG6HpimOGMaqynj1q+yAkEgfL2pLlGkAI7ccVansHI2ZkhBHy9uopqMduW/CpZUC5x1qJ2YpgDC+tbrUiUbyI5lY89M1CkQU7mYVYJ3oMZOKJEIhxgZPr2q07KwnBTZz/iW3jvdJuI1XdIg3ofQivMq9ZmUBsN0PB968316xNhqUsQUiMncn0r3cuqJJ0/mfHcRYbWNaPTR/oZ1FFFeofLhWv4XsxeazCrDKJ+8b6Csiut8BQEy3M/QABQa58VPkoyaN8NDnqxR1NxG7S7hyDUEsR3HHGa1rWAlxjkGrM1moORjNfNe2UXY+hjDmMizhwRjNS6gPLUgCp0geKTBPHWnzQ+eSc4Whz967OulS92xiKQMhCSfWtPT5TuXPWs+e3eGQ7RnNaGlgowZlz7VtVacLnRTtHQ6W1cCPL9W6VPGuHy5YoTjB/nVS22uwyD9PSrdw+GQnIANeNNa2OuOpoINuOMgUtxctFGRnr09qrxzNgN2qK8dXwV5audQvLU7IRQ2e4GwdM1SkmO4EDNHlMTvboaSRMMCOAO1dcYxR0LQmDAoecE9qgjch/VaV03EYP604qVGKasjaNiZTvGM4q3DCGI5Gfes9AQQcVoqFByrZz6+tZVNNiieWTygAFPy8EjvUUcTXAVucHPFEUwjlHmng9RVuO7SBGMaZB6Gud3jstRPQoNtQkP8Ae7Ve0v7RdSLFGG+Y4qgsLzz5P3mNeieEdL+zQLM6gseh9KyxdeNGnd6s5a9VU48zLukaFFbIGlG+Qjv2rcS36bR+FTRJxz2q1GnHAr5WrXlN3kz56riJSd2ymYQBjFMaMg9D9a09lRsmRWKmYqqZF5BG8DFh82MCuR1zw85w1uc8ZPFdzNGWmx/COaiePbuY8iuyhiZUneLOujiHT2PKmhFmP3gG/oAe1ZNwdzsQee9df4z0xin2qIggHkCuOwSPQ19LhaiqR5z2qdTnSkVZGI5akA8wAAVNImRjqaIYcNjOB6123SRutQUMiMBg0xTI79akuD5IOOfeqbStjk8H0pxTepaSLRwAf71VpZWGRuwB/dqeMxqoLtkkcCqt5Mu7KginBa2Cb0IcZOSTQUDgg8DtTWnUDbg896inlAwB/wDrroUWTdRVx+0RoSO9VpbgnrwPephzF/Ss+4YmNwATitYRu9TmxFXkSsROdzH3rlvHcGYrWfqVJQ4/OurgdHgOVKgd6ydet1vNMnRD8wG4celd+GnyVUzx8fD22GlFa3R5zRS0lfRHwYV33hOA2+lo3RpCXNcF3r0nTYhHbQrn7qD+VefmMrQUe53YFe+5G7ZyYU7SAa0bdvN5YYI7Vh2pAc4NbNsQ0fDYI/Wvm60bHuUpXJLxFcjaPm71A1u2ARwP51oR7Whz36YpvIYDHFYKbWh6FN2RQ8hS25lFOSFTkAAYq7hWyMAU9I127VX5upNN1WdC1C2iLD5Ogqw8TmQCTp24qSyj+QjOCankxub5ixXv6VzSn7x0QSIZlKRjPAHU1XjKkHBzmppCWX/ZPamrCqqSAeaFotTqXkMjH8ORn606RFBxkD1qEKPPDE4z0pLmQkkHt0NXa7KTZDJtQ0wTDd1pkpD5GeRUapkV0KKtqdKNFXHlgx4OasRyE4PHFVLaIhRzUoGwNg5x1rCSWyNEuo6c7mJOOKBMSoQHAB5NQjc5Ocn0poUoxDDnNHKrWMqjNvTMG6j3DjIr1rS41W1jA6Y6V5ZoIU3sRYA16vZN+5j47V85mz1SPJzFuyRoRKOhq3GtVoulWkIAHpXgSPAqNkmzoe1RyqByeBT/ADVGR3puQxy5ye1SjNXRUCfMGI61FcpkYxgVdYqXAB5qtdnr7Vom7m8JNswbyBJI2ikUFG4IrzTVrF7e9nRU2xg8fSvU7hcHHVj1rgPGzOl0BGPlxyfWvcy2pLn5V1PawU3exzDj5tqj8TTJH8tSMjP1qZV83HJU4qhcR4dl5+tfQQSbsz1U7IbMTIm7d8oqnIwxxxirOCy7RnFRLAW69R0Ga6YWW5a1IGcqc9RTJW3ENk49KsSwEAksOOoqB147cVtFp6obWmpCrru/eHg9KY2PMJzx2qCU5YEEZpd24HJrfl6kXTWorzPuIRvyqN/kU5PJqMEq25TnHUUrLuUknnrWiikccl1ZDKSsW0dOtQB94C4AHf6VPISyncO3aqWNo47+taxWhxzVtEee3ieXdTJjGGIqGr2trt1S4H+1mqNfRQd4pnwFaPJUlHs2Pi/1qf7wr0a1YPEOTwBXnMJxKh/2hXe2E25cjrjkVwY9XSOnB9TUjbY4Oa07eXewA6VkqynnuauWhYD5QMZ714tSN0etSep0SlUGM84pJpV288HHFZqynfy/bpRvYnBPAri9l3PQhIvxvxjt61dhYFdpPJrGfdxgnHtVqOURhADUzp32OyBuxlYlwaQtGGPo1ZyTGQ8N2p6t1DdK5XTtudcB5cGQgdB3onY7OOKbwI+nNNOdoyOBVpHXFOwwKXzuNRTfKwAJxU6uMli1QuTI+ccVpHc1UbkGACec1PAh68YPrTTgDgUqtuG0Vbdza1tDRRkVNvBzUbGNvUCqqkg/Snxy4PzAYrHktqUTmQBlwPoajdhJIM8EGmOVJLA8dPpSR5PPemo21Inqb+lOltcIzHNen6RIJbKJwe1eNxSZBOST712XhHVZI5IoZHzGTjmvGzLDOceZbo87GUnUhddD0eKTHeraNuAGazI3GBtIqxG/PoK+ZlE+fnAs+SN+7JBprMHJjcEN600THqDxUZkzcoTjBFJJkKL6lsbUAA/Oq1w2eFpJJACfWo5XypwaIrUcIa3M66IOQuc964jxYge5U57c12F24Qbn4A61xmu3CXEsm1lAAr2MAmp3R7ODi07nI3z+Ux2nA9qzZpSwLAnn3q1qON+WbjtWY74X5R+NfWUYaJnoSlbQekkjKdxxjsKVWIXOSKhj3bSxpC53YA4ro5TWnpHUWafPJ4qsW35+firMifLk1V8sZHNaQsOcZSduhHIvQio27kjmrpTapBXI7VUmOGKgfXFaRd9BVfciRIMnDHFNDjed2eaejjv09acqpkkEEkflV3PPm29ERMylQAOapzjb9449Ku8Kc4/Gq85VwNwyfWrg7Mhp8rbOI8UxeXqIb++gNY1dL40H721bHOwiuar3sM+alFnwmYx5cTNDo/8AWL9a67RyzZDfnXIx/fX612GjQSISWxg81ljLcheDtZo2o1x9PWrkRyBtPIqryVAqaHMf3/wrxJanpQWpeQ8cfe9anjwwyx59qqwugbL52mpEcF/lGFrnlE9Kii2sh5UdKePujOKgVgF68GjaWX5ZOKz5T04QVi2XKKGU/WnrM7MPSqCsQ4UmrJn8s9ORUuB1U43LrTFAN1P8weWfm61nyXIdeQd1Pi3uvoPas3SstTpSLS/vEwBgdzRHgZ/KkDHovHHShQcCpNEB5AznFOjQc4OMUkqnGR0NHIGP1pbosci7WGTkGmz7M5GcA1KingEHFRzxktt6jvQnrqUkQNPnagHFWoGJ+VRVVownbg1Nb5XAH4ZqppNaAybkNtU55wat21xJbyoQTgGqqFixA6+1SEcZPGOtYSSejMZRseneHNZS5gCOcOPeujWXp6V4nZXstvJlSR+NdbpniCUhVL5Poa8DF5a1LmhseVWwfM7xPQkk4NQzzbZoVxgHmsaHWoVgBlbB6kVWvtctj5UnmEBWwa86OFm5bHLDDS5tjoppxyR1qrJdiM7nOB6Vyl/4qijaRYefQmucuNZnu5S5lYDpjNdlHLaktZKyOingn9rQ73VrpJbchOp6muA1UGNn2NuHepbnU8IpEmVYYPNZMs5Vzg5B969PCYV0jto0XTVkZV3JvOfSq4BdDngCtFhHcKQhCn6VC9u0YwQPevZhNJWNoU7u7KS527TTUH7zIqeYDHFVypXbjrXQtTp5bDpn69h3zVYMGOfQ026dskCoo/u8cGtYw0Mpz1sW7mYkDAxisuR3y5A4PerbkiPBwarkHaQTgVdNJHLVnzMpmc7sNxzVhpAnzAdqbJCh5Xk0x2HllD1rWyex584VE7k6y+bHkDrUBXbyD9aS3ZdpVsj0IqO6cIoG78u9Uo2dkaufLTuzn/GpGLXHvXLV0Xixtwtgc5wetc7XtYRWpJHw+aO+Jk/T8h0ZxIv1Fdjp83zdwcVxorqbaYIsbjgbRUYuN0jPCu1zoImJAqwORzyKyba63nOOelaMO9vumvHnBx3PUpO5ZRCetSorKBnNCKqsN+RVpVTZgZz2rnlI9bDqwwyEqQozSxlthLHAHWmgiMHbTBJvBU5pWvserCzsWFYFQQcj37VLGAwO/oKrLtVepzUkbEgk9KmS7HbTSuWtyEdAPenwvt6dKqZ49qkhbAqHDQ3aNGNWMZkAG0d6YsrbzxUG4ocbs5pQ5XpWPIDROZGJ68U9GJ4wSKhLHgAAk08kqozwBUtFIvQkuAoGMUzIR2wDjpzUcEpEilefX2p87BupJz6VjazsUiG4XOdp3CmxZQ5I6VJGAHx2qzFEZVJAxjqTVOXKrMbIoG6svBFOZizA9W9KnhscMduc9acsIhcGXJ9qyc430JauRO21QNvPerun5j/fAc9gaieEMwOOOwpLq4CjanHFQ/fXKjNwW7Jb/UJAMbst1IFVnume2O5sZPes6ebc+aVwzwHJ5BzWsaMYpGUX7xO8uQSemKrrcYyMe9TSpsjBYcYBxVKQAkH1PStIRTHKLTJ45WuN8bdhkYq9bQpJa7psh14/CqkREUqMvPrU97cN/BwpHSondu0QiuXVldlVJMIQQaY9wQDuwVNQAFGwTnd09qilyo55IreME9zSErq5YAWXJj79qrPGRz3HalR/lyODU3nhlCuD9a01jsaq1tTMmxnGOaYuVHTvVyaIjJI4NQtwa3Uroxl2KzH5tvVTST7QhyeR096WVN3XIUc1BLg9+laxVznnZK5Asm1uehNJKqsxpGXJI/KnynCgYz74rY5ltZkAZIgw/nVSR2lbGMKD1pbtHmkGBx60LGFjG4/nWqSWp5uJqSlLlS0Rz3ixgbi3RTnEdYNaOvSb9SkGMBPlrOr2KEeWmkfH42fPXk/MK07SfMSrnGBisyrFqcE1U43RGHlyzOo02QFlBx1/Ougt5FHII+lcnprYbcTW5bTKc5rx8TT1PXhLlehsg7uh/OrEJcKD196z7WTcCO1XRJhduDXnzVtD0sO76smcLgY61AeCSB+NIHUDGcU3ceRnrTjGx7NJoerDIDdBT2YhjjOP5VXOccdTUgbI5OfaqaO6D1siaNyzYzVpcY461SiJ8zPrVpB1xzWc0dEXdaknVv8Aa9KkU7mC5OR2qB02yKwyfX2qeLjLLgetZS2GtWTN+7A2jvzTyodS+CT6Ui/OoI/GoVmaNsc7e4rGzYN2LETbAAD161bUx8YPHvWdvViTjipY2XB5qJQuUmi/5SsN8fQnkVcs4jhQThc9PWqNtchOPUVYtpXklCqODxXNNStYbZfu7ncQsC7COCajKecE8w4ao7tGim2lfmzS3F1mHgjco6CsYx0XKSrdB915aLgHkVgTzMXIFSSXTOMMciqZILMQehrso0uXcUtQDgTfP261b3ZRyPu44qoiCbJPU06YOhKHIGK3kk3YhKzuaKP5luu/061T8n95gHINFuSbUsWxgdKIZghDEZzxWai43sbSSa1AOqSYAOO9SyFpYxsPFLe24jCOrZ3849KZExHygAg0tGuZGfIKISYsAcjnNV7kNgHHTih5ZorjDH93ipY0MhyRlWNWrx1ZMpJe6iKOH5CT0qOVBtGDmrrxFOCODVN3YSldoGOlOMm3czqT5EQrKRnPIFO8oTqCmMjrSquWww60jIYDuU4BrS/bcalZXZRukZR/SqMqtgnbjitb/WN+94HrRcRRqOBn61vCpy6GM4OpqjHiUuBkc1bDLEDvwQB2qC6fYNq8D2quzMYiGAye9b25jmnWVLTqOlCO5ZSQPSq58sOu/J9qZuYE4yKr3kvk2kr45Vc5raMehwTrQtzM47VZFl1G4dPulziqlKx3MSepOaSveirJI+GqS55OXcKkgOJB71HSg4NNkxdnc1LeQqwINatgXwSeBWZap5ioV71uxqQFA4z1FefXaWh7UdUadk/zY7Vouy+WRn61k24IcDp71cSQLgEk15dSN3c9KhKysxZGxgN0NKj7m68CnPgLz1PaoFXaCOcGnHVHpUW4tPoXCVx15oBPTGDVZS2cA/nVmIHGWPIpNWPVoT5izEwwFIyalU7ThD+FVVxuPPzHtU8bDaRxxWMkdFywflByakgIwvoarI4K88t2qWJwXUHt2rKS0LU0iSSTY3y5AB/OnHdIA4yM9qS5GeeMVGjkHDk4xUJXV0Q3qSnl1HepUIU465qsWG70PbNTK2QNppNFw7liMEOeee1aFmSJVeL747VRgDZJbHSrEN4LfIXBY9/SuaonLRFkmoXrCRjnLHqazJLpiCOmf1pl25+Ynv0qiHO7nnFb0qKUTKcraFtmYYHHrRA6nIP41COVJ60icNx+Na8uhLb0sXbdwZR14Na19bKx3hxu21jJ+7w4rQllQ2jyKxLkYxXLUT5k0aw7FdPlhAYfjUW0AHaacrDyU3ckcmoyNz98GtEtWaSY7ziYvmPFFvKBOgwSuabeR7EUFiajt1OBz3p2Tjc5pTlexo6qU2qVGPapbM5iXI5A6VVm3SKG2kgcc1JbuGCr/F3xWDj7lid3dj3kdnKnHXioZoGVsvjNPu4yHDDtUE9w3lAhsnPNOKenKErW1CNf3+1u1LPGHPzH5e1QRXAMhU9SOanH3gXJxVu6dyFNSV2VjDjPOQO2KZOheMkenFXHRhkr0PaqNw+xc5wa0jJtkVZ8iMuZCxxikktvl65qxJIGYDOCakKLuHPJ7V1c7R5zSk31Mw257cgdTWB4sbyLBEU/61sH8K66U4JVcZ9K4HxjdCbUFgXpANrfWu3BXqVV5Hl5pKNKg7bvQ5+iiivdPkQooooA0NOuShCZ4robabco5BPrXIxttcGte1m2sM5Irkr0r6o9LCT5lZ9DqITk845qf5fMBAJ7VlJc4Xjk46Vat5MqG9OorzZQa1PXoO5o5I6jJpzDHQYGM1FFMrqSOCOlSo+U+lYO6PTp1FsiPGWznirAYAYzyajwsgzkZHao+j5PQVW530Z2J0bB561ZVs9Bg1UZhtyBzSxy9QRmpcb6nRGprqXIpF8wgg5oVvnB6c1Bvwopochsg5JqOU09ojSldwQR0pXYugBYZqqkysuCaUtuI28etZchbkrXJ8EYJ5Ip8LeYxUcAVX7bT93HJpySDhRwtJq6JVTU0WuFjjwh571WaTf3warFxuJHShXG0nBJqVTSH7TWxamIaLAYbu9Ux7/hTk5PfmpNmce1Uvd0F8WoR5xzU1vtZufl5qLy9yk5xSCJlj3bsg81Lsyopp7Fm7O3hTle1P8ANC2wXdhSearu48s5GfTHaobmRiIonHOc0lC9kauSiX3CkMQ2BjiprFR5BfgsD37Vl3DnjnpVu2LJAXDY3HpWc4e6R7TWxPeOZMMQM1Wj5JOeQe1AkLH5Tge9KJNibOueM0KPKrEN8zv0NAXIa3ZWAzjAqjBIRJ0OBSGJolU9VJqwIzk4GRjNZpRje3Um99w80vncee1JDHhG3rkE8VCMAk5q1K++2XAwo60PTREymtys9uVmDBflPeo1ncP5bj5R0NXHm34BHygYqsVLqxUZ561UXf4jnm7vQVb3P7twMjpVeXEznI7dKkkRNyknLCq7yJ5oYZyO1XGK3iTJ3VpMgOwR7ynz52ioi/3lbAxyDVuV0MZY1XkeGRAm371bRZyzSXUo3k4hgmnl/gUsD/KvM55XmmeSQ5dyWJ967DxpqKw266bFyzYd39uwri693L6fLDnfX8j5XN6/PUVNPb8wooor0DyAooooAKuWkhI2k8iqdORijAilJXRrSqezlc3IpMd60rSTKqd2KxoWDAMOhq3DcGJuQMVw1IX2PfhPS5vQvt6/LmrW7CbdxrAN75g3EY2+nerEd8SAc/WuSVGR10qljXjlUe7d/enSFQucjJrIS4z82e/FE1wxAFJUnc76VdGkkuWPtTwxPzZ49qxo7hgfmJxVyO4+UHGB0+tOVKxtGsi40vO0Gno6kkEnHtVFZAZD05q1C6hOvNZyjZFwqpvVlyJSejZNTISp+f7o71TtJcSYGakupBgKufesXFt2N/apxuicyl34Py9KkUjduYjAqjCpx/s5p0occDkHpUuC2MfadSeQkvlTwasx4MOM4qpGh+XP3sVMvykA8samS6FRqWdxyGRXwOB61cWVfLIbJJ6e9VZW+UBeM1JFxCPrnJrOSvqdEKnKyR5Aoxj5SOahkdigHIHtTJ5drDPNR/aMqeMgdqqMOpaq3JoHLZTGeetALTXgwcmMc1XimEamUdfSp7DKB5W5Ld6cla7CMrq7EkYtP83XPNaU+BDGBgcdKz5nyfMAxzT0uGlj5/h6VlKLdmZRqKLcWXIdiod5pqiMAuT9BVPzyEIxyaga5YIeMkUvZtmdTExRde6Mp+U8DtWgr5hUngMK560m3BwRg1oxzN9n2sOlTUpW0RhCvzMtzKNw29D1p906xWiJnnPNVFcuq+npTr0qxQucAVHLqkzapL3HYkEjFOmKfbH5GBYimxlWh3AnPSiIfK5AOcdaT2YJ2SKc5kLERjce1M2SPEd64IHWn7mjkUZ60k0pAKntWyv0OW6SbZVZ9i7MZBqrfyCzs2nm4Ref/rCpJ2ORgHFcn4q1p54f7PUDajZdvf0rsw9F1ZpLbqeXi8SqUHKXyMDUbt768luJOrnp6CqtFFfRJKKsj5OUnJuT3YUUUUxBRRRQAUUUUAWLWXY20n5TV95FOAvGOtZFWIpMggnms5QvqdmHxDiuRl5XwMdqlRjiqStnpU4Y9KzaPQp1S0rFzyTxVyE4IB7+tZ0Zwc1KZiSADWUo3PQo1lFXe5eDqHIxmmyMVGFJOT+VReY3l/Lz+FSQZcZIyM81k1bU1c23YmtmIfkc4rQiBLcnDdapDIkUhcCrDsCwKmsZamlKaj8RcSQK24jpSI7OxY8gVXEhL4UdatkbI+AOaxdkdLrJrTYck/7wZzV0vuxgDmsrYd/oe1TrKVIBcDHXms5RvsRCtLY0P4gAeadt+YHNVPt0SAFnGaF1BDkgMRn0rLkl2N+ZI0JVBjyOSOtNLD5UzVSDUY92HY4zzkVK9zbebxIKnkktGjX2qauh0ijDDOR/KqZVQSd2FHWpJLyJZDllx7VBKhnkCx5EZ5LdM1rCLW4n72qJLXFy5Y8RLWkj+ZnYQsa1Qf8AcL5UfAIzn1p0MzKmOSKma5tUOWJUfdJzlgwGNopYcBD82AahbgA7vl64qN5A/BPIqeW5h7azv1J5GAXCk5qBicDaMmoFkYuQDUglYAqehquWxx1K6lqTIMjAwCKu28gK7e/es4usfOCTjtTknbaGxhiaiUOYVKtyy1NVm8sAEc44qndyFoVA9ac8xeMOfvdDUDBnj+XnH6VEY21Z0VazkuWJNa3DLDt7g/nV+3kaVWIGMDpWHEdrYzWhZyuyGNOWNKpDqiaGIcmkxZ5lZQx4KnHFQT7t6kHKtUt8gSJVCkNnmqslzFa2zz3b/uYhn3+lVBX2HOouZxm/mVNd1KLTbENJlpnBESj+ZrzZ2LuWYksTkmr2tanLql400nCDhE/uis+voMJh/Yw13e58pmGL+s1Pd+Fbf5hRRRXWcAUUUUAFFFFABRRRQAUtJRQBZhbIJ7irEbZwKzwSDxVyGZCBu4PfNZyR24erfRuxbZSn3jT4lBGQaheSHYCJQWpkUkan/WisrNo9BVYxktV95r20ZKN83HcVZtwsfy4/OqFvewKmPOUEdc96kW/tV+9KrfSuaUZNvQ6oYimne5eV1ZiMGnsVAGB16VmnUoQD5TJ9WNRC4ibmS6TJ7A1Psn1LlWg+qNuMZHYD1q19pTy9gAdh0rEiuLTaQ1whPu1TRahbxj5Zov8Avqs5Ur9DeFelHqXJHncnLBF/WmJCikFiWz71QOowM+TMmc+tSfbLc9bmP/vqnySWlifrMNbMnlnihmCqoOasxXhAzgY9KxZpYBMGFxER67qmiuIA/NxFg99wpypXRl9ZV7NmwkvmOPkHrVyO2juGAZQDisUXVsh3LdQkj/bFXY9StQFb7VDk8n5xXPOEvso6KdeP2mWDYLHMFClj1rWCqIVG0fLWSNVtAc/arfn/AKaCgapa8k3sBBGMeYKxnGpLdG0cXTV0mW5z8+44IHalQfIRxzWT/aVpuIF1D/32KlGpWS/8vcP/AH2KbpStsYvExk73RamJCj0HFVmkw5wKry6haHOLqHP++KhS/tFOXuYjntuFaRpytsYTxCvoy+hKDcOppyNySeR3rOTUYPOYtcQ7MYUbxT1vbVjk3UAx23jmm6cuxj7VWWpfjlB3YFL5pJCEAL61Qjv7MMS1zAPo4pBqNo3DXMOP98UvZPsL6xG+5ro28BVOaCfIGY5NxPBArGfUrVG/d3EWOmA4pYtRtScfaIgPdxU+xl2NI4iDWj1NCRzsyDg+lTadLJbx70bJJ6VkSX1s2cXUPH+2KvWWo2C2rl7u3Eh7FxROnLl2Jo1F7S/N0NCVnJyzZyec1wXiTUJbi8eAho4ojtCnv7muvi1Sx8ko91CWJ6lxWLryafe27ulzB9pQZUhx8w9DW2D/AHdT3omOP/eU/ckchRRRXtnz4UUUUAFFFFAH6e/8IxoP/QE0z/wFT/Cj/hGNB/6Ammf+Aqf4UUUAH/CMaD/0BNM/8BU/wo/4RjQf+gJpn/gKn+FFFAB/wjGg/wDQE0z/AMBU/wAKP+EY0H/oCaZ/4Cp/hRRQAf8ACMaD/wBATTP/AAFT/Cj/AIRjQf8AoCaZ/wCAqf4UUUAH/CL6B/0BNM/8BY/8KP8AhGNA/wCgJpn/AICp/hRRQAn/AAi+gf8AQE0z/wABU/wpf+EX0D/oCaZ/4Cx/4UUUAJ/wi+gf9ATTP/AWP/Cj/hF9A/6Ammf+Asf+FFFAB/wi+gf9ATS//ASP/Cj/AIRfQP8AoCaX/wCAkf8AhRRQAf8ACL6B/wBATS//AAFj/wAKP+EX0D/oCaX/AOAkf+FFFAB/wi+gf9ATS/8AwFj/AMKP+EX0D/oB6X/4Cx/4UUUAIPC+gf8AQD0v/wABI/8ACg+FvD//AEA9L/8AASP/AAoooCwHwt4f/wCgHpf/AICR/wCFL/wi3h//AKAel/8AgJH/AIUUUBYP+EW8P/8AQD0v/wABI/8ACj/hFvD/AP0A9L/8BI/8KKKBB/wi3h//AKAel/8AgJH/AIUf8IvoH/QD0v8A8BI/8KKKBh/wi2gf9APS/wDwFj/wo/4Rbw//ANAPS/8AwEj/AMKKKAD/AIRbQP8AoB6X/wCAsf8AhR/wi2gf9APS/wDwFj/woooAP+EX0D/oB6X/AOAsf+FH/CLaB/0A9L/8BY/8KKKAD/hFtA/6Ael/+Akf+FH/AAi3h/8A6Ael/wDgJH/hRRQAf8It4f8A+gHpf/gJH/hR/wAIt4f/AOgHpf8A4CR/4UUUAL/wjGg/9ATTP/AVP8KP+EY0H/oCaZ/4Cp/hRRQAf8IxoP8A0BNM/wDAVP8ACj/hGNB/6Ammf+Aqf4UUUAH/AAjGg/8AQE0z/wABU/wo/wCEY0H/AKAmmf8AgKn+FFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph shows advanced retinal ischemia and optic nerve pallor in a patient with Behcet's disease and several previous attacks of severe vasoocclusive disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_7_11391=[""].join("\n");
var outline_f11_7_11391=null;
